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i 
Abstract 
 
The growth hormone secretagogue receptor-1a (GHS-R1a) is expressed in many 
human tissues, most notably the hypothalamus, and causes an increase in appetite upon 
activation by its endogenous ligand, ghrelin. GHS-R1a is differentially expressed in 
malignant compared to benign tumours. Therefore, there is an interest in developing 
GHS-R1a-targeted peptides as novel drugs to modulate signaling for diseases such as 
cancer cachexia and obesity and to image the receptor for disease diagnosis and following 
progression. 
Chapter 2 discusses a fluorescently labelled ghrelin analogue for imaging GHS-
R1a in ex vivo biopsy analysis and in vivo distribution studies. The analogue was created 
through side-chain cyclization resulting in an improved affinity and stability compared to 
natural ghrelin. This stapled peptide was used as a cancer cell-specific fluorescent stain. 
G7039, a peptidomimetic ghrelin agonist (IC50 5.2 nM/EC50 0.18 nM), underwent 
structure-activity relationship studies to generate improved ligands and positron emission 
tomography (PET) agents. The first generation peptidomimetic (Chapter 3) [1-Nal4,Lys5 
(4-fluorobenzoyl-4-FB)]G7039 (IC50 69 nM/EC50 1.1 nM) was radiolabelled with 18F in a 
radiochemical yield of 48%, radio purity of ≥ 99%, and molar activity of ≥ 34 GBq/μmol. 
Despite success in radiolabelling, its solubility (cLogP = 8.76) and binding affinity 
needed improvement. 
The second generation peptidomimetic (Chapter 4) [Tyr4,Lys5(2-fluoropropionyl 
(2-FP)]G7039 (IC50 0.28 nM/EC50 0.12 nM) had improved binding and lipophilicity 
(cLogP = 4.36). Labeling of this ligand was low yielding, however, a unique H-bond 
interaction was identified with molecular docking.  
The third generation (Chapter 5) required a modified prosthetic group (2-FP to 
ammonium methyltrifluoroborate-AMBF3) to radiolabel in higher yields, resulting in 
[Tyr4,Lys5(AMBF3)]G7039 (IC50 0.85 nM). This compound was radiolabelled in a single 
step and with improved radiochemical data.  
Finally, in Chapter 6 a homobivalent G7039 ligand (IC50high 0.43 nM:IC50low 0.42 
pM /EC50 1.8-2.1 nM) was found to bind to GHS-R1a homo-oligomer and was designed 
to study GHS-R1a homo-oligomerization. Differential signalling with the GHS-R1a 
 
 
ii 
homo-oligomer was observed by measuring cellular signals such as b-arrestin, ERK, and 
gene reporters. A successful series of GHS-R1a targeting probes have been synthesized 
and characterized with applications driven towards imaging and therapy. 
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iv 
Summary for Lay Audience 
 
 Within health care there is a growing need to better diagnose and monitor human 
diseases to have the best possible outcome for the patient. Improvements in disease 
diagnosis and monitoring is due to new and emerging biomarkers (human proteins) that 
can be targeted by fluorescent and/or radioactive pharmaceuticals. These various 
pharmaceuticals can also allow us to study a biomarker from a molecular pharmacology 
standpoint (i.e. signalling and regulation). The pharmaceuticals that are designed to 
image human diseases can also have the dual purpose in treating the human disease by 
targeting and regulating the biomarkers.  
This thesis describes the development of chemical tools that target a very 
attractive G-protein coupled receptor (a specific family of human proteins): the growth 
hormone secretagogue receptor-1a (GHS-R1a). This is a protein that is found on the 
cellular membrane of human tissues such as the heart, lungs, and brain. GHS-R1a is an 
attractive protein target because of its wide range of physiological functions in the human 
body including metabolism, cardiac output, depression, and neuroprotection. This protein 
is also regulated differently when there is disease present. Within malignant prostate, 
ovarian, lung, and uterine cancer the GHS-R1a has greater expression. The upregulation 
or downregulation of GHS-R1a can change the outcome of human diseases, leading to 
worse or better prognosis. GHS-R1a is also highly promiscuous as it couples (hetero-
oligomerizes) with many other GPCRs (i.e. dopamine, melanocortin), as well as it has 
been shown to couple (homo-olgiomerize) with itself. When it couples with itself or other 
GPCRs there are changes to the normal human cellular events leading to different 
physiological outcomes in humans. This can alter the human disease to make the 
prognosis either worse or better. 
Overall in my PhD I was able to develop several different styles of drug 
molecules targeting GHS-R1a. Each of these drugs was modified in such a way as to 
have applications in either imaging or therapy. This work opens the doors to further drug 
development to study this protein in human physiology and disease.  
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Chapter 1 
 
1 Introduction  
1.1 Peptides as Molecular Imaging Tools  
Abnormal expression of proteins is largely due to dysregulated or mutated genes 
that can be seen across a wide variety of diseases such as cancer and cardiovascular 
disease. These dysregulated proteins are considered hallmark biomarkers to track the 
progression of and treat human diseases. Tracking and monitoring these biomarkers are 
the reason in the development of molecular probes to monitor these biomarkers in real 
time. Molecular imaging is a wide and ever-growing field that has allowed many 
researchers and clinicians to be able to better understand the complexity of living 
systems. It has allowed for non-invasive techniques to diagnose and treat patients in a 
time sensitive manner1. This field is enabling researchers and clinicians to visualize 
biochemical processes in both normal and disease states. This is performed in real time 
on tissues, living cells, and whole organisms1. There are many chemical classes of 
molecular imaging agents such as small molecules, peptides, aptamers, engineered 
proteins and nanoparticles. However, the focus within the thesis will be the development 
of peptide molecular imaging agents to target a specific cell surface receptor1. Molecular 
imaging is a multidisciplinary field that involves many scientific fields such as 
biophysics, biology, bioengineering, molecular biology, chemistry, and clinical sciences2. 
All of these disciplines work together in designing, testing, and validating a molecular 
imaging probe. However, chemistry has been a key discipline for many years in the field 
of molecular imaging, and in many cases has been the rate-limiting step, due to 
complications in chemical synthesis with challenges associated with chemical purity, 
yields and complex synthetic routes2. Once a compound begins the crucial stages of a 
clinical trial it can also fail to make it as a clinically used pharmaceutical due to the 
complications that may occur in human physiology such as off target effects and toxicity. 
This is also another rate-limiting step in the development of novel pharmaceuticals.  
Molecular imaging is widely used in the detection and treatment of cancer and has 
many advantages in this area. Molecular imaging techniques can perform whole body 
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readouts in an intact system, which is more reliable than in vitro or ex vitro studies3. This 
helps decrease the work load and accelerate the diagnosis and treatment plan for 
patients3. By doing so the patient can have a better overall all prognosis. Molecular 
imaging of cancer patients also allows for longitudinal studies being performed on the 
same patient to assess the progression of the diseases state and validate the success of the 
selected treatment plan3. Therefore, the detection of molecular markers such as cell 
surface receptors can allow for an earlier diagnosis, earlier treatment, and an overall 
better prognosis for the patient3. All imaging probes have some commonalities in that 
they must be biocompatible, have target specificity, high disease-to-normal-tissue signal 
ratio, and rapid clearance. There are three main components to most imaging agents; a 
targeting moiety, a linker, and an imaging moiety (Figure 1.1).   
 
 
 
 
 
 
 
 
 
 
The targeting moiety is selective to only one target and typically needs to bind with a 
high affinity (high ki). The targeting moiety should also possess a high selectivity, a 
strong metabolic stability, and potentially membrane permeability if the target of interest 
is an intracellular protein. The linker provides enough space between the targeting and 
imaging moiety to ensure the imaging moiety does not interfere with binding to the 
receptor. 
The development of a novel molecular imaging agent has a number of key steps 
in order to have a successful probe in the end. These key steps are highlighted in Figure 
1.2 below. These steps are guidelines that help direct the research in a uniform fashion 
towards the end goal, however in some cases these steps are altered due changes in 
 
Targeting Moiety 
Linker 
Imaging Moiety 
Figure 1.1 - Typical three component imaging agents. The targeting moiety is specific 
to the biomarker, the linker provides space between the targeting moiety and the 
imaging moiety, and the imaging moiety allows for visualization of the biomarker 
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project design such that the imaging agent might target another biomarker more selective 
then the original choice. First (step one Figure 1.2) a disease state must be chosen, such 
as a certain class of cancer. The disease state that is being targeted in this thesis is 
prostate cancer (PCa). Cancer is only one type of disease that can be targeted by the use 
of molecular imaging agents; however, this general scheme can be used in the 
development of imaging agents used in the detection and monitoring of other diseases 
such as cardiovascular disease. A biological target that is highly expressed must be 
identified within the disease state chosen (step two Figure 1.2)3. Identification of this 
biomarker is done through various techniques such as genotyping a population of people 
with a common disease. This is usually followed up by pathology of the tissue identifying 
the biomarker with an antibody or chemical stain. Typically, a target that may show 
differential expression between disease states (i.e. malignant vs. benign) is preferred 
along with a target that is overexpressed within the chosen disease state3 (step three 
Figure 1.2). Choosing a target that is unexpressed would not be beneficial since the 
expression is far too low for most imaging techniques. An imaging technique that 
satisfies the signaling target must be decided upon before devising a synthetic route for 
the molecular agent as the addition of the signalling entity is incorporated in the chemical 
design of all the probes being studied. For instance using fluoride-18 (18F) in conjunction 
with positron emission tomography (PET)2. There are several imaging modalities that 
exist such as single-photon emission computed tomography (SPECT) and magnetic 
resonance imaging (MRI), however the focus of this thesis is utilizing PET in conjunction 
with the radioisotope 18F. The major reason for this choice is the wide spread use of both 
this imaging technique and isotope among healthcare. It will be discussed later that one of 
the most widely used PET imaging agents is fluorinated glucose. The next stage is the the 
design and chemical synthesis of a molecular imaging probe (step four Figure 1.2). This 
is because chemical synthesis is time consuming and requires careful planning to create a 
target that will have a high affinity for the receptor4. This requires the consideration that 
the imaging probe has a binding property with a fast on-rate (kon) and a slow off-rate 
(koff)3. Also, the imaging probe will need to have appropriate pharmacodynamic and 
pharmacokinetic properties for in vivo use. Pharmacokinetics is the effect the body has on 
the chemical probe such as absorption, distribution, metabolism, and excretion5. These 
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properties can be controlled based on the chemical structure of the probe, including the 
linker, and the signalling entity. In the case of using peptides as imaging agents the 
chemical nature of the amino acids can directly affect the pharmacokinetic properties.  
However, pharmacodynamics refers to the chemical probes’ effects on the body such as 
adverse effects and off target effects5. Again the chemical nature of the probe greatly 
dictates the pharmacodynamics. In vitro assays help confirm the effectiveness of the 
probe on the target under non-radioactive conditions before moving into animal studies 
(step five Figure 1.2). These types of assays involve competitive radioactive probes to 
assess the binding of novel chemical probes, and this competitor itself can change the 
chemical and structural properties of the novel chemical probe and the target itself. In 
vitro studies are able to directly assess product performance on an isolated target5. 
However directly assessing an isolated target with success does not directly translate to 
the same success in the initial animal models. This is because the isolated target is most 
likely a purified protein or an overexpressed protein in a given cell line or membrane 
fragmentation preparation. Typically experiments on a chemical probe switch between 
step four to five (Figure 1.2) until an optimal molecular probe is identified with 
specificity and selectivity for the given target. When designing a molecular imaging 
probe, a site for labeling must be considered at this stage (step six Figure 1.2) making it 
easier for a synthetic scheme to label the molecular probe with the appropriate 
radionuclide such as 18F. Incorporation of the imaging modality after the design of the 
core pharmacophore can leads to changes in both selectivity and specificity for the given 
target leading to further optimization and synthetic challenges such as the location to 
attached the imaging component. Once the compound can be successfully labelled with 
high yield, purity, and reproducibility the study can progress into an appropriate animal 
model for the disease being studied (step seven Figure 1.2). In vivo studies are 
considered the gold standard in assessing the pharmacokinetics and pharmacodynamics 
of the probe6. Increasing the animal number within all desired control groups (step eight 
Figure 1.2) ensures that the images are reproducible among many trials. This sometimes 
requires the study to go back to step four (Figure 1.2) to improve the pharmacokinetics 
and pharmacodynamics, which in turn will improve the PET images in order to have a 
higher level of confidence when identifying cancerous tissue in the image6. Then finally 
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clinical studies (step nine Figure 1.2) with a lead compound will begin if there has been 
success at steps one through eight. Clinical studies pose their own challenges as now the 
molecular imaging agent will have been challenged against human immunity and a 
potential increase in off target effects due to the larger number of biomarkers, they 
regulate human pharmacology and physiology. 
 
Figure 1.2 - The nine critical steps in designing a successful imaging probe. These 
steps are just a guideline in designing a successful imaging agent. As these steps 
progress changes can occur with both the imaging agent and the target of interest 
1.2 Prostate Cancer 
Within the scope of this thesis the disease state of interest is prostate carcinoma 
(PCa). The prostate is a major male reproductive organ that is involved in the addition of 
nutrients and fluid to the sperm7. It takes the shape of a walnut that is divided into right 
and left lobes and is located on the ventral side of the rectum below the bladder7. Cell 
growth in the prostate is modulated by testosterone, regardless whether the cells are 
cancerous or healthy7. There are three zones of the prostate that include the peripheral 
zone (p-zone), the central zone (c-zone), and the transitional zone (t-zone). It is known 
that about 75% of malignant tumours originate in the p-zone, and typically benign masses 
are found in the t-zone8-9. PCa is the most common cancer among Canadian men. The 
statistic as of 2018 is that one in seven men will be diagnosed with PCa in their lifetime7. 
PCa acts similar to that of all cancers as it has uncontrolled growth, abnormal structure, 
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and has the ability to metastasize7. PCa can persist for many years without showing 
noticeable symptoms, hence the importance in the development of imaging agents for 
earlier detection7. According to Prostate Cancer Canada (PCC) there are five major risk 
factors that males should be aware of in order to ensure early diagnosis of the carcinoma. 
It is recommended that men over the age of 40 should be tested for prostate specific 
antigen (PSA) levels to establish a baseline and monitor fluctuations as the years pass 
on7. PSA is a protein produced in the prostate gland that is secreted into the seminal 
fluid7. There is free PSA and complex PSA. Free PSA moves freely in the blood stream, 
and complex PSA is associated with other blood proteins such as human serum albumin7. 
The PSA test is a blood test that measures the amount of PSA found in blood protein a 
and above 4 ng/mL is considered higher than normal. Free PSA is usually associated with 
benign prostatic hyperplasia (BPH)7. However, this relatively non-invasive test cannot 
stage the progression of the cancer, and also this is not a definitive diagnosis, and 
therefore further testing is required7. Elevated PSA levels are also associated with 
prostate inflammation, and this is highly treatable with pharmaceuticals and diet. If there 
are elevated PSA levels, then a digital rectal exam (DRE) is a next logical step. This is 
when the physician examines the size and shape of the prostate and feels for lumps or 
hard areas within and around the prostate7. Hard areas are signs of tumour growth, where 
as soft tissue enlargement is usually indicative of inflammation. If cancer tissue is 
suspected, then a trans-rectal ultrasound (TRUS)-guided biopsy is performed to obtain a 
small segment of prostate tissue. Pathology of the tissue can be examined to determine 
whether or not it is cancerous. This is then scored from one to five depending how much 
of the tissue is cancerous. This is known as the Gleason score, where a score of one 
indicates mostly normal prostate tissue is observed, and a score of five is when growth 
patterns of the prostate tissue is highly abnormal and considered to be an aggressive form 
of prostate cancer. However, all of these techniques have sampling errors, especially with 
the biopsy, leading to missed and late diagnoses7. This is why there is a need for non-
invasive imaging methods to improve the disease identification through the detection of a 
specific overexpressed biomarker in the disease. If this can be done at earlier stages, this 
leads to improvement in patient prognosis and survival.  
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1.3 Imaging Modalities  
The typical imaging modality used to detect prostate cancer is magnetic resonance 
imaging (MRI), and this is performed before a biopsy8-9. This technique is performed as a 
whole-body scan to detect if the cancer has metastasized to other tissues. MRI uses a 
magnetic field and radio waves in order to create a detailed image of organs and tissue in 
a biological system10. The magnetic field temporality realigns the hydrogen atoms of 
water within a tissue and the radio waves allow these aligned atoms to create signals that 
are transferred to a series of detectors to reconstruct an image10. The advantages to MRI 
are that there is no ionizing radiation and the images have a high spatial resolution (less 
then 1 mm) without compromising the image. However, there are still signal-to-noise and 
contrast-to-noise issues with MRI that need to be improved. There have been attempts to 
use stronger magnets and dedicated computational software to help with contrast and 
noise, but in the past 30 years it is the contrast agents (CA) that have been able to 
enhance the image to provide a better diagnosis and treatment plan4. MRI contrast agents 
such as gadolinium (Gd) are used to alter the longitudinal (T1) and transverse (T2) 
relaxation rates of the surrounding water protons in a tissue. An MRI CA must be a 
biocompatible magnetic material to be able to alter these relaxation rates, and CAs are 
classified based on their magnetic properties and relaxation mechanisms. This type of 
technology is used to show the invasiveness of the cancer and whether other tissues may 
also need to be biopsied. However, MRI shows limited lesion detection in the central 
gland of the prostate making it difficult to delineate between benign and malignant 
tumours11-13. Computed tomography (CT) can also be used to localize and identify a 
tumour, however it lacks accuracy, sensitivity, and specificity when identifying is the 
tissue is cancerous or benign14.  
1.4 Fluorine-18 Positron Emission Tomography 
Positron emission tomography (PET) is another non-invasive imaging modality 
with decent spatial resolution (5 to 7 mm), however it has superior sensitivity (100 to 
1000 fM) compared to other imaging techniques. This sensitivity is important as very 
little of the imaging pharmaceutical is used in order to have a detectable signal in the 
affected tissue. This imaging method allows for the detection of a pharmacological 
process in patients using a positron emitting radioisotope15. Fluorine-18 (18F) is a 
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radioactive isotope with a half-life of 109 min, and a Beta+ (β+) emission. It is created by 
a cyclotron by bombarding water that is enriched with the oxygen-18 (18O) isotope with 
high energy protons (18 Mega-electronvolts). The desired radionuclide 18F is then created 
with a highly unstable nuclease with 9 protons and 9 neutrons in the nuclease and 9 
electrons. There is a production of two gamma (γ) photons of 511 keV in 180° direction 
from each other after an annihilation event occurs between the radionuclide and the 
electrons in surrounding tissues (releasing the β+)15. The half-life of 18F being two hours 
is beneficial as the decay rate is long enough to perform a lengthier radiosynthesis route, 
but short enough lived that the radiation does not persist too long in a biological system 
reducing radiation exposure for patients. PET has the capability of detecting two 
coincident gamma emissions simultaneously (Figure 1.3)15. 
 
Figure 1.3 – Beta Positron Annihilation with Electron in Body Tissue to Release 
Gamma Photons of 511 KeV 
 
The images acquired from a clinical PET camera have spatial and temporal 
resolution of 5-7 mm and second-minutes respectively15. PET also has a sensitivity of 10-
12 to 10-13 M, meaning that a very low concentration of the radiolabelled imaging probe 
can be used15. All of these factors above make PET a very good imaging modality for the 
clinician and patient.  
Currently the most common clinical PET probe is fluorodeoxyglucose 
([18F]FDG). The reason for using glucose in the detection of carcinoma is that cancerous 
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cells metabolize glucose at a much faster rate than normal cells, which creates a different 
contrast on the PET image, and this is known as the Warburg effect16. Since glucose 
passes through the body by renal excretion, it causes a buildup of the tracer in the 
bladder16. With the bladder in close proximity to the prostate, there are difficulties 
associated with visualizing the disease tissue16. The current PET imaging agents are 
unable to delineate between malignant and benign PCa. This is why there is a need for 
more specific PET imaging agents in order to improve the accuracy in diagnosis of PCa 
within patients. 
1.5 Peptides as Molecular Imaging Agents 
The major advantage to using peptides as imaging agents is that they show a high 
binding affinity and specificity with cell receptors both in vitro and in vivo17. The other 
advantage to peptides as imaging agents is that they show good pharmacokinetic 
characteristics such as absorption and distribution in an in vivo scenario when targeting 
cell receptors that are overexpressed in tumour cells18. Peptides are biologically 
synthesized in many different organs in the body but have multiple functions else were 
controlling human pharmacology and physiology18. Peptides have a particular target of 
interest within a given tissue in order to elicit their response. Peptides are able to also 
target proteins/peptides in cancerous tissue leading the progression or regression of 
disease18. A majority of these peptide targets are overexpressed receptors called G-
protein coupled receptors (GPCRs). Peptide based radiopharmaceuticals have been in the 
clinic for over 2 decades and have showed promising results in the diagnosis of cancer18. 
The first peptide that showed success was 111In-DTPAO-octreotide a somatostatin (SST) 
analog18. This receptor is overexpressed in neuroendocrine tumours18. This success has 
led many to develop peptides as imaging agents over these past decades.  
Major success has also been seen when it comes to imaging the melanocortin-1 
receptor (MC1R) that is expressed in melanocytes. MC1R aids in the synthesis of 
epidermal melanin pigments, as well as aids in the photoprotective response via DNA-
repair pathways and antioxidant defences. However, MC1R is highly overexpressed in 
primary melanomas and their metastasis leading to the development of peptide imaging 
probes19. The development stemmed from the natural ligand for the MC1R: α-
melanocyte-stimulating hormone (αMSH). In 2014 a 18F-labelled benzamide derivative, 
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[18F]N-(2-diethylaminoethyl)-4-[2-(2-(2-fluoroethoxy) ethoxy)ethoxy]benzamide 
([18F]FPBZA) was developed by Shih-Yen Wu and co-workers to specifically target 
primary melanomas and their metastasis in mice bearing B16F0 melanoma (non-
metastatic) or A375 amelanotic melanoma (metastatic) tumour tissue20. More recently 
Chengcheng Zang and co-workers developed a lactam bridge-cyclized αMSH (Ac-Nle 
(norleucine)4-cyclo(5, 10) [Asp5-Hid-DPhe7-Arg-Trp-Lys10]-NH2) analogue tagged with 
gallium-68 (68Ga) via a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) 
chelator. They made a couple variants of this analogue and each of their variants showed 
successful single-photon emission computed tomography (SPECT) images in mice 
bearing non-metastatic and metastatic tumour tissue21. These are just a few of the 
peptide-based imaging probes that have been developed in order to image disease in a 
non-invasive fashion19. Currently there are over 150 peptides that are in clinical trials for 
the purpose of both diagnosing and treating disease22-23.   
In particular within this thesis, the peptides being developed are small therefore 
allowing them to have many advantages. Small peptides are easy to synthesize, and easier 
to radiolabel. They are amenable to chemical and molecular modifications and have the 
ability to be conjugated to metal chelators or other imaging components on either the N 
or C terminus of the peptide. They tend to have higher receptor binding affinities, higher 
tumour penetration, and higher retention in the target tissue than small molecules. They 
have favourable pharmacodynamics, rapid clearance from off target tissues, and the rate 
and route of excretion can be modified by changing the chemical structure. They tend to 
have fewer side effects, they are highly non-immunogenic, and, in some cases, they can 
be used for more than one biological target of interest18-19. These are the main reasons for 
using lower molecular weight peptides as imaging agents.  
1.6 Modifying Peptides for Improved In Vivo Stability and Target Affinity  
Peptides are natural molecules that can have several disadvantages in terms of 
their oral bioavailability and lower metabolic stability. In terms of imaging agents, 
bioavailability is not always a concern as the typical route of administration will be 
intravenous (IV). However metabolic stability for imaging agents is highly important as 
the probe must be able to make it to the target tissue in order to bind to its receptor. 
Structural modifications are needed in order to inhibit or reduce enzymatic degradation. 
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Exopeptidases are one of the major enzymes that hydrolyze the C and N termini of linear 
peptides. One approach to prevent this degradation is to synthesize a peptide to have the 
C terminus as an amide and perform an N terminal acetylation although this may cause a 
reduction in binding in some cases24. Within the scope of this thesis all peptides have a C 
terminus that is amidated in order to slow the degradation by exopeptidases. Hydrolyzing 
peptide bonds is caused by endopeptidases that recognize the natural L-amino acid within 
the peptide sequence. One particular way to prevent this is to replace L-amino acids with 
D-amino acids or other unnatural amino acids. For instance, the use of D-amino acids 
was highly used in the peptidomimetics designed within Chapters 3 to 5. The main choice 
was unnatural aromatic D-amino acids (D-1-naphthylalanine, D-2-naphthylalanine) as 
they prove to be involved in a series of hydrophobic interactions within the binding 
pocket of GHS-R1a as determined by MD simulations. Other modifications are the use of 
the unnatural beta and gamma amino acid substitution in comparison to the standard 
alpha amino acids25. This allows the amino acid side chains to arrange in very specific 
three-dimensional conformations forming helical or pleated sheet secondary structural 
motifs. These are some of the modifications that can enhance in vivo stability while only 
making minor changes to the natural peptide sequence in order to maintain affinity 
towards the target25 (Figure 1.4).  
 
Figure 1.4 - Stereochemistry of natural and unnatural amino acids 
 
Pseudo peptides is another way to enhance the stability of peptides, since they contain 
chemical modifications within the backbone of the peptides, therefore resulting in 
improved resistance against peptidases. Examples of this are peptoids, aza-peptides, and 
several amide bond surrogates (Figure 1.5)25. Peptoids or N-substituted glycine can 
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increase the peptide stability as well as the cell permeability if we are considering a target 
that may be cytoplasmic or nuclear. Attachment of the peptide side chain to the backbone 
nitrogen this will cause the elimination of the polar N-H bond, driving up lipophilicity to 
enhance cell permeability even further. Aza-peptides refers to the replacement of one or 
more alpha carbons with nitrogen25. This causes a lost in stereogenicity and reduces the 
flexibility by switching the rotatable alpha carbon-C(O) bond with a rigid alpha nitrogen-
C(O) bond. When an aza residue is placed in the i + 1 or i + 2 position this can cause the 
induction of beta turns changing the conformation and enhancing peptide stability 
overall. Amide bond surrogate examples are thioamides, esters, alkenes, and 
fluoroalkenes and these modifications will mimic the geometric structure of a peptide 
bond but lead to an increase in peptide stability in most cases26-27. However, based on the 
number of atoms and valence arrangement, thioamides most accurately mimic that of a 
natural peptide bond. The drawback to thioamides is that sulphur is a poorer H-bond 
acceptor in comparison to oxygen, but the nitrogen compensates for this loss in 
thioamides. Ester substitution can destabilize secondary structure of a peptide since they 
are unable to perform H-bond donation acting as poorer H-bond acceptors. Esters also 
have the tendency to undergo hydrolysis. Alkene surrogates can mimic bond rigidity, 
angle and length even though they lack a heteroatom for non-covalent interactions26-27. 
Alkenes can also undergo isomerization, oxidation, and chemical liability in vivo even 
though they have been incorporated into previous natural peptides and proteins to 
enhance stability (e.g. C-X-C chemokine receptor 4 CXCR4 and the tripeptide RGD). 1, 
2, 4-Oxadiazole, 1,3,4-oxadiazole, and 1,2,4-triazole can be used as heterocyclic moieties 
mimicking amide bonds30-31. All of these modifications are highly dependent on the 
overall structure of the natural peptide, the target of interest and the intent of the chemical 
probe (e.g. imaging versus therapeutic). However, they all come with challenges and 
disadvantages that must be considered when performing structure activity relationships 
(SARs) on natural peptide sequences30-31. This process is always the limiting step but is 
highly necessary in order to advance a lead peptide drug candidate towards clinical trials. 
This approach can be used whether the intended chemical probe is to act as an agonist, 
antagonist, inverse agonist (induces opposite response to that of an agonists), or partial 
agonist (partial efficacy towards the receptor) and this can be a way to alter the chemical 
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probe towards these specific pharmacological molecules. The focus for chemical 
modifications within this thesis will be using unnatural amino acids, D-amino acids and a 
backbone bridging technique (lactam bridge) in order to enhance the lead peptides as 
possible future drug candidates in a clinical trial. The lactam bridge stabilization will be 
discussed further in section 1.13.   
 
Figure 1.5 - Backbone modifications to help increase in vivo stability of natural 
peptides 
1.7 Peptide Design and Structure Activity Relationship 
The peptides that are being designed in this project are based on a discovery in 
1977 by Bowers et al32-34. The group was interested in Met (methionine in the 5th position 
of this peptide)-enkephalin (EF) analogues in order to understand structure activity 
relationship (SAR) in relation to pituitary hormone secretion. The natural structure of 
enkephalin is a pentapeptide and its function is in the regulation of nociception in humans 
by binding to the delta and mu opioid receptors. The naturally occurring enkephalin 
derivatives differ by either a Met or Leu on the C-terminus of the pentapeptide (Figure 
1.6).  
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Figure 1.6 - Natural occurring Met-enkephalin and Leu-enkephalin pentapeptide 
structures 
 
Bowers et al32-34 set out to design enkephalin analogues that would also be 
involved in the release of growth hormone (GH) from the pituitary gland in the female 
rats. They discovered early on through a series of structure activity relationship studies 
that position-2 in their analogues was highly conserved for very select amino acids in 
order to still maintain GH release. Two of their first analogues (H-Tyr-DTrp-Gly-Phe-
Met-NH2 and H-Tyr-DPhe-Gly-Phe-Met-NH2) they discovered that an aromatic residue 
was required in the second position (DTrp and DPhe) in order for in vitro GH-releasing 
activity32-34. Seven other analogues they developed without an aromatic amino acid in the 
second position didn’t have any GH-releasing activity. It was also discovered that the L 
amino acids of Phe and Tyr did not cause any GH-releasing activity. Upon the discovery 
of these enkephalin analogues Bowers et al created a hexamer H-His-D-Trp-Ala-Trp-D-
Phe-Lys-NH2 (GHRP-6). This then became the first synthetic peptide to release GH both 
in vivo and in vitro32-34. From this point on many researchers began to develop peptides 
that had the ability to release GH. These classes of compounds then became known as 
growth hormone secretagogues (GHSs)35. They are in their own chemical class based on 
the function of secreting GH from the pituitary instead of the alternative route from GH 
releasing hormone (GHRH)35. These various GHSs encompassed peptides: GHRP-136, 
hexarelin37, KP-102 (later designated GHRP-2)38, peptidomimetics (e.g. G703939, [1-
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Nal]4G703940and ipamorelin41) and small-molecules (e.g. L-692,42942-44and MK-067742-
44). The structure of these representative GHSs can be seen in Figure 1.7. 
 
Figure 1.7 - Chemical structures of the peptides, peptidomimetics, and small 
molecules that cause GH-releasing activity in rats and/or humans 
 
It wasn’t until 1996 that the growth hormone secretagogue recptor-1a (GHS-R1a) 
was discovered by the group of R. Smith at Merck Sharp and Dohme Research 
Laboratory in the United States45-47. Their discovery was made possible by various 
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expression cloning methods (i.e. point mutations) and they were the first to identify that 
GHS-R1a interacted with these various GHSs causing GH-releasing activity. This 
receptor belongs to the rhodopsin-like family of GPCRs48. Its seven transmembrane (TM) 
alpha helical domains consist of 366 amino acids having an approximate mass of 41 KDa 
(Figure 1.9)46-47. GHS-R1a has a known splice variant (GHS-R1b) which only has five 
TMs consisting of 289 amino acids. To date this splice variant has no known biological 
activity44-48. GHS-R1a is expressed in a wide variety of tissues and organs including the 
hypothalamus, pituitary gland, thyroid gland, stomach, intestines, pancreases, spleen, 
ventricular myocardium, aorta, lung, adrenal gland, kidney, testis, adipose tissue, ovaries 
and lymphocytes48. Because it is widely spread in so many tissues and organs it has 
several human physiological outcomes that are highlighted in Figure 1.849.  
 
Figure 1.8 - Physiological effects of GHS-R1a in humans (modified from 47, 
copyright permission number 11855562) 
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Figure 1.9 - Homology model of GHS-R1a. This model is based on sequence 
alignment with variations of the neurotensin receptor with various ligands docked 
in its pocket. The 7-alpha helical domains (in red) span the cellular membrane (in 
green) 
 
In 1999 Kojima et al isolated the natural ligand ghrelin from a rat’s stomach50. 
Before this date GHS-R1a was considered to be an orphaned GPCR. Human ghrelin is a 
28-amino acid peptide that is derived from a 117- amino acid sequence (preproghrelin) 
and through post-translational modifications, terminating with the octanoylation of Ser-3 
by ghrelin O-acyl transferase (GOAT) the active form is produced50. Without this fatty 
acid chain ghrelin is unable to bind to its receptor. This is the only known instance of a 
peptide being post-translationally modified with a fatty acid, and it is required for its 
binding to and biologically activating GHS-R1a47 (Figure 1.10). 
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Figure 1.10 - Proteolytic cleavage of preproghrelin to the 28 amino acid variant and 
the enzyme GOAT catalyzing the addition of the octanoyl chain on Ser position 3 
 
Merck then continued to investigate the interaction between ghrelin and GHS-R1a 
and learned that the first 5 N-terminal amino acids of ghrelin were essential in binding to 
and activating the receptor51. They discovered this through the development of truncated 
versions of the ghrelin peptide by measuring the EC50 (half-maximal effective 
concentration) in HEK293T cells that transiently overexpressed GHS-R1a. The EC50 was 
calculated by monitoring the intracellular calcium release from the endoplasmic 
reticulum downstream of the Gaq51. These truncated versions can be seen in Figure 1.11.  
Since then many ghrelin derivatives have been developed and tested that have similar 
properties to that of the natural ligand. Some of these include small molecules that have 
been developed by Merck52, Bristol-Myers Squibb53, Sumitomo Pharmaceuticals and 
Abbott Laboratories54. Also, many have worked on the development of peptidomimetic 
and pseudo peptide agonists developed by Novo Nordisk (DK). When developing novel 
ligands targeting this receptor certain criteria must be carefully considered55-65. Deciding 
the nature of the ligand (e.g. agonist, antagonist, partial agonist, inverse agonist) is the 
first major step in beginning an extensive structure activity relationship (SAR) study. The 
structural nature of the ligand must be decided before beginning synthesis. This could be 
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choosing the development of small molecules, peptides, peptidomimetics, proteins, or 
antibodies as the initial starting framework. Then in terms of having these ligands be 
suitable imaging agents one must choose the location and method of radioisotope 
incorporation into the structure of the ligand.  
 
 
Figure 1.11 - Derivates of ghrelin developed by Merck indicated that the first 
5 amino acids are essential to binding to and activating GHS-R1a 
1.8 Molecular Imaging Agents Designed to be either Agonists or Antagonists  
 A peptide agonist has been the most frequently used radiolabelled molecular 
imaging tool when it comes to targeting overexpressed proteins in cancerous tissue.  
Agonists become internalized when binding to the receptor, allowing them to accumulate 
and be retained in the targeted cells66. This became a well-established concept in the 
1980s being studied with the somatostatin receptors that has been shown to be 
upregulated in a variety of neuroendocrine tumours67-68. For examples an indium-111 
labelled somatostatin derivative developed by Reubi et al. showed specificity in targeting 
the highly expressed somatostatin receptors within neuroendocrine tumours in a mouse 
model68. Upon binding of an agonist such as this somatostatin derivative to its given 
target a receptor-radioligand complex forms and this becomes internalized into the 
tumour cell69. This allows for an increase in radioactivity in the tumour tissue compared 
to other organs such as the liver, lungs and spleen. As the radioligand accumulates in the 
tumour tissue there is a contrast enhancement allowing the in vivo target to be visualized 
by PET. This is one of the main reasons why most decided on using agonists versus 
antagonists. This is because when an antagonist binds to a receptor it has a purpose is to 
block the natural ligand from interacting with its natural target68.   
Others in the field of imaging probe design focus on using an antagonist as the 
target entity to be tagged with a radionuclide. For example, Ginj et al. showed that a 
somatostatin derivative designed to be an antagonist showed improved in vivo results 
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(less buildup of the radiotracer in noncancerous tissues) then a variety of radiolabelled 
agonists70. Another example when using an antagonist as an imaging probe was Wadas et 
al. and their comparison between the antagonist 64Cu-CB-TE2A-sst2-ANT and the 
agonist 64Cu-CB-TE2A-Y3-TATE, when targeting the gastrin-releasing peptide receptor 
(GRPr) that is overexpressed in prostate cancer (PCa). Their results indicated a reduction 
in kidney and intestine uptake while maintaining tumour uptake of the imaging probe. 
The preference between using an agonist versus an antagonist is receptor dependent, and 
therefore when designing an imaging probe both agonists and antagonist peptides for the 
same target may be beneficial to design at the chemical synthesis phase71-72.  
1.9 Designing Agonist Imaging Probes Through Structure Activity Relationships.  
 Within this thesis it was decided to generate growth hormone secretagogues 
(GHSs) as imaging agents allowing for a rapid synthesis by either manual or automated 
fluorenylmethyloxycarbonyl solid phase peptide synthesis (Fmoc-SPPS). Synthesising 
small molecules in most cases requires lengthier synthetic procedures. Small molecules 
also typically are designed to consist mostly of the pharmacophore in order to interact 
with the receptor. Slight changes to a small molecule pharmacophore can drastically 
reduce its binding towards a given target. Peptides tend to have a non-pharmacophore 
portion thereby allowing for the attachment of a desired radionuclide to form the imaging 
agent without interfering with receptor binding. Lastly there has been a large number of 
previous studies that probed the interaction between GHS-R1a and growth hormone 
releasing peptides (GHRPs), pseudo-peptides and peptidomimetic GHSs. This gives us a 
great starting scaffold to do further SAR studies as well as to modify the peptides in the 
appropriate way to generate imaging probes73-78.  
Rationale of these agonists was based on Feighner et al.77 who utilized site 
directed mutagenesis79 and molecular modelling to determine the key residues in GHS-
R1a that interacted with specific ligands (GHRP-6, MK-0677, and L-692585) (Figure 
1.7) 77. The activation of GHS-R1a signalling by these various ligands was measured by 
an aequorin bioluminescence assay detecting the changes in intracellular calcium ion 
levels.  
A homology model based on the helical impression of bacteriorhodopsin and a 2-
dimensional sequence alignment of repeated motifs across many GPCRs (neurotensin, 
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somatostatin-2, angiotensin-2, beta-2-adrenergic, human/swine/rat GHS-Rs) was used to 
determine the number of amino acids that are needed to allow for a successful ligand 
interaction with GHS-R1a 77.  Figure 1.12 below is the 366 amino acid GHS-R1a 
discovered by homology modeling, with the indicated mutated residues in red. 
 
Figure 1.12 - The GHS-R1a with mutated sites in red performed by Feighner et al36. 
Adapted from 36  
 
 
It was from here that are larger number of residues in the receptor were identified 
as key for the binding and activation by a variety of synthetic ligands. For instance, E124 
in transmembrane 3 (TM3) forms a salt bridge with the primary ammonium cation on the 
N terminus of a peptide ligand or an amino group that is on a small molecule ligand77. 
This interaction was confirmed by site directed mutation from E124 to Q124. Residue 
M213 was crucial to the binding of L-692585 (ghrelin small molecule)80, and when 
mutated to D213 binding and activity was lost. D99 (TM2) was also key as the functional 
activity decreased by half when mutated to N99 (again with L-692585)77. Residue C116 
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was also key for the binding, since all activity was lost when mutated to A116 (TM2) 
(proven with various ligands listed in Figure 1.7). This Cys116 residue forms a disulfide 
interaction with Cys198 that is crucial in the stabilization of the receptor in an active 
conformation. Also, residues S123 and Q120 were shown to have a high importance in 
the binding of ligands to GHS-R1a. This was confirmed by using [35S]-MK-067781 and 
mutating S123 to A123 and Q120 to H120 in TM377.  
Several follow up studies utilized computational methods to further investigate 
the interaction of GHS-R1a and various ligands. In 2001 Huang et al.78 identified 6 key 
pharmacophoric regions in GHS-R1a by using six peptide-based and 4 non-peptide-based 
ligands. They first identified the low-energy conformers for each of the ligands and used 
a mutated version of GHRP-6 as a negative control ([Val3]GHRP-6). The computer 
program that was designed by Huang et al. (DistComp)82 was used to identify the 3-
dimensional pharmacophore and its functional groups that are required to activate GHS-
R1a. The key functional groups identified were: two aromatic rings, a proton acceptor, a 
protonated amine and a small hydrophobic group. Once this pharmacophore region with 
the key residues was identified it was further screened against a larger database of 
compounds in order to find potential hit ligands. This resulted in the identification of a hit 
ligand agonist benzothiazepin GH secretagogue (Figure 1.13) with an EC50 of 1 nM. This 
was a conformation that the computational method developed by Huang et al. was a valid 
way to identify hit ligands that target GHS-R1a78.  
 
Figure 1.13 - Benzothiazepin identified to have 1 nM potency when targeting 
GHS-R1a 
 
The protonated C-terminal amine (previously identified by Feighner et al.) and 
aromatic groups in benzothiazepin was the establishment in the necessary molecular 
framework in designing peptide base agonist that targeted GHS-R1a. Hansen et al. also 
confirmed through the design of ipamorelin (Figure 1.7) derivatives that there is a need 
for C-terminal aromatic groups in order to maintain binding towards GHS-R1a 59.   
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Pedretti et al. then conducted a fragment based computational study of GHS-R1a 
in order to further study its interaction with various ligands. The 7TM GHS-R1a was 
divided into 15 fragments and these fragments were modelled against rhodopsin. The 
active core of the ghrelin peptide (Gly-Ser-Ser(n-octanoyl)-Phe-NH2 in Figure 1.11) 
along with 35 literature peptidomimetic GHSs was docked against this fragmentation-
based model for each of the 15 fragments. Additional sub-pockets in the binding domain 
of GHS-R1a were identified. There was the identification of a polar sub-pocket bordered 
by TM2 and TM3 and a non-polar/aromatic pocket surrounded by TM5 and TM6. Since 
these binding pockets are too far apart for a single ligand to interact at both sites it was 
determined that there is a cooperative effect between the various binding modes. The 
receptor goes into an active state when GHSs bind to the aromatic sub-pocket by way of a 
non-competitive mechanism through partial agonism79.  
Martin-Pastor et al. and Jӧrg Groβauer et al. conducted a 1H-NMR study on the 
interaction between the ghrelin ligand with/without the octanoyl chain and GHS-R1a. 
This was an in vitro NMR study using both human embryonic kidney (HEK293) and 
Chinese hamster ovary (CHO) cells stably transfected with GHS-R1a. 2-dimensional total 
correlation spectroscopy (2D-TOCSY), chemical shift perturbations (CSP) and slow 
conformational exchange (SCE) were used to better understand the interaction between 
GHS-R1a and its natural ligand. There were a number of residues affected by the 
interaction between the octanoylated version of human ghrelin and GHS-R1a, most 
notably the octanoyl chain itself, indicating its importance for binding and activating the 
receptor81-82. 
 More recently Hou et al. investigated the interaction between G7039 (agonists 
developed by Genentech in Figure 1.7) and GHS-R1a by means of computational 
studies; homology modelling, molecular docking, molecular dynamics simulations, and 
binding free energy calculation. This investigation included altering the amino acid 
structure of G7039 and its consequences on binding. Glu124 in TM3 was a key residue 
identified in agonist binding and activation of GHS-R1a. One of the binding models 
within this work indicated that pronated amine on the N-terminus of G7039 forms a salt 
bridge with the negatively charged residue Glu124. Other interactions identified was a 
cation- π interaction between the charged amine of G7039 and Phe279, a hydrophobic 
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interaction between the Phe of G7039 and Phe286 and a π-π interaction between the 
aromatic (D2Nal) residue of G7039 and the amide of Asn305. These interactions indicate 
that the first 4 positions are highly vulnerable to change and altering them could lead to a 
loss in binding. This was showed by the removal of these groups in Hou et al.83  
The extensive literature that has been reported on various ligands and their 
interaction with GHS-R1a sets the ground work to further optimizing these ghrelin 
peptidomimetics in order to chemically convert them into useable imaging agents. 
1.10 Radiolabelling Strategy 
One final important step in designing an appropriate molecular probe is to 
determine if the addition of radionuclide can be done either in a direct or indirect method, 
as this can determine the success of the potential imaging agent for industrial production3. 
A direct labeling approach is usually favored, as it requires fewer steps allowing for a 
more efficient synthesis and a less radiochemical decay. This method is done when the 
precursor chemical molecule is synthesized with a designated site for substitution, 
elimination, or insertion of the radionuclide of interest (e.g. the chelation of a metal). This 
also requires the radionuclide to be non-reactive with other sites on the molecule3. In 
contrast, a prosthetic group labeling approach is when a precursor is synthesized that will 
first be reacted to the radionuclide, and then can be coupled or reacted to the molecular 
probe via a linker on the targeting entity. This method is required when the ligand may 
have too many other reactive sites towards the radionuclide that was chosen. Prosthetic 
group labelling requires more steps and can be less efficient. However, this approach is 
used a lot of the time, as to design a molecular probe for direct labeling requires for the 
reactivity of the molecule to be changed for efficient synthesis, and this could cause 
changes in binding affinity for the target3. Both labelling approaches can be seen in 
Figure 1.14 below. Within the scope of the thesis both a prosthetic group and direct 
labelling will be used in order to design the lead imaging candidates.  
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1.11 Development of Heterobivalent and Homobivalent Ligands Targeting the GHS-
R1a Homo-Oligomer  
 G-protein-coupled receptors (GPCRs) until very recently were thought of as 
monomers that are expressed on the surface of both neuronal and non-neuronal cells. 
However, GPCRs have been shown by many to exist as oligomers impacting both their 
pharmacology and physiology84. However, GPCR oligomerization in terms of 
neurotransmission is more accepted by the scientific community and therefore is more 
well studied. This is because neurotransmitter receptors cannot be considered as a single 
unit, but a multimolecular subunits of proteins that lie on the plasma membrane. This idea 
began in the mid-1970s and was shown with the use of radioligand binding assays that 
there was a negative cooperative interaction with the Beta-adrenergic receptor binding 
sites84. Initially it was thought that the ligand was binding to two separate monomeric 
entities; uncoupled or coupled G protein. Then in the 1980s this was further backed up 
with the use of Western blotting and/or coimmunoprecipitation with the Beta-adrenergic 
and muscarinic acetylcholine receptors in both transfected cells and tissues samples 
isolated from the brain85. Techniques such as fluorescence and bioluminescence 
resonance energy transfer (FRET and BRET) have become other accepted methods to 
indicate oligomerization of GPCRs in cells. However, FRET and BRET are common 
techniques to show receptor homo-oligomerization over hetero-oligomerization. When a 
ligand interacts with a GPCR oligomer there can be the occurrence of two independent 
binding sites, with different affinities for the ligand85. Franco et al devised a receptor-
oligomer model that allowed for the quantification of cooperativity and termed this the: 
“oligomer cooperativity index”85. This allows for the measurement in the extent of 
Figure 1.14 – Prosthetic group labelling versus direct labelling strategy in 
radiochemistry. The orange circle is the leaving group (LG), and the red bar is the 
linker 
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binding from one orthosteric center to another in the GPCR oligomer complex. We then 
can consider this as a measure of intermolecular cross-talk that occurs in a receptor 
oligomer. We often see a biphasic binding curve when measuring the affinity of a ligand 
towards a receptor oligomer85. A biphasic curve is due to conformational changes in one 
receptor when the ligand binds altering the state of a neighbouring receptor, and this is 
considered a cooperative mechanism in receptor oligomerization. Cooperativity can 
either be negative or positive during oligomerization of GPCRs86. So far, many have 
targeted GPCR hetero-oligomers with two separate ligands. This approach has a major 
limitation when it comes to designing a novel drug for a receptor oligomer in terms of 
drug dosing and formulation. Knowing that this is a possible mechanism in which a 
ligand can bind and change the active state of a GPCR oligomer, one can develop novel 
heterobivalent and homobivalent ligands that would modulate the signalling in a 
differential fashion when compared to the monomeric receptor86-87. By selectively 
connecting two ligands together by a given linker length one can create a signal ligand 
that will have the same effect as the two ligands separately. The chemical nature of the 
linker can also improve pharmacokinetic and pharmacodynamic properties of a chemical 
probe, such as enhancing solubility, metabolic stability and enhanced affinity. There have 
been many examples in the literature of successful attempts at designing bivalent-based 
ligands88-90. Most recently Lensing and co-workers developed a bivalent ligand that 
targeted the human melanocortin-4 receptor oligomer (hMC4R). This led to a biased 
signalling stimulating cyclic adenosine monophosphate (cAMP, adenylyl cyclase 
pathway) signalling, but minimal activation of b-arrestin signalling88.   
GHS-R1a has potential therapeutic application towards a wide range of diseases 
such as obesity, diabetes, cancer, etc90-94. GHS-R exists in two isoforms: GHS-R1a and 
GHS-R1b. GHS-R1a is activated by its endogenous ligand, ghrelin, to induce growth 
hormone release,88  while GHS-R1b is functionally inactive and has no binding affinity 
for ghrelin95. Along with numerous other GPCRs, GHS-R1a has been shown to form a 
homo-oligomer. In 2005, Holst et al. were the first to propose the homo-oligomerization  
of GHS-R1a. In this study it was shown that, in the presence of the endogenous agonist 
ghrelin, and co-administration of other agonists (GHRPs) acted as a neutral, positive, or 
negative modulators of the GHS-R1a receptor in COS-7 cells transfected with GHS-
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R1a96. Further evidence of GHS-R1a homo-oligomerization was provided by Jiang et al. 
using a HEK293 derived cell line co-transfected with GHS-R1a-green fluorescent protein 
(GFP) and GHS-R1a-Renilla luciferase (rluc)97. The BRET (bioluminescence resonance 
energy transfer) study showed a hyperbolic function of GHS-R1a-GFP/GHS-R1a-rluc 
ratio, suggesting oligomerization rather than molecular crowding. Kern et al. observed a 
FRET signal when CLIP-GHS-R1a and SNAP-GHS-R1a are overexpressed in HEK293 
cell through time-resolved (Tr) FRET measurement, again suggesting the formation of 
the GHS-R1a homo-oligomer98. Leung et al., also confirmed homo-oligomeric GHS-R1a 
in HEK293 cell using BRET and co-immunoprecipitation99. A visual representation of 
the GHS-R1a homo-oligomer docked with the novel homobivalent ligand developed in 
Chapter 6 can be seen in Figure 1.15. In addition, evidence suggested that the GHS-R1a 
receptor has the ability to not only oligomerize with itself but also with other GPCRs, 
including GHS-R1b receptor,100 prostaglandin E2 receptor (EP3-1),101 prostacyclin 
receptor (IP),101 thromboxane A2 receptor (TPα),101 Somatostatin receptor 5(SST5),102 
dopamine receptors (D1 and D2),99,102 melanocortin 3 receptor (MC3),102-103 and serotonin 
2C receptor (5-HT2C)102. The first of these interactions to be observed was with the D1- 
and D2-like dopamine receptors as both of these receptors are coexpressed in a number of 
sites (e.g. brain regions that are linked to food intake and reward behaviours). Kern et al. 
in 2012 was able to demonstrate that when there is a lack of ghrelin circulation in the 
brain, GHS-R1a will oligomerize with D2R leading to anorexigenic effects98. Another 
example in which GHS-R1a oligomerizes with another GPCRs and changes the 
downstream signalling is with MC3R. Rediger et al. demonstrated that in the arcuate 
nuclease GHS-R1a is coexpressed in neurons with MC3R by the use of FRET. Typical 
signalling by means of MC3R is the Gαs pathway causing an accumulation of cAMP104. 
However, when oligomerization occurs with GHS-R1a cAMP accumulation increases by 
2-fold, and GHS-R1a constitutive activity along with ghrelin induced activity cause a 
decrease of intracellular calcium by 40%. And when the MC3R receptor is 
downregulated, this leads to in an increase in GHS-R1a signalling explaining an increase 
in fat mass within a MC3R-/- knockout model104. These are just a few of the examples in 
which GHS-R1a can oligomerize with another receptor and change the downstream 
signalling events leading to different physiological outcomes.  
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Rational design of a bivalent ligand is further discussed in section 6.2.1. Ligands 
that are capable of targeting these receptor oligomers holds great promise as a new class 
of therapeutics, but equally important, are a powerful chemical biology tool for 
understanding the function, mechanism, and disease significance of GPCR oligomers, for 
which there is limited knowledge to date. 
 
Figure 1.15 - Visual representation of the GHS-R1a homo-oligomer docked with the 
homobivalent ligand designed in Chapter 6. This is not the actual interface that 
occurs between the GHS-R1a homo-oligomer   
1.12 Tagging Molecular Probes with Fluorescent Moieties 
 Fluorescently tagged ligands can help us better understand the physiological and 
pathological mechanisms of model cell systems. Cells by their inherent nature are 
complex, and without the appropriate molecular probes it is difficult to interrogate the 
complex cellular structures and gain a deeper insight into molecular interactions, enzyme 
activity, and the many other cellular processes that are occurring every second. The 
ability for using labelled peptides with platforms such as fluorescence energy transfer 
(FRET), bioluminescence resonance energy transfer (BRET), flow cytometry,  and 
fluorescent microscopy (in vitro, in vivo, and ex vivo) allows us to probe the key cellular 
processes involved in human physiology and disease105.  
 Fluorophores work by absorbing light in the ultraviolet or visible range and re-
emit part of their energy as radiation (fluorescence). A longer wavelength is seen within 
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the emitted radiation then the excitation light and this is called the Stokes shift. The 
emission wavelength depends on the wavelength of the excitation light106. Fluorescence 
is highly controlled based on the chemical structure of the fluorophore and many of these 
fluorophores are commercially available. For the purpose of this thesis a sulfo-cyanine5 
dye is used and is commercially available as a pre-activated N-Hydroxysuccinimide 
(NHS) ester in order to couple onto a primary amine of a Lys located on the C-terminal 
portion of a ghrelin ligand in Chapter 2.  
 Conjugating a fluorophore to a peptide is similar to designing a radiolabelled 
peptide probe. The location of the fluorophore addition to the biomolecule is carefully 
considered as to not affect the binding properties of the peptide towards the target. The 
decision to use a certain fluorophore depends on the experimental conditions for the 
particular in vitro, in vivo, or ex vivo application. For example, fluorophores within the 
visible range have an emission between 400 nm and 700 nm (e.g. 7 amino-4-
methylcoumarin (AMC), fluorescein isothiocyanate (FITC), and 5-
carboxytetramethylrhodamine (TAMRA)). These fluorophores are typically seen for uses 
in cellular applications such as confocal microscopy experiments. However, in the case of 
in vivo applications fluorophores in the emission range of 650 nm to 900 nm (near-
infrared – NIR) are required as they will produce less autofluorescence with body 
components such as water and hemoglobin. There are a number of commercially 
available dyes in the NIR range such as the Cyanine dyes, Alexa Fluor dyes, and IR dyes 
that can be used in vivo. All of these commercially available dyes have been chemically 
modified to allow for the conjugation to a target peptide in a variety of ways, including 
click chemistry and amide bond formation107.  
This is the method to design an imaging agent that is almost identical to the PET 
probe (same targeting entity), however it differs by only its imaging modality, providing 
a dual-purpose ligand towards the same target.  
There are many past examples of using peptides conjugated to fluorophores in 
both in vitro and in vivo applications. There has been a series of somatostatin derivatives 
that have been conjugated to NIR dyes in order to perform in vivo imaging of mice 
bearing cells that overexpress the somatostatin receptor-2 (SSTr-2). One of these 
derivatives is the conjugation between octreotate and indotricarbocyanine (ITCC) NIR 
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dye that was able to show high levels of fluorescence in the mouse tumours even after 24 
hours post intravenous (IV) injection107-108.  
 Within our own group there has been a recent publication using a NIR inulin 
optical probe for measuring the glomerular filtration rate (GFR). Inulin is a 
polysaccharide that is considered the clinical gold standard for measuring GFR in order to 
assess the filtering capacity of the kidney and renal function helping to indicate the 
occurrence of chronic kidney disease (CKD). Inulin was conjugated to a Cyanine-7.5 dye 
and used to measure the GFR in a pig model non-invasively109.  
 Within this current work (Chapter 2) I report the design of a ghrelin analogue 
conjugated to a sulfo-cyanine-5 dye that has been shown thus far to image both tissue in 
an in vitro and ex vivo scenario. However, since sulfo-cyanine-5 is a NIR dye with an 
emission maximum at 669 nm, this probe can be used for optical imaging in an in vivo 
scenario.  
  This imaging tool presented in Chapter 2 has the potential to be used in the clinic 
as a marker for GHS-R1a (Figure 1.16). In addition, it could serve as a probe to screen 
for ghrelin expression in a broad array of cancer cell lines and tumour tissues, as well as 
for quantification using flow cytometry techniques.   
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Figure 1.16 - Stabilized fluorescent ghrelin analogue developed in chapter 2 
targeting and visualizing GHS-R1a in an in vitro scenario. DAPI stained blue 
nucleus, Sulf-Cy5 tagged G(1-20) analogue in red. Cells are OVCAR8 stably 
transfected with GHS-R1a  
1.13 Stapling Peptides to Enhance Both Stability and Binding Towards a Target of 
Interest  
Ghrelin is a peptide that is mainly α-helical. This was determined by 2D NMR 
indicating Pro-7 to Pro-21 being helical, and molecular dynamics simulations showing 
the same helical region from Pro-7 to Gly-13110-111. The α-helicity of ghrelin is stabilized 
upon binding to GHS-R1a112. The first five amino acids are essential in binding to GHS-
R1a, shown by the fact that ghrelin(1-5) still retains its affinity to GHS-R1a. Shorter eight 
amino acid ghrelin derivatives have been developed for the purpose of molecular imaging 
and were determined to have similar GHS-R1a affinity compared to ghrelin112-113. 
Ghrelin is therefore an ideal candidate for modification in designing a molecular imaging 
probe113-114.  
The use of natural peptides in various in vitro and in vivo assays is difficult 
because they tend to have lower stability, as well as a high cost of production (usually a 
longer amino acid sequence)115. Shortening a natural peptide is a way to overcome this 
particular problem. Stabilizing H-bonds seen within physiological conditions of natural 
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peptides is drastically reduced when the peptide becomes truncated, as there is a loss in 
alpha helical stabilizing amino acids. These additional physiological interactions also 
facilitate complete binding towards a target of interest115-116, as confirmation is vital for 
ligand recognition116. Many biological processes rely on a secondary helical 
structure112,116. However, there is a high energy cost that is required to generate a 
secondary structure limiting the stability of truncated natural peptides116.  
A possible way to overcome this high energic barrier is by pre-folding, or stapling 
peptides. The truncated peptides are then able to adopt a desired secondary structure to 
increase both stability and biological activity112,116. When choosing location for 
cyclization it is often by means of the positions at i and either i+4 or i+7 as these are 
positioned on the same face of the helical secondary structure. The four common methods 
for constraining a peptide to promote α-helix formation include a lactam bridge, a 
hydrocarbon bridge, a metal-ion clip, or a hydrogen bond surrogate115-116. These 
variations in cyclization can be visualized in Figure 1.17. 
 
Figure 1.17 - 4 common methods of stapling. (A) Lactam bridge, (B) hydrocarbon 
bridge, (C) metal ion clip, and (D) hydrogen bond surrogate (permission granted by 
author)117 
 
These various stapling strategies described above have successfully produced 
cyclic peptides with improved target affinity. However, both the hydrocarbon and lactam 
cyclization method show a greater level of in vivo stability115-118. The lactam bridge is a 
more appropriate method of cyclization for use in a clinical setting due to its natural 
amide bond composition119. This is because when this amide bond becomes cleaved it 
reveals two natural amino acid side chains. There must be careful consideration for the 
location of the staple as to not block the face of the helix that is important in binding 
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towards the target of interest. As well as the amino acids altered to incorporate the staple 
can also affect secondary structure and binding of the ligand towards the given target120. 
‘Staple scanning’ is the preferred method for identifying a peptide sequence that will 
exhibit optimal binding, secondary structure, and stability of the modified ligand121. A 
staple scan is performed by modifying each residue not essential for binding and 
measuring the peptide’s new affinity and secondary structure121. The staple is moved 
along the peptide through the modification of the amino acids in the i and either i+4 or 
i+7 positions in order to find its optimal location. This method will allow for the best 
staple candidate to be identified and further tested. It has been shown that using a 
glutamic acid residue in the i position and a lysine residue in the i+4 or i+7 position 
provides peptides with maximum helicity and reversing the placement of these amino 
acids decreases helicity122-125 (Figure 1.18). This alteration is thought because reversing 
the order could change the dipole direction of the amide bonds with respect to the dipole 
direction of the helix.   
 
Figure 1.18 - Synthesis route to forming a lactam bridge with Glu in the i position 
and Lys in the i + 4 position 
 
Within Chapter 2 of this thesis a staple scan is reported for ghrelin(1-20) 
analogues starting in position four and working the staple all the way to position 19, in 
order to identify the optimal location for the staple based on alpha helicity and binding to 
GHS-R1a (Figure 1.19). This optimization provided a cyclic ghrelin analogue with 
greater binding affinity towards GHS-R1a as well as having improved stability.  
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Figure 1.19 - Stabilizing ghrelin(1-20) analogues with a lactam bridge (i,i+4 
or i,i+7) in order to improve the secondary alpha-helical structure and maintain 
binding towards GHS-R1a 
1.14 Scope of this Thesis   
GHS-R1a is expressed in many human tissues (most notably the hypothalamus) 
and causes an increase in appetite upon activation by its endogenous ligand; ghrelin. 
GHS-R1a is differentially expressed in malignant compared to benign tumours (e.g. 
prostate). Therefore, there is an interest in developing GHS-R1a-targeted peptides as 
novel drugs to modulate signaling (e.g. cancer cachexia and obesity) and image receptor 
(e.g. disease diagnosis and progression). The focus of this thesis is the development of 
ghrelin analogues that act as agonists when targeting GHS-R1a. 
The first of these analogues was the development of a stabilized ghrelin 1 to 20 
analogue by means of a lactam bridge (Chapter 2). The lead analogue with a sulfo-
cyanine-5 (Cy5) conjugated to the C-terminal lysine (cyclo-12, 16(H-
GSXFLSPEHQR[EQQRK]ESKK(Sulfo-Cy5)-NH2)) has an [θ]222/[θ]208 ratio of 0.84, 
and an IC50 of 1.0 nM. This probe was highly successful in imaging GHS-R1a by 
fluorescent microscopy in both cell lines and tissue samples from different disease states 
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(cancer, cardiovascular disease, and stroke) associated with the overexpression of GHS-
R1a. This probe has the potential to image the receptor in an in vivo scenario due to the 
high emission maximum of sulfo-Cy5.  
Chapters 3 to 6 focussed on the development of ghrelin peptidomimetic analogues 
with applications driven to both therapy and imaging. The initial compound G7039, a 
peptidomimetic ghrelin agonist (IC50 5.2 nM/EC50 0.18 nM) underwent structure-activity 
relationship (SAR) studies to generate ligands and positron emission tomography (PET) 
agents to study/image the GHS-R1a. The first generation peptidomimetic (Chapter 3) [1-
Nal4,Lys5 (4-fluorobenzoyl-4-FB)]G7039 (IC50 69 nM/EC50 1.1 nM) was radiolabelled 
with 18F in a decay-corrected radiochemical yield of 48%, radio purity of ≥ 99%, and 
molar activity of ≥ 34 GBq/μmol. Despite its success as a PET imaging agent, its 
solubility (cLogP = 8.27) and binding affinity (IC50 = 69 nM) needed improvement.   
The second generation peptidomimetic (Chapter 4) [Tyr4,Lys5(2-fluoropropionyl 
(2-FP)]G7039 (IC50 0.28 nM/EC50 0.12 nM) had improved binding (IC50 = 0.28 nM) and 
lipophilicity (cLogP = 4.36). Labeling of this ligand was low yielding, however two 
peptides from this project were identified as partial agonists.  
The third generation (Chapter 5) required a modified prosthetic group (2-FP to 
ammonium methyltrifluoroborate-AMBF3) in order to radiolabel in higher yields, 
resulting in [Tyr4,Lys5(AMBF3)]G7039 (IC50 0.85 nM). This compound was 
radiolabelled in a single step, with a decay-corrected radiochemical yield of 28%, 
radiopurity of ≥ 99%, and molar activity ≥ 15 GBq/μmol. Currently this lead compound 
is ready to be evaluated in an in vivo scenario.   
Finally, the fourth generation (Chapter 6), a homobivalent G7039 ligand (IC50high 
0.43 nM:IC50low 0.42 pM /EC50 1.8-2.1 nM) was found to bind to the GHS-R1a homo-
oligomer and was designed to study GHS-R1a homo/hetero-oligomerization. This 
homobivalent ligand when targeting the GHS-R1a is able to change the downstream 
signalling compared to the natural signalling mechanisms seen when activating the 
monomeric version of GHS-R1a. Four generations of unique peptidomimetics eliciting 
differences in receptor binding and activation have been synthesized with potential 
applications towards imaging and therapy (Figure 1.20).  
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Overall several ghrelin analogues have been developed in this thesis that have 
applications both driven towards imaging and therapy.  
 
Figure 1.20 - The various chemical tools developed within this thesis that all have a 
heavy appetite for GHS-R1a 
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Chapter 21 
 
Stapled Ghrelin Peptides as Fluorescent Imaging Probes 
2.1 Introduction 
Ghrelin was first discovered in 1999 by Kojima et al., when it was identified to be 
the endogenous ligand of the growth hormone secretagogue receptor type 1a (GHS-
R1a)1,2. It was originally reported that GHS-R1a was found within the pituitary and 
hypothalamus2. GHS-R1a is a seven trans-membrane α-helical G-protein coupled 
receptor with an extracellular binding domain, and its activation has been shown to 
increase cellular proliferation in prostate cancer through the ERK1/2 MAPK pathway3–6. 
The overexpression of GHS-R1a increases the motile phenotype in astrocytomas, in 
which increased GHS-R1a expression is correlated with a higher tumour grade 7. 
Overexpression of GHS-R1a has more recently been demonstrated in some ovarian 
epithelial carcinomas, a disease with poor prognosis due to the late stages in which it is 
usually diagnosed8,9.  
Human ghrelin is a 28-amino acid peptide that is derived from a 117- amino acid 
sequence (preproghrelin) through post-translational modifications, terminating with the 
octanoylation of Ser-3 by ghrelin O-acyl transferase (GOAT) to produce the active 
form3,10. This is the only known instance of a peptide being post-translationally modified 
with a fatty acid, and it is required for its binding to and activating GHS-R1a1,11,12. 
Ghrelin is a peptide that is mainly α-helical, with 2D NMR studies showing Pro-7 to Pro-
21 being helical, and molecular dynamics simulations showing that there is a helical 
region from Pro-7 to Gly-1313,14. The α-helicity of ghrelin is stabilized by its natural 
environment in addition to its binding to GHS-R1a 15. The first five amino acids have 
been shown to be key in binding to GHS-R1a, as ghrelin(1-5) still retains its affinity to 
the receptor16. Recently, ghrelin derivatives have been developed for the purpose of 
molecular imaging and were determined to have similar GHS-R1a affinity as that of the 
endogenous ligand, even when truncated to eight amino acids length16,17.  This makes it 
                                               
1 Lalonde, T.; Shepherd, T. G.; Dhanvantari, S.; Luyt, L. G. Stapled Ghrelin Peptides as 
Fluorescent Imaging Probes. Pept. Sci. 2018, e24055, 1–9. (Special Canadian Issue). 
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an ideal candidate for modification for the purpose of imaging GHS-R1a using 
fluorescence microscopy18,19.  
Using natural peptides within in vitro/in vivo assays is challenging due to the 
typically low stability of a linear peptide, as well as a high cost of production20. To 
increase the stability of ghrelin and attempt to decrease production costs, the amino acid 
sequence can be shortened. However, truncated peptides are unlikely to retain their 
secondary structure in physiological conditions due to the decrease in stabilizing 
hydrogen bonding from the backbone. These interactions also facilitate complete 
binding21,22, as conformation is vital for ligand recognition15.  Helical structures play an 
important role in many biological processes15,22; however, the energy required to generate 
this conformation is very high, which limits the structural stability of truncated 
peptides23.  
Pre-folding, or stapling the peptide assists in overcoming this energy barrier. This 
enables the truncated peptides to adopt the desired secondary structure, potentially 
increasing its biological activity and reducing susceptibility to hydrolysis15,25. Cyclization 
typically occurs at positions i and either i+4 or i+7 as they are positioned on the same 
face of a helix 22,24. There are four commonly used methods of constraining a peptide and 
promoting α-helix formation: a lactam bridge, a hydrocarbon bridge, a metal-ion clip, or a 
hydrogen bond surrogate20,22. 
All of these stapling strategies have successfully produced cyclic peptides with 
increased target affinity. Peptides constrained with hydrocarbon and lactam bridges 
typically having greater stability in vivo21,22. The lactam bridge is predicted to be more 
appropriate for use in therapeutics due to its natural amide bond composition25. The 
location of a staple is an important consideration in constrained peptides, as improper 
choice may block one face of the peptide 23. ‘Staple scanning’ is the preferred method for 
identifying a peptide sequence that will exhibit optimal agonist properties21. This is done 
by manipulating each residue not essential for binding, and measuring the peptide’s 
affinity and secondary structure21. This method will allow for the best staple candidate to 
be identified and further tested. The use of a glutamic acid residue in the i position and a 
lysine residue in the i+4 or i+7 position appear to give peptides maximum helicity, as 
reversing the placement of these amino acids results in a decrease in helicity26.  
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The aim of this project was to create an improved fluorescently-tagged ghrelin-
peptide as a novel GHS-R1a detection tool, while gaining a better understanding of the 
secondary structure of ghrelin as the natural ligand for GHS-R1a. Only the first 20 amino 
acids of ghrelin were used in this study, as these amino acids demonstrated α-helical 
character based on 2D NMR studies13,14, while the 8 amino acids at the C-terminus of 
ghrelin are predicted to be a random coil. In an attempt to recover α-helicity in the 
truncated peptide, lactam bridges were created in the i, i+4 and the i, i+7 positions with a 
staple scan utilizing amino acids 4 to 19 of ghrelin(1-20) being performed. Each peptide 
in this library was analyzed by circular dichroism (CD) spectroscopy and competitive 
receptor binding assay in order to determine α-helical character and binding affinity to 
GHS-R1a, respectively.  
2.2 Results and Discussion  
GHS-R1a has been shown to have increased expression in 32% of patient samples 
from ovarian cancer tissue27,28. We propose that an improved ghrelin imaging probe, for 
fluorescence imaging of ovarian cancer cells or tissue samples through the use of chemi-
staining or confocal microscopy, can be developed through the creation of stapled ghrelin 
analogues. Previous studies have shown that truncated fluorescently labelled ghrelin 
analogs, where the fluorescent dye is attached through a Lys19 ε-amine of a modified 
ghrelin(1-19), provides a fluorescent probe with comparable GHS-R1a affinity to that of 
natural ghrelin(1-28) and was demonstrated to bind to GHS-R1a in cardiac tissues18,19. 
This imaging probe was also used to distinguish between prostate cancer and benign 
hyperplasia in ex vivo prostate tissue29 and for in vivo biodistribution analysis30. There is 
also a report indicating that a DOTA chelator attached to Lys19 can be used to form a 
gallium-68 radiolabelled ghrelin analogue for PET imaging31. These previous analogues 
have reduced binding affinity towards GHS-R1a.  
To establish a baseline and enable measurement of the effect synthetic staples 
have on α-helicity and binding to GHS-R1a, the natural ghrelin(1-20) sequence was 
synthesized by standard Fmoc solid-phase peptide synthesis (SPPS). In order to 
incorporate the unnatural n-octanyl side chain at position three, diaminopropionic acid 
was used. This allows for the coupling of octanoic acid via an amide linkage, which 
offers increased stability and ease of synthesis over the natural ester linkage (Figure 2.1).  
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Figure 2.1 - Depiction of ghrelin(1-20) indicating the region that is predicted to be 
coiled or part of an a-helix. X indicates the unnatural amino acid, diaminopropionic 
acid, which was used in order to attach the n-octanyl side chain at the third position. 
The dashed line shows the region of the sequence in which i, i+4 or i, i+7 staples 
were systematically placed 
 
The lactam bridge in the ghrelin(1-20) derivatives was formed utilizing glutamic 
acid in position i and lysine in position i+4 or i+7. To synthesize the stapled peptides, the 
linear peptide was first synthesized by SPPS, incorporating allylester-protected glutamic 
acid and alloxycarbonyl-protected lysine residues in the i and i+4 or i+7 positions 
respectively. These protecting groups were used because they can be selectively 
deprotected using a palladium (0) catalyst under basic conditions, allowing for lactam 
bridge formation without removing any other protecting groups or cleaving the peptide 
from the resin. After completing global deprotection and cleaving the peptide from the 
resin, the peptides were purified and characterized by LC-MS. Both i, i+4 (Table 2.1) 
and i, i+7 (Table 2.2) staple libraries were synthesized to observe any staple-related 
differences in helicity and binding when compared to the linear sequence (1).  
 
  
G S X F L S P E H Q R V Q Q R K E S K K
NH
O
Coil Helix
Location of staples 
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Table 2.1 - Sequences of ghrelin(1-20) containing (i, i+4) staples. Mean residue 
ellipticity at 222 nm ([θ]222) and ratios of mean residue ellipticities at 222 and 208 
nm ([θ]222/[θ]208) at 20°C. Competitive binding affinity data (IC50) was determined 
using HEK293 cells expressing GHS-R1a and [125I]ghrelin 
 
 
  
 
 
53 
 
Table 2.2 - Sequences of ghrelin(1-20) containing (i, i+7) staples. Mean residue 
ellipticity at 222 nm ([θ]222) and ratios of mean residue ellipticities at 222 and 208 
nm ([θ]222/[θ]208) at 20°C are included to demonstrate helicity. Competitive binding 
affinity data (IC50) was determined using HEK293 cells expressing GHS-R1a and 
[125I]ghrelin 
 
 
 
To determine the degree of α-helicity, all compounds were analyzed by CD 
spectroscopy in either deionized water or 40% TFE, which is used to stabilize the α-helix 
to observe the maximum possible helicity for each peptide32. To analyze the degree of a-
helicity induced by these staples, the mean residue ellipticity at 222 nm ([θ]222) and the 
ratio of the mean residue ellipticities at 222 and 208 nm ([θ]222/[θ]208) were utilized. The 
unstapled peptide (1) has the CD spectra characteristic of a random coil, with a maximum 
at 220 nm and a minimum at 190 nm. This was expected due to the lack of stabilizing 
factors. When the i, i+4 staples are introduced, the α-helicity increases for all sequences, 
with greater helicity (represented by a smaller [θ]222 value and a [θ]222/[θ]208 ratio nearing 
1.00) observed in peptides with the staple introduced near the C-terminus. Compounds 7, 
9, and 10 exhibited the greatest helicity in both deionized water and 40% TFE. The 
observed differences in helicity could be due to differences in amino acid sequence. The 
region in between the glutamic acid and the lysine in compounds 9 and 10 is rich in 
glutamine, a helix-stabilizing residue, which may decrease the energy barrier for helix 
formation33.  
The increase in helicity induced by the i, i+7 staples is not as great relative to the 
increase generated by the i, i+4 staples. This could be due to the increased distance 
between the residues that generate the staple, which could be increasing the strain on the 
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cyclic peptide and discouraging helix formation. There is currently little agreement in the 
literature about the most effective ring size of the staple, as the effectiveness of stapling is 
very case dependent33; it is possible that in this case, the ring size of the i+7 staple is too 
great. Regardless, compounds 18, 19 and 22 all show relatively large increases in helicity 
in both water and 40% TFE. Notably, compound 16 does not exhibit any appreciable 
increase in helicity; the proline residue adjacent to the glutamic acid could cause this. 
Proline is a helix destabilizing residue, as it causes more strain within the backbone, and 
therefore could have countered the helix-promoting effects of the staple33. 
 
 
Figure 2.2 - CD spectra of linear unstapled sequence of ghrelin (1-20) (1) and the (i, 
i+4) (10) and (i, i+7) (18) peptides that showed the greatest increase in helicity 
  
The peptides were tested in 25% human serum, to determine if the cyclization 
provides improved stability to enzymatic hydrolysis. The linear sequence (1) saw a 40% 
degradation of the peptide within the first four hours, while both 10 and 18 were stable 
for 24 hours. This indicates that the presence of the staple has improved the stability of 
this truncated sequence, which plausibly is due to the increase in helicity.  
The unstapled [Dpr3-octanoyl]ghrelin(1-20) (1) peptide was used as a reference in 
order to compare how well the introduced staples improved the binding affinity of the 
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truncated sequence. To test the affinity of these peptides towards GHS-R1a, a 
competitive binding assay was performed with both unstapled and stapled peptides, with 
[125I] human ghrelin as the competitor. The IC50 for the i, i+4 and i, i+7 staples can be 
seen in Table 2.1 and Table 2.2, respectively.  The greatest binding affinity is observed 
in peptides with staples close to the C-terminus. In general, binding affinity is lower than 
the linear peptide when the staple is within the first 7 amino acids, and greater when in 
the 8th position or further. These results correlate to those of the CD spectra, as the 
binding improves with increased α-helicity. This relates to earlier findings that have 
noted that the first 5-8 amino acids are critical for receptor binding17. Therefore, 
modifying these positions to incorporate a lactam bridge would interfere with receptor 
recognition.  
As with the helicity data, the binding affinities of the i, i+7 staples were lower 
than that of the i, i+4 staples and the unstapled ghrelin(1-20) (1), with the exception of 18 
and 20. This could be due to the decrease in helicity relative to the i, i+4 staples; it is also 
possible that the staple could be blocking the binding surface or forcing the peptide into a 
conformation that is incompatible with the receptor binding site. 
 Based on the helicity data and the IC50 values, one compound from the i, i+4 (10) 
and i, i+7 (18) staple libraries was chosen (Table 2.3). These compounds exhibited the 
optimal combination of α-helicity and receptor binding. 
Table 2.3 - Summary of IC50 (nM) and [θ]222/[θ]208 values (in deionized water) for 
the best compounds from the i, i+4 and i, i+7 staple libraries. The values of the 
unstapled sequence are included for reference 
 
 
 
To identify the effect of staple orientation on the binding of the peptides to GHS-
R1a, a helical wheel projection was used. This will model the spatial location of the i, i+4 
and i, i+7 staples in peptides 10 and 18, and will facilitate comparison by showing the 
positioning of amino acid residues, assuming that the ghrelin(8-20) region forms a perfect 
helix (Figure 2.3). While it is likely that this region is not perfectly helical, this is the 
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portion of natural ghrelin that is predicted to be helical13,14.  Both the i, i+4 and i, i+7 
staples fall on the same face of the helix, indicating that the positioning of the staple may 
be imperative for binding.  
 
 
Figure 2.3 - Helical wheel projection of ghrelin(8-20). Indicated on the image are the 
locations of the staple in compound 10 (i ,i+4) and 18 (i, i+7). This projection 
assumes that ghrelin(8-20) forms a perfect helix 
 
2.2.1 Modifying the best cyclic peptides for use in imaging GHS-R1a using confocal 
microscopy 
The lead peptides identified from the staple scan (10 and 18) were labelled with a 
Sulfo-Cyanine 5 dye (Cy5) by forming an amide bond with the side chain of Lys20 
(Table 2.4). This allowed for the dye to be as removed as possible from the binding areas 
of the peptide, as well as allowing for facile attachment of the dye. Sulfo-Cy5 was chosen 
due to its favourable properties such as its high solubility in water and high extinction 
coefficient (271000 M-1 cm-1 at 646 nm).  
 
Table 2.4 - Sequences of linear, (i, i+4), and (i, i+7) stapled ghrelin(1-20) peptides 
with a sulfo-cyanine5 dye attached to Lys19. Mean residue ellipticity at 222 nm 
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([θ]222) and ratios of mean residue ellipticities at 222 and 208 nm ([θ]222/[θ]208) at 
20°C are included to demonstrate helicity. Binding affinity data (IC50) is also 
included 
 
 
  
These labelled peptides were analyzed to determine whether the Cy5 dye had an 
effect on secondary structure and ability to bind GHS-R1a. Interestingly, the α-helicity of 
the linear peptide with Cy5 (23) was greater than that of 1. This was unexpected, as the 
addition of Cy5 to the lead i, i+4 and i, i+7 sequences (24 and 25, respectively), did not 
elicit the same increase in helicity (Figure 2.4). 
 
Figure 2.4 - CD spectra of linear unstapled ghrelin(1-20) (1), the lead (i, i+4) stapled 
sequence (10), and the lead (i, i+7) stapled sequence (18) compared to their 
respective sequences containing the Sulfo-Cy5 dye (23-25) 
 
 However, this increase in helicity of the Cy5-labelled linear peptide did not 
correlate with a significant change in binding to GHS-R1a. All labelled sequences had 
similar, or slightly improved, binding to GHS-R1a compared to the unlabelled sequences. 
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Considering the improved stability data for 10 and 18, this suggests that these probes 
have both improved GHS-R1a affinity and stability as compared to linear dye-ghrelin 
entities. 
 These compounds were then tested in a group of selected ovarian cancer cell 
lines. These cell lines were previously assessed for their relative GHS-R1a expression 
level by confocal microscopy using established linear dye-ghrelin probes (Figure 2.S1). 
Two cell lines (HEYA8 and OvCar3) express detectable endogenous GHS-R1a, while 
one cell line (OvCar8) had nearly undetectable expression. Thus, OvCar8 cells were 
stably transfected to express GFP-tagged GHS-R1a to generate a high expression line. 
The OvCar8-GHS-R1a cell line also served as a positive control to verify that these 
peptides were specifically binding to GHS-R1a and no other targets at the cell surface. 
Compounds 23-25 were incubated with the cells in order to identify if the binding assay 
results positively correlated with the ability of the peptides to bind to GHS-R1a in situ 
(Figure 2.5). 
 
Figure 2.5 - Confocal microscopy of compounds 23-25 incubated with various 
ovarian cancer cell lines expressing GHS-R1a. One cell line (OvCar8) does not 
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express GHS-R1a, one cell line (OvCar8-GHS-R1a+/+) was stably transfected with 
GHS-R1a, and two cell lines (HEYA8 and OvCar3) have naturally high expression 
of GHS-R1a. Cy5 signal can be seen in red and DAPI can be seen in blue 
  
The i, i+4 sequence (24) exhibited increased binding to GHS-R1a in vitro 
compared to the linear sequence (23) and the i, i+7 sequence (25). This was expected, as 
23 and 25 have a lower IC50 value than 24. This difference is observed with the 
endogenous GHS-R1a expression in HEYA8 and OvCar3 cells, but most evident within 
the OvCar8 cells-GHS-R1a overexpressing cell line when compared with parental 
OvCar8 cells. Also compounds 23, 24, and 25 were co-incubated with a 10x 
concentration of compound 1 in each of the cell lines presented in Figure 5. This blocking 
study confirmed specificity towards GHS-R1a (Figure 2.S2 and 2.S3). 
 
 
2.3 Conclusions 
A staple scan of ghrelin(1-20) utilizing both i, i+4 and i, i+7 lactam bridge staples 
was performed and two peptides (10 and 18) were identified with superior qualities, in 
terms of increased helical content and greater binding affinity to GHS-R1a compared to 
the linear sequence. Modification of the lead sequences and the linear sequence with a 
Sulfo-Cy5 dye was then done in order to identify a better tool for fluorescence imaging of 
GHS-R1a. The dye-labelled version of the i, i+4 stapled peptide (24) had greatly 
increased affinity for GHS-R1a with similar helical content. Compound 24 was shown to 
bind to GHS-R1a in vitro when expressed by ovarian cancer cell lines that are stably-
transfected with GHS-R1a, as well as cells with elevated endogenous expression. This 
potentially allows 24 to act as a specific and sensitive imaging tool for the identification 
and quantification of GHS-R1a among ovarian cancer cell lines, and potentially tumours. 
We propose that compound 24 could be further tested as an improved stain to aid in 
differentiating between malignant and benign tissue. This imaging tool therefore has the 
potential to be used in the clinic as a marker for GHS-R1a, a biomarker of aggressive 
malignancy within ovarian, prostate, and other cancer tissues29. In addition, compound 24 
could serve as a probe to screen for GHS-R1a expression in a broad array of cancer cell 
lines and tumour tissues, as well as quantification using flow cytometry techniques.  
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2.5 Materials and Methods 
2.5.1 General Information 
All reagents were obtained from the commercial suppliers and used without 
further purification. Fmoc-protected amino acids, HCTU, HATU, and Rink amide 
MBHA resin (4-(2’,4’-dimethoxyphenyl-(9-fluorenylmethoxycarbonyl)-aminomethyl)-
phenoxy-acetamidonorleucyl-4-methyl benzhydrylamine resin) were obtained from 
ChemImpex. Tetrakis(triphenylphosphine)palladium(0), and phenylsilane were obtained 
from Sigma-Aldrich. All solvents were obtained from Fischer Thermo-Scientific. Sulfo-
Cyanine-5 NHS Ester was obtained from Lumiprobe.  
2.5.2 Solid-Phase Peptide Synthesis 
Fmoc-based solid-phase synthesis was carried out manually and automatically 
using a Biotage® Syro Wave™ automated peptide synthesizer. Synthesis was done on a 
0.1 mmol scale with 0.52 mmol/g Fmoc-Rink amide MBHA resin and a 3-fold excess of 
the protected amino acids. The resin was allowed to swell in DCM (2.0 mL, 15 min) and 
then solvent was removed. The resin was then rinsed with DMF (1.0 mL, 1 min); after 
removal of the solvent, Fmoc deprotection was performed by adding a solution of 20% 
piperidine/DMF (1.5 mL) to the resin and vortexing for 5 minutes. The resin was then 
washed three times with DMF (2.0 mL, vortex 30 sec) and the resin was vortexed for 15 
min with 20% piperidine/DMF (1.5 mL). The resin was then washed with DMF six times 
to remove any unreacted products (2.0 mL, vortex 30 sec). A Kaiser test was performed 
after the Fmoc removal to verify the presence of a free primary amino group. The desired 
Fmoc-protected amino acid (0.3 mmol) and the coupling reagent HCTU (0.3 mmol) was 
dissolved in DMF (1.5 mL) and added to the resin. The mixture was vortexed for 30 
seconds and then DIPEA (0.6 mmol) was added to the mixture and was vortexed for 1 
hour. This deprotection/amino acid coupling cycle was repeated until the desired amino 
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acid sequence was obtained. After the final amino acid was coupled, the resin was 
washed 3 times with DMF (2.0 mL, vortex 30 sec) and then 3 times with DCM (2.0 mL, 
vortex 30 sec), dried under vacuum, and stored in the freezer at -20°C. The removal of 
the final Fmoc protecting group on the N-terminus was achieved using the previously 
described procedure.  
To determine if the correct peptide has been synthesized, a microcleave was 
performed before full cleavage from the resin. A small amount of resin (<5 mg) was 
added to a small peptide vessel and a solution of 95% trifluoroacetic acid/2.5% 
triisopropylsilane/2.5% water (500 μL) was added. The mixture was vortexed for 3-4 
hours, and the resulting liquid was precipitated with cold tert-butyl methyl ether (TBME) 
(2 mL). The precipitate was centrifuged (3000 xg for 10 min), and the mother liquor was 
decanted. The pellet was dissolved in water (2 mL), frozen, and lyophilized. If the correct 
peptide was synthesized as determined by analytical HPLC/MS, then a full cleave was 
performed. The procedure for full cleaves identical to the microcleave procedure: a 
solution of 95% trifluoroacetic acid/2.5% triisopropylsilane/2.5% water (3 mL) was 
added to the resin and vortexed for 4-6 hours. The solution was drained, precipitated in 
TBMe (20 mL) and centrifuged (3000 xg for 10 min). The mother liquor was decanted, 
and the pellet was dissolved in water (20 mL) and lyophilized to obtain the crude fully 
deprotected peptide. 
2.5.3 Kaiser Test 
To qualitatively determine if there is free amine present (i.e. after a Fmoc-
deprotection, amino acid coupling, or alloc/allylester deprotection), a Kaiser test was 
performed. A small amount of resin (<5 mg) was placed in a small test tube. To the test 
tube, solutions of Phenol:EtOH (8:2 v/v), 0.001M KCN:pyridine (2:98 v/v) and ninhydrin 
in EtOH (5% w/v) were added. The test tube was heated to 70°C and the presence of a 
free amine was indicated by the resin beads turning blue. The lack of free amine was 
indicated by the presence of clear/yellow resin beads. 
2.5.4 Deprotection of Allyloxycarbonyl (Alloc) and Allylester (OAll) Protecting Groups 
Selective deprotection of the allyloxycarbonyl and the allylester protecting groups 
was accomplished by adding DCM (4.5 mL) to the resin-bound peptide and shaking 
gently for 10 minutes. After addition of phenylsilane (24 equiv.), the peptide vessel was 
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flushed with nitrogen and allowed to react for 5 minutes. Then, 
tetrakis(triphenylphosphine) palladium (0) (0.1 equiv.) was added to the mixture and the 
peptide vessel was again flushed with nitrogen, and the reaction was allowed to proceed 
for 10 minutes. Next, the peptide-resin was washed with DCM four times (1.5 mL), 
followed by a series of washings with 1.5 mL of DCM, DMF, MeOH, DMF, and DCM 
(30 sec each).  
2.5.5 Lactam Bridge Formation 
After the resin-bound peptide was selectively alloc- and allylester-deprotected, 
HATU (3 equiv.) was dissolved in DMF (1.5 mL) and allowed to vortex for 30 seconds. 
DIPEA (6 equiv.) was then added to the peptide vessel in order to form lactam bridge and 
the reaction was vortexed for 2 hours. Final washings with DMF and DCM (2.0 mL, 3 x 
30 sec each) were performed to remove any residual reactants. 
2.5.6 4-Methyltrityl (Mtt) Deprotection  
Selective deprotection of the 4-methyltrityl (Mtt) protecting group was 
accomplished by swelling the resin in DCM (3 mL) for 15 minutes. The DCM was then 
drained and a cocktail of 95% DCM, 4% TIPS, and 1% TFA was added to the resin (2 
mL). The resin was then vortexed for 2 minutes followed by a thorough rinse with DCM. 
This addition of the cocktail and vortexing was done 10 times, or until the yellow colour 
was no longer seen. 
2.5.7 Coupling of Octanoic Acid 
After the Mtt protecting group has been removed, octanoic acid was coupled to 
the modified serine residue in the third position. This was accomplished by adding 
octanoic acid (0.3 mmol) and the coupling reagent HATU (0.3 mmol) dissolved in DMF 
(1.5 mL) to the resin. This mixture was vortexed for 2 hours, and the resin was then 
washed 3 times with DMF (2.0 mL, vortex 30 sec) and 3 times with DCM (2.0 mL, 
vortex 30 sec), then dried under vacuum. 
2.5.8 Purification of RP-HPLC/ESI-MS 
Peptides were analyzed using a reverse-phase analytical HPLC column (Agilent 
Zorbax SB-C8 column 4.6 x 150 mm, 3.5 μm). This system was equipped with a Waters 
600 136 controller, Waters Prep degasser, and Waters Masslynx software (version 4.1). 
Employed mobile phases were 0.1% TFA in deionized water (eluent A) and 0.1% TFA in 
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acetonitrile (eluent B). The flow rate was set at 1.5 mLmin-1 over 15 minutes. The 
column eluate was monitored using a Waters 2998 Photodiode array detector set at 220 
nm, 254 nm and 400 nm. Peptides were purified using a reverse-phase preparative HPLC 
column (Agilent Zorbax SB-C18 column 21.2 x 150 mm, 5 μm) on the same system 
mentioned above. The detection method and eluents were the same was mentioned above 
for the analytical system and the flow rate was set at 20 mLmin-1. The collected fractions 
were then lyophilized to a solid and analyzed by ESI-MS. Purity of final products was 
determined by analytical RP-HPLC (200-800 nm).  
2.5.9 Circular Dichroism (CD) Spectroscopy 
CD spectra were obtained on a Jasco J-810 spectropolarimeter and recorded in the 
range of 180-260 nm. Peptide solutions were prepared with a 0.1 M phosphate buffer 
solution to a concentration of 0.5 mM. The measurements were performed in quartz 
cuvettes with a path length of 1 mm and a scanning speed of 10-50 nm/min. Five 
individual data points were averaged by the instrument to obtain reported CD spectra. 
The measurements were carried out at 20ᴼC. A blank solution of 0.1 M phosphate buffer 
solution was run before every measurement in order to correct for any UV interference 
from the buffer. 
2.5.10 Receptor Ligand Binding Assay 
Competitive ligand binding assays were performed in triplicate using 
HEK293/GHS-R1a cells and [125I]Ghrelin as the competitive ligand, as previously 
described17–19. Receptor binding affinities were calculated as IC50 values as previously 
described17–19. In brief HEK293T cells were transiently transfected with GHS-R1a for 48 
hours by means of calcium phosphate. Post transfection cells were harvested by 
membrane fragmentation at 50, 000 g and stored at -80oC at 2 million cells per vial. The 
day of the experiment cells were thawed, and a complete vial was used per binding assay.  
2.5.11 Transfection of OvCar8 with GFP-GHS-R1a 
The OvCar8 human ovarian cancer cell line (ATCC) was maintained in RPMI 
medium (Wisent) supplemented with 10% fetal bovine serum (FBS; Wisent). Cells were 
seeded into 6-well tissue culture plates (Sarstedt) at a density of 1.5 x 105 cells per 35-
mm well. The following day, the culture media were removed and replaced with 
OptiMEM (Invitrogen) containing 10% FBS, and cells were transfected with 0.5 µg 
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pCMV6-GHS-R1a-EGFP plasmid using LipofectAMINE 3000 (Invitrogen) as per 
manufacturer’s instructions. Forty-eight hours later, cells were trypsinized and expanded 
into 4 separate 100-mm plates containing RPMI/10% FBS media. Stable clones were 
selected in 400 µg/ml G418 (Wisent) and maintained (in the same concentration of G418 
for 7 to 10 days). GFP-positive colonies were visualized by indirect fluorescence using a 
Leica DMI 4000B inverted microscope, isolated using cloning rings, and transferred to 
24-well plates containing RPMI/10% FBS. 
2.5.12 Confocal Microscopy 
OvCar3, HEYA8, OvCar8 and OvCar8 cells stably transfected with GHS-R1a 
(OvCar-GHS-R1a) were trypsinized and seeded onto coverslips at a density of 75000 
cells/well. The following day, media were removed and replaced with serum-free RPMI 
containing 0.1 µM of compounds 23, 24, and 25 and incubated at 37°C for 1 hour. Cells 
were then washed three times with phosphate buffered saline (PBS), fixed with 4% 
paraformaldehyde in PBS and mounted onto slides containing Pro-Long Gold Antifade 
mounting medium with DAPI. Images were acquired using an Olympus FluoView FV 
1000 confocal microscope.   
Blocking experiments were conducted using OvCar8-GHS-R1a cells. Cells were 
suspended in serum-free RPMI and incubated with 0.1 µM of compounds 23, 24, and 25, 
together with a 10-fold excess of compound 1, at 37 °C for one hour. Cells were washed 3 
times with PBS, reseeded onto coverslips, cultured in RPMI and allowed to adhere. Cells 
were washed with PBS, fixed with 4% formaldehyde in PBS and mounted onto slides. 
Images were then acquired as described above.   
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Chapter 2 Supplementary Information 
 
Peptide Characterization Tables 
 
Supplementary Table 2.1 - Characterization of synthesized unstapled truncated 
Ghrelin(1-20) (Where X is modified serine residue with an octanyl side chain) 
 
 
Compoun
d 
Sequence [M+3H]3+ Purit
y 
(%)* 
Yiel
d 
(%) 
Expected 
m/z 
Observed m/z 
1 GSXFLSPEHQRVQQR
KESKK-NH2 
620.8769 620.8730 >99 15 
 
 
Supplementary Table 2.2 - Characterization of synthesized i, i+4 lactam stapled 
truncated Ghrelin 1-20 (Where X is modified serine residue with an octanyl side 
chain) 
 
Compoun
d 
Sequence [M+3H]3+ Purit
y (%) 
Yiel
d 
(%) 
Expecte
d m/z 
Observe
d m/z 
2 H-(cyclo-4, 8)-
GSX[ELSPK]HQRVQQRKESKK
-NH2 
815.170
6 
815.8046 >99 3 
3 H-(cyclo-5, 9)-
GSXF[ESPEK]QRVQQRKESKK
-NH2 
824.826
6 
824.3851 >99 10 
4 H-(cyclo-6, 10)-
GSXFL[EPEHK]RVQQRKESKK
-NH2 
836.511
4 
836.0917 >99 5 
5 H-(cyclo-7, 11)-
GSXFLS[EEHQK]VQQRKESKK
-NH2 
823.823
3 
823.4539 >99 7 
6 H-(cyclo-8, 12)-
GSXFLSP[EHQRK]QQRKESKK
-NH2 
831.178
9 
831.7017 >99 9 
7 H-(cyclo-9, 13)-
GSXFLSPE[EQRVK]QRKESKK-
NH2 
819.833
3 
819.4630 >99 12 
8 H-(cyclo-10, 14)-
GSXFLSPEH[ERVQK]RKESKK-
NH2 
822.833
3 
822.3869 >99 8 
9 H-(cyclo-11, 15)-
GSXFLSPEHQ[EVQQK]KESKK
-NH2 
803.149
6 
803.6989 >99 15 
 
 
69 
10 H-(cyclo-12, 16)-
GSXFLSPEHQR[EQQRK]ESKK-
NH2 
832.486
6 
832.1008 >99 12 
11 H-(cyclo-13, 17)-
GSXFLSPEHQRV[EQRKK]SKK
-NH2 
822.836
4 
822.0571 >99 16 
12 H-(cyclo-14, 18)-
GSXFLSPEHQRVQ[ERKEK]KK
-NH2 
836.511
4 
836.0917 >99 10 
13 H-(cyclo-15, 19)-
GSXFLSPEHQRVQQ[EKESK]K
-NH2 
813.473
3 
813.0776 >99 6 
 
Supplementary Table 2.3 - Characterization of synthesized i, i+7 lactam stapled 
truncated Ghrelin 1-20 (Where X is modified serine residue with an octanyl side 
chain) 
 
Compound Sequence [M+3H]3+ Purity 
(%) 
Yield 
(%) Expected 
m/z 
Observed 
m/z 
14 H-(cyclo-4, 11)-
GSX[ELSPEHQK]VQQRKESKK-
NH2 
806.1198 806.6921 >95 7 
15 H-(cyclo-5, 12)-
GSXF[ESPEHQRK]QQRKESKK-
NH2 
836.4574 836.9563 >95 10 
16 H-(cyclo-6, 13)-
GSXFL[EPEHQRVK]QRKESKK-
NH2 
835.4705 678.2541 
([M+4H]4+) 
>95 16 
17 H-(cyclo-7, 14)-
GSXFLS[EEHQRVQK]RKESKK-
NH2 
678.3984 678.4536 
([M+4H]4+) 
>95 6 
18 H-(cyclo-8, 15)-
GSXFLSP[EHQRVQQK]KESKK-
NH2 
845.2495 845.6032 >95 9 
19 H-(cyclo-9, 16)-
GSXFLSPE[EQRVQQRK]ESKK-
NH2 
818.7833 819.2634 >95 5 
20 H-(cyclo-10, 17)-
GSXFLSPEH[ERVQQRKK]SKK-
NH2 
821.4666 822.1901 >95 7 
21 H-(cyclo-11, 18)-
GSXFLSPEHQ[EVQQRKEK]KK-
NH2 
826.1233 826.7796 >95 10 
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22 H-(cyclo-12, 19)-
GSXFLSPEHQR[EQQRKESK]K-
NH2 
831.4466 832.1008 >95 13 
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IC50 competition binding curves for compounds 1-22 using HEK 293 cells in a 
competitive binding assay with [125I]human ghrelin 
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Compound 3 
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Compound 5 
 
 
Compound 6 
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Compound 7 
 
 
Compound 8 
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Compound 9 
 
 
Compound 10 
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Compound 11 
 
 
Compound 12 
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Compound 13 
 
 
Compound 14 
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Compound 15 
 
 
Compound 16 
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HPLC and MS traces for compounds 1-22 
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Additional Confocal Images  
 
 
 
 
 
 
Supplementary Figure 2.1 - (top) Confocal microscopy images incubated with the 
Cy5-Ghrelin(1-19) in 5 different ovarian cancer cell lines; (middle) Confocal 
microscopy images incubated with the Cy5-Ghrelin(1-19) and blocked with 10x 
concentrated Ghrelin(1-19) in 5 different ovarian cancer cell lines; (bottom) 
Confocal microscopy images incubated with the scrambled-Cy5-Ghrelin(1-19) in 5 
different ovarian cancer cell lines 
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Supplementary Figure 2.2 - (a) Confocal microscopy of compound 25 incubated 
with compound 1 in the Ovcar8 GHS-R1a+/+ cell line; (b) Confocal microscopy of 
compound 24 incubated with compound 1 in the Ovcar8 GHS-R1a+/+ cell line; (c) 
Confocal microscopy of compound 23 incubated with compound 1 in the Ovcar8 
GHS-R1a+/+ cell line; (d) Confocal microscopy of compound 25 incubated with 
compound 1 in the Ovcar8 cell line; (e) Confocal microscopy of compound 24 
incubated with compound 1 in the Ovcar8 cell line; (f) Confocal microscopy of 
compound 23 incubated with compound 1 in the Ovcar8 cell line 
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Supplementary Figure 2.3 - (a) Confocal microscopy of compound 25 incubated 
with compound 1 in the Ovcar8 GHS-R1a+/+ cell line; (b) Confocal microscopy of 
compound 24 incubated with compound 1 in the Ovcar8 GHS-R1a+/+ cell line; (c) 
Confocal microscopy of compound 23 incubated with compound 1 in the Ovcar8 
GHS-R1a+/+ cell line; (d) Confocal microscopy of compound 25 incubated with 
compound 1 in the Ovcar8 cell line; (e) Confocal microscopy of compound 24 
incubated with compound 1 in the Ovcar8 cell line; (f) Confocal microscopy of 
compound 23 incubated with compound 1 in the Ovcar8 cell line 
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Chapter 32 
 
Peptidomimetic growth hormone secretagogue derivatives for positron emission 
tomography imaging of GHS-R1a 
3.1 Introduction 
Growth hormone secretagogues (GHSs) are a class of compounds that stimulate 
the secretion of growth hormone (GH) by acting on the growth hormone secretagogue 
receptor type-1a (GHS-R1a)1. This receptor is predominantly found in the hypothalamus 
and pituitary gland1 and its secretion occurs through a route disparate from that of growth 
hormone-releasing hormone (GHRH)2. The first GHSs to show GH release in vitro were 
a series of Met-enkephalin analogues described by Bowers et al in 19803. Further 
development of these analogues led to a hexamer that released GH in vivo in a number of 
animals4-5, including humans6. This peptide was later termed growth hormone-releasing 
peptide-6 (GHRP-6), and a number of GHSs were subsequently synthesised in order to 
find alternatives to recombinant human GH therapy. These encompassed peptides (e.g. 
GHRP-17, hexarelin8, KP-102 ((later designated GHRP-2)9), peptidomimetics (e.g. 
G703910, [1-Nal]4G703911and ipamorelin12) and small-molecules (e.g. L-692,42913and 
MK-067714). The amino acid sequences of the peptidic GHSs and the structures of the 
peptidomimetic and small-molecule GHSs are shown in Figure 3.1. The endogenous 
ligand for GHS-R1a is ghrelin, a 28-mer peptide with an n-octanoyl group on the Ser3 
side-chain, which was discovered in 199915 and exhibits a multitude of biological 
activities, such as the regulation of food intake and glucose metabolism16-17.  
 
 
 
 
 
 
 
                                               
2 Fowkes, M.M.; Lalonde, T.; Yu, L.; Dhanvantari, S.; Kovacs, M.S.; Luyt, L.G. 
Peptidomimetic growth hormone secretagogue derivatives for positron emission 
tomography imaging of the ghrelin receptor. Eur. J. Med. Chem. 2018, 157, 1500-1511. 
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GHS-R1a is expressed in a number of human malignancies including prostatic 
carcinoma cell lines18-19 and tissues20, breast carcinoma tumours and cell lines21, testicular 
tumours22, and malignant ovarian cysts and tumours23. In addition, it has an elevated level 
of expression in tissues from patients with atherosclerosis24 and in biopsies from those 
with chronic heart failure25. GHS-R1a thus represents a potential target for molecular 
imaging of carcinoma and cardiovascular disease. Among the imaging modalities most 
commonly utilised in the clinic, positron emission tomography (PET) combines a high 
spatial resolution with high sensitivity26. A number of recent publications have thus 
described the development of PET radiotracers for visualising the GHS-R1a receptor in 
disease27-30. For example, Hou and co-workers synthesized the first picomolar 
quinazolinone binder of GHS-R1a and successfully radiolabelled two nanomolar 
compounds in high radiochemical purity30. In another study on small-molecule 
derivatives, in vivo imaging in mice with a [11C]radiotracer revealed a higher specific 
uptake in the pancreas compared to other organs28. However, these studies27-29 and 
others30-31 have primarily focused on either small-molecule quinazolinones27-31 or ghrelin-
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Figure 3.1 - Peptidic, peptidomimetic and small-molecule growth hormone 
secretagogues. All amino acids are designated by the standard three-letter code. D-
2-Nal, D-2-naphthylalanine; Inp, 
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derived compounds29,30,33. To the best of our knowledge, a growth hormone 
secretagogue-based PET probe has not been reported to date. We reasoned that 
modification of peptidic and peptidomimetic GHSs should result in a clinically 
translatable PET agent with high target specificity, in vivo stability and favourable 
pharmacokinetic properties. Fluorine-18 was our preferred choice of radioisotope as it is 
a small innocuous unit that can be easily installed in the absence of a chelator using the 
[18F]fluorobenzoyl ([18F]FB) prosthetic group. This modification can be initially trialled 
with 4-[19F]fluorobenzoic acid ([19F]FBA), in order to determine the optimal location for 
the 18F-radioisotope without significantly affecting peptide/peptidomimetic binding to 
GHS-R1a. 
We describe herein the design, synthesis and biological evaluation of 4-
fluorobenzoylated derivatives of GHSs with peptidic (GHRP-1, GHRP-2 and GHRP-6) 
and peptidomimetic (G7039, [1-Nal4]G7039 and ipamorelin) structures; the 
determination of their IC50 values for GHS-R1a; the identification of the lead peptide [1-
Nal4,Lys5(4-FB)]G7039 with nanomolar IC50 and EC50 values; and the 18F-radiolabelling 
of its precursor [1-Nal4]G7039 to furnish the peptidomimetic growth hormone 
secretagogue [1-Nal4,Lys5(4-[18F]-FB)]G7039, which could be applied to PET imaging of 
carcinoma and cardiovascular disease via targeting of GHS-R1a. 
3.2 Results and Discussion 
3.2.1 Design strategy for peptidic and peptidomimetic growth hormone secretagogues 
Initially, we sought to determine the location for 18F insertion into the peptidic 
and peptidomimetic GHSs without significantly affecting receptor binding affinity. A 
study of the literature revealed that Huang and co-workers had designed a 3D 
pharmacophore for GHS activity using peptidic and non-peptidic compounds without 
inclusion of the lysine side-chain34. This led to the synthesis of a benzothiazepin 
compound with low nanomolar in vitro efficacy for GHS-R1a34. In addition, we recently 
reported a GHS-R1a homology model based on neurotensin and opioid receptors with 
docking of the peptidomimetic G703935. The lysine residue was found to be unimportant 
for G7039-GHS-R1a binding owing to an unfavourable interaction energy between its 
side-chain amino group and polar Glu197/Arg199 residues35. This led us to select the lysine 
side-chain for 18F-radioisotope insertion in the peptidic (GHRP-1, GHRP-2 and GHRP-6) 
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and peptidomimetic (G7039, [1-Nal4]G7039 and  ipamorelin) GHSs using the [18F]FB 
prosthetic group via the pre-activated N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB)36. 
This modification was first tested by coupling a non-radioactive [18F]FB mimic 
([19F]FBA) to the lysine side-chain of each individual GHS class using the orthogonal 
allyloxycarbonyl (Alloc) protecting group by standard Fmoc-solid phase peptide 
synthesis (SPPS). Any change in binding affinity for GHS-R1a (expressed in terms of the 
IC50) was determined experimentally through a competitive receptor-ligand binding 
assay. Each parent growth hormone secretagogue (Figure 3.1) would be modified in turn 
until an IC50 < 100 nM was achieved.  
3.2.2 Synthesis and characterisation of peptidic and peptidomimetic growth hormone 
secretagogues  
The peptidic and peptidomimetic GHSs were synthesised through manual or 
automated Fmoc-SPPS and purified by reverse-phase (RP)-HPLC. Amino acids 
sequences for these GHSs are shown in the supporting information (Table 3.S1), with 
characterisation data listed in Table 3.1. 
Table 3.1 - HRMS data, purities and yields for synthesised peptides and 
peptidomimetics. All amino acids are designated by the standard three-letter code. 
4-FB, 4-fluorobenzoyl; AEEA, 2-(2-(2-aminoethoxy)ethoxy)acetic acid; D-2-Nal, D-
2-naphthylalanine; D-2-Thi, D-2-thienylalanine; Dpr, 2,3-diaminopropionic acid; 
Inp, isonipecotic acid. *Characterisation data reported previously35 
 
 
Peptide/Peptidomimetic 
HRMS 
(calculated) 
[M + H]+ 
HRMS  
(found) 
[M + H]+ 
% 
Purity 
% Yield 
Ipamorelin 712.3935 712.3959 > 97 19 
[Lys5(4-FB)]ipamorelin 834.4103 834.4133 > 99 15 
[Lys5(AEEA-4-FB)]ipamorelin 979.4842 979.4868 > 98 8 
[D-2-Thi4, Lys5(4-
FB)]ipamorelin 
840.3667 840.3693 > 98 4 
[Inp1, Lys5(4-FB)]ipamorelin 860.4259 860.4284 > 96 6 
[Inp1, D-2-Nal4, Lys5(4-
FB)]ipamorelin 
910.4416 910.4400 > 98 10 
[Inp1, D-2-Thi4, Lys5(4-
FB)]ipamorelin 
866.3824 866.3850 > 99 13 
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3.2.3 Structure-activity relationships of peptidic and peptidomimetic growth hormone 
secretagogues 
The IC50 values of the peptidic and peptidomimetic GHSs were determined 
through receptor-ligand binding assays utilising human embryonic kidney 293 
(HEK293)/GHS-R1a cells and [125I]ghrelin as the competitive radioligand. In order to 
ascertain whether overexpression of the receptor in HEK293 cells had been achieved, the 
endogenous ligand ghrelin was assayed first. An IC50 value of 7.63 nM was obtained 
(Figure 3.S1), indicating a satisfactory level of receptor expression and maintaining 
consistency with previously reported values37. 
The initial peptidomimetic that was chosen for 19F-fluorobenzoylation was the 
pentapeptide ipamorelin (H-Aib-His-D-2-Nal-D-Phe-Lys-NH2, compound 1, Table 3.2). 
This is because it displayed a nanomolar binding affinity in previous work using 
HEK293/GHS-R1a cells (Ki = 240 nM)38.  
 
 
 
 
 
 
GHRP-1 955.4943 955.4964 > 99 19 
GHRP-2 840.4204  
[M + Na]+ 
840.4173  
[M + Na]+ 
> 99 17 
GHRP-6 873.4524 873.4531 > 97 14 
[Lys6(4-FB)]GHRP-6 1017.4511  
[M + Na]+ 
1017.4522  
[M + Na]+ 
> 96 7 
[Dpr6]GHRP-6 831.4055 831.4070 > 99 3 
[Dpr6(4-FB)]GHRP-6 953.4223 953.4237 > 98 14 
G7039* 798.4343* 798.4339* > 99* 7* 
[Lys5(4-FB)]G7039 920.4511 920.4529 > 97 6 
[1-Nal4]G7039 848.4499 848.4501 > 99 23 
[1-Nal4, Lys5(4-FB)]G7039 970.4667 970.4693 > 96 9 
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Table 3.2 - IC50 values of ipamorelin and a series of derivatives thereof. The listed 
IC50 values were determined in triplicate using HEK293/GHS-R1a cells. For 
corresponding displacement curves, the reader is referred to the supporting 
information 
 
Compound Name IC50, nM 
1 Ipamorelin 483 
2 [Lys5(4-FB)]ipamorelin 170 
3 [Lys5(AEEA-4-FB)]ipamorelin 474 
4 [D-2-Thi4, Lys5(4-FB)]ipamorelin 161 
5 [Inp1, Lys5(4-FB)]ipamorelin 688 
6 [Inp1, D-2-Nal4, Lys5(4-FB)]ipamorelin 1920 
7 [Inp1, D-2-Thi4, Lys5(4-FB)]ipamorelin 1170 
Introduction of a fluorobenzoyl moiety into the lysine side-chain caused the IC50 
value of ipamorelin to decrease from 483 nM to 170 nM (compound 2, [Lys5(4-
FB)]ipamorelin). This could be a consequence of the fluorobenzoyl group strengthening 
hydrophobic interactions with aromatic residues (e.g. Phe222 and Phe226) in the non-
polar sub-pocket described in the open GHS-R1a homology model of Pedretti and co-
workers39. Ipamorelin also possesses the same three C-terminal residues as G7039 (the 
only difference being D-Phe4 as opposed to Phe4, respectively) and thus the additional 
fluorobenzene ring could also be interacting with residues in one of the hydrophobic sub-
pockets (e.g. Phe286) detailed by Hou et al35. Extension of the lysine side-chain through 
a short mini-PEG linker (2-(2-(2-aminoethoxy)ethoxy)acetic acid, AEEA) prior to 4-
fluorobenzoyl group coupling furnished [Lys5(AEEA-4-FB)]ipamorelin, compound 3. 
This had a higher IC50 value compared to compound 2 (cf. 474 nM for [Lys5(AEEA-4-
FB)]ipamorelin to 170 nM for [Lys5(4-FB)]ipamorelin). This may result from the 
additional flexibility afforded by the mini-PEG linker, which could cause a reduction in 
important hydrophobic interactions of the 4-fluorobenzoyl moiety when compared to the 
less flexible compound 2. Replacement of the D-Phe residue with D-2-thienylalanine (D-
2-Thi) was expected to improve binding affinity. This strategy was based on a study by 
Hansen and co-workers on dipeptide ipamorelin derivatives, where this alteration caused 
the EC50 value to improve by an order of magnitude40. Unfortunately, this modification 
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furnished a compound with comparable affinity to the [Lys5(4-FB)]ipamorelin analogue 2 
with an IC50 = 161 nM ([D-2-Thi4,Lys5(4-FB)]ipamorelin, compound 4).  
The primary amine at the N-terminus of ipamorelin was then exchanged for the 
secondary amine isonipecotic acid (Inp) so as to make the subsequent compound 
([Inp1,Lys5(4-FB)]ipamorelin, compound 5) similar to the peptidomimetic G7039, known 
to have an EC50 = 0.18 nM10. This led to a rise in the IC50 value (cf. [Lys5(4-
FB)]ipamorelin, IC50 = 170 nM, compound 2 to [Inp1,Lys5(4-FB)]ipamorelin, IC50 = 688 
nM, compound 5).  
In order to probe the significance of the D-Phe residue in sub-pocket binding, this 
residue was replaced with D-2-Nal in [Inp1,Lys5(4-FB)]ipamorelin (5) to give [Inp1,D-2-
Nal4,Lys5(4-FB)]ipamorelin (IC50 = 1920 nM, compound 6). This caused an 
approximately three-fold reduction in binding affinity for GHS-R1a compared to the 
parent compound 5. This suggests that D-Phe may be taking part in π-π or hydrophobic 
interactions with Phe119 in TM339,41, playing the same role as it does in the active tetra-
peptide core of ghrelin42. The synthesis of compound 7 ([Inp1,D-2-Thi4,Lys5(4-
FB)]ipamorelin) and its corresponding IC50 value (1170 nM) could be seen as an 
approximately two-fold reduction in binding affinity for GHS-R1a from switching D-2-
Thi for D-Phe in compound 5 ([Inp1,Lys5(4-FB)]ipamorelin); or an approximately seven-
fold decrease in binding resulting from insertion of an unfavourable secondary amine 
(Inp) into compound 4 ([D-2-Thi4,Lys5(4-FB)]ipamorelin). In summary, the various 
synthesised derivatives of ipamorelin did not yield the desired IC50 of < 100 nM, despite 
some improvements to its initial IC50 value. 
Next, our attention turned to the peptidic GHSs (GHRP-1, GHRP-2 and GHRP-6) 
due to the low nanomolar Ki values that were obtained for GHRP-2 and GHRP-6 (1.4 nM 
and 3.3 nM, respectively) using HEK293/GHS-R1a cells38. The IC50 values of GHRP-1, 
GHRP-2 and GHRP-6 are shown in Table 3.3 (compounds 8-10, respectively).  
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Table 3.3 - IC50 values of peptidic GHSs and their derivatives. The listed IC50 values 
were determined in triplicate using HEK293/GHS-R1a cells. For corresponding 
displacement curves, the reader is referred to the supporting information 
 
Compound Name IC50, nM 
8 GHRP-1 181 
9 GHRP-2 449 
10 GHRP-6 73 
11 [Lys6(4-FB)]GHRP-6 384 
12 [Dpr6]GHRP-6 397 
13 [Dpr6(4-FB)]GHRP-6 1060 
It was found that GHRP-6, (H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) had the 
strongest binding to GHS-R1a (IC50 = 73 nM, compound 10) compared to GHRP-1 (IC50 
= 181 nM, compound 8) and GHRP-2 (IC50 = 449 nM, compound 9). This peptide was 
therefore transformed into the fluorobenzoylated analogue [Lys6(4-FB)]GHRP-6 (IC50 = 
384 nM, compound 11). Unfortunately, this alteration was not tolerated by GHS-R1a in 
spite of prior success with ipamorelin (cf. compound 11, IC50 = 384 nM to compound 2, 
IC50 = 170 nM). One possible explanation for this is that the lysine residue of GHRP-6 is 
involved in binding to polar sub-pocket residues (e.g. Arg199)39. 
Endeavouring to increase affinity for GHS-R1a, the lysine of GHRP-6 was 
replaced with 2,3-diaminopropionic acid (Dpr) to furnish [Dpr6]GHRP-6 (IC50 = 397 nM, 
compound 12). This increase in IC50 could be a product of the shorter side-chain of Dpr 
which could be decreasing lysine’s charge-transfer interactions with Arg199 in the polar 
sub-pocket. This would also explain the greater loss in binding affinity after the 
attachment of the 4-fluorobenzoyl group ([Dpr6(4-FB)]GHRP-6, IC50 = 1060 nM, 
compound 13). Not only does the lysine side-chain appear to play an important role in 
receptor binding for GHRP-6 (a result contrary to that obtained for ipamorelin), but the 
length of the alkyl chain also appears to be essential. Further derivatisation of this class of 
peptides was not pursued owing to the high initial IC50 values of GHRP-1 (181 nM, 
compound 8) and GHRP-2 (449 nM, compound 9) and the assumption that the lysine 
residue in these peptides was also important for receptor interaction. 
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Finally, two Genentech 5-mers G7039 (H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2) 
and [1-Nal4]G7039 (H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2) were investigated as a 
consequence of their reported low nanomolar in vitro efficacies (EC50 = 0.18 nM for 
G703910 and 0.10 nM for [1-Nal4]G703911, respectively) and our recent computational 
study on the docking of G7039 to GHS-R1a, which suggested that the lysine residue was 
not critical for receptor binding35. The parent compounds G7039 (compound 14) and [1-
Nal4]G7039 (compound 16) and their fluorobenzoyl congeners (compounds 15 and 17, 
respectively) can be viewed in Table 3.4. 
Table 3.4 - IC50 values of Genentech peptidomimetics and their derivatives. The 
listed IC50 values were determined in triplicate using HEK293/GHS-R1a cells. For 
corresponding displacement curves, the reader is referred to the supporting 
information. *Literature data35 
 
Compound Name IC50, nM 
14 G7039* 5.2* 
15 [Lys5(4-FB)]G7039 242 
16 [1-Nal4]G7039 28 
17 [1-Nal4, Lys5(4-FB)]G7039 69 
Attaching G7039 to para-fluorobenzoic acid had the effect of increasing the half-
maximal inhibitory concentration (5.2 nM to 242 nM for [Lys5(4-FB)]G7039, compound 
15), whilst a smaller increase in the IC50 value was observed for [1-Nal4]G7039 (28 nM 
to 69 nM for [1-Nal4,Lys5(4-FB)]G7039, compound 17). The smaller increase observed 
for [1-Nal4]G7039 compared to G7039 indicates that the introduction of an additional 
aromatic functionality (fluorobenzene) along with the already present 1-Nal4 residue is 
simply strengthening hydrophobic sub-pocket binding, whereas for G7039 this 
modification is less favourable; perhaps due to the reduction of salt-bridge interactions 
with Glu197 in the polar sub-pocket35. In spite of the increase in IC50 value for [1-
Nal4,Lys5(4-FB)]G7039, this peptidomimetic represents the first lead compound to be 
synthesised with the required nanomolar IC50 value (< 100 nM) making it the most 
suitable candidate for further study of physical and biochemical characteristics prior to 
[18F]-radiolabelling with [18F]SFB. 
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3.2.4 Determination of lipophilicity of peptidic and peptidomimetic growth hormone 
secretagogues 
The logP value of [1-Nal4,Lys5(4-FB)]G7039 as well as the other peptidic and 
peptidomimetic GHSs were computed using ACD/LogP software (Table 3.S2). Inserting 
the 4-fluorobenzoyl moiety into any peptidomimetic parent compound resulted in an 
increase in hydrophobicity for all derivatives (+ 2.25). Most of the parent compounds 
exhibited a favourable logP value in the 1-3 unit range, except for G7039 (5.28 ± 0.82) 
and [1-Nal4]G7039 (6.51 ± 0.82). This is virtue of the smaller size of these 
peptidomimetics compared to GHRP-1, GHRP-2 and GHRP-6, and the prevalence of 
more hydrophobic aromatic residues compared to ipamorelin (D-2-Nal and 1-Nal). 
Regrettably, the lead compound [1-Nal4,Lys5(4-FB)]G7039 had a logP value of 8.76 ± 
0.88, suggesting a lack of suitability for in vivo PET imaging due to potential solubility 
issues. Nevertheless, [1-Nal4,Lys5(4-FB)]G7039 possesses a considerably lower IC50 
value compared to the next best compound [D-2-Thi4, Lys5(4-FB)]ipamorelin (cf. 69 nM 
to 161 nM) and was thus investigated in further in vitro assays. 
3.2.5 Determination of efficacy of lead peptidomimetic [1-Nal4,Lys5(4-FB)]G7039 
The EC50 value of [1-Nal4,Lys5(4-FB)]G7039 was calculated in terms of the 
release of intracellular calcium ions (Figure 3.2). As expected, the control ligand ghrelin 
had a low in vitro potency of 1.6 nM, whilst the EC50 value of [1-Nal4,Lys5(4-FB)]G7039 
was determined as 1.1 nM. This low nanomolar efficacy signifies that the final compound 
remains a potent GHS-R1a agonist despite blocking of the lysine side-chain with the 4-
fluorobenzoyl group. 
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Figure 3.2 - Dose-response curves for the lead peptidomimetic [1-Nal4,Lys5(4-
FB)]G7039 (red) and the control ligand ghrelin (blue). The EC50 value for these 
compounds was determined in terms of intracellular Ca2+ release. The percentage 
activation was normalised to the maximal response (Emax) of the control agonist 
ghrelin. Each assay concentration was performed in duplicate 
3.2.6 Stability of lead peptidomimetic [1-Nal4,Lys5(4-FB)]G7039 in human serum 
The lead peptidomimetic agonist [1-Nal4,Lys5(4-FB)]G7039 was tested for 
stability in human serum in order to assess its biological half-life. This serum half-life 
was found to be 718 minutes, indicating a good potential time-frame for in vivo PET 
imaging in small animal models of carcinoma or cardiovascular disease. The [1-
Nal4]G7039 lead precursor was thus carried forward for radiolabelling with [18F]SFB.  
3.2.7 Synthesis of [18F]SFB and 18F-radiolabelling of the lead precursor [1-Nal4]G7039 
The synthesis of the [18F]SFB prosthetic group is shown in scheme 1. Acid 
catalysed esterification of the 4-dimethylaminobenzoic acid starting material 18 furnished 
the intermediate t-butyl ester 19. Methylation with trifluoromethanesulfonate (MeOTf) 
gave the triflate salt 20 in a yield of 38% and ≥ 95% purity by UHPLC. Having 
synthesized the precursor salt 20, nucleophilic aromatic substitution with the [18F-] anion 
(acquired from the PET cyclotron by irradiation of [18O]H2O) led to the formation of the 
radioactive compound 21.  
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Scheme 3.1 - Synthesis of the [18F]SFB prosthetic group and subsequent 18F-
radiolabelling of [1-Nal4]G7039. Reagents and Conditions: a) i) trifluoroacetic 
anhydride, THF, 0°C ii) tBuOH, room temperature, 2 hrs; b) MeOTf, N2, 0 °C, 1 
hour; c) 18F-, K2CO3, Kryptofix 2.2.2, DMSO, 120 °C, 10 minutes; d) 6M HCl, 120 
°C, 10 minutes; e) NHS, EDC, MeCN, room temperature, 15-20 minutes; f) [1-
Nal4]G7039, N,N-diisopropylethylamine (DIPEA), MeCN/H2O (1:1 ratio), 65 °C, 15-
20 minutes 
 
Acid-catalysed de-esterification furnished [18F]FBA (22) with an average d.c. 
(decay-corrected) radiochemical yield of 82%. The product was confirmed by co-
injection with [19F]FBA (see Figure 3.S3 for representative radiochromatogram). 
Compound 22 was then coupled to N-hydroxysuccinimide (NHS) using the coupling 
reagent N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC) which led to the 
formation of the [18F]SFB prosthetic group 23. The crude compound was purified by 
reverse-phase HPLC to give an average decay-corrected radiochemical yield of 71% and 
radiochemical purity ³ 99% (see Figure 3.S4 for representative radiochromatogram). The 
pure [18F]SFB was added to the peptide precursor [1-Nal4]G7039 in a mixture of 
MeCN/H2O using a small quantity of the hindered base DIPEA. After 15-20 minutes, the 
crude [1-Nal4,Lys5(4-[18F]-FB)]G7039 lead compound was obtained and purified by 
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semi-preparative HPLC. The final radiolabelled peptide [1-Nal4,Lys5(4-[18F]-FB)]G7039 
(24) was obtained in an average decay-corrected radiochemical yield of 81%. For the 
entire synthesis, an overall average d.c. radiochemical yield of 48% was achieved (n = 3), 
an average molar activity of > 34 GBq/μmol and a radiochemical purity of ≥ 99%. Figure 
3 displays a series of stacked chromatograms including the peptidomimetic precursor [1-
Nal4]G7039 (16), the cold standard [1-Nal4,Lys5(4-FB)]G7039 (17) as well as the 
radiolabelled [1-Nal4,Lys5(4-[18F]-FB)]G7039 peptidomimetic (24). 
 
 
 
 
 
 
 
 
 
 
 
The retention times of the cold standard and “hot” peptide are almost identical 
([1-Nal4, Lys5(4-FB)]G7039, tR = 6.70 mins compared to tR = 6.65 mins for the “hot” 
peptide), indicating that the precursor [1-Nal4]G7039 has been selectively radiolabelled at 
the amino group of the lysine side-chain. Further evidence for successful coupling of 
[18F]SFB to [1-Nal4]G7039 via the lysine side-chain was provided by a co-injection of a 
pre-mixed solution of the cold standard and “hot” peptidomimetic (Figure 3.4).  
 
 
 
Figure 3.3 - Stacked HPLC Chromatograms for [1-Nal4]G7039, [1-Nal4,Lys5(4-
FB)]G7039 (both λ = 254 nm) and [1-Nal4, Lys5(4-[18F]-FB)]G7039 
 
 
125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Once again, this showed very similar retention times between the two 
peptidomimetic species ([1-Nal4, Lys5(4-FB)]G7039 tR = 6.26 mins and [1-Nal4,Lys5(4-
[18F]-FB)]G7039 tR = 6.17 mins) lending further credence to regioselective 18F-
fluorobenzoylation at the lysine side-chain.  
3.3 Conclusions 
In this study, several families of peptidic (GHRP-1, GHRP-2 and GHRP-6) and 
peptidomimetic (ipamorelin, G7039, [1-Nal4]G7039) GHS-R1a agonists were derivatised 
through 4-fluorobenzoylation of the lysine side-chain. This led to a range of half-maximal 
inhibitory concentrations ranging from 69 nM ([1-Nal4, Lys5(4-FB)]G7039) to 1920 nM 
([Inp1, D-2-Nal4, Lys5(4-FB)]ipamorelin). The peptidomimetic [1-Nal4]G7039 was 
identified as the most suitable candidate for 18F-radiolabelling, as its 19F-congener ([1-
Nal4,Lys5(4-FB)]G7039, compound 17) had a nanomolar binding affinity (IC50 = 69 nM), 
high in vitro potency (EC50 = 1.1 nM) and good serum stability (t1/2 = 718 mins). This is 
most likely due to the presence of a core framework of aromatic amino acids that are 
involved in strong hydrophobic interactions with hydrophobic pockets of the GHS-R1a. 
Prosthetic group radiolabelling of [1-Nal4]G7039 with [18F]SFB delivered the 
radiolabelled peptidomimetic in an overall average decay-corrected radiochemical yield 
Figure 3.4 - Stacked HPLC chromatograms resulting from the co-injection of cold 
standard [1-Nal4,Lys5(4-FB)]G7039 (λ = 254 nm) and [1-Nal4,Lys5(4-[18F]-
FB)]G7039 
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of 48%, a radio-purity ≥ 99% and an average molar activity of > 34 GBq/μmol. This 
compound could potentially be used as a PET probe for the detection of diseases that are 
characterised by overexpression of GHS-R1a. 
3.4 Materials and Methods 
3.4.1 General information 
All starting peptide reagents (resin, amino acids, coupling agents, and bases) were 
obtained from commercial suppliers and used without further purification. Peptides were 
either synthesised manually or through the use of a Biotage SyroWave automated peptide 
synthesizer. Peptide vessels were shaken using an IKA Vibrax VXR basic shaker with 
centrifugation performed on a Beckman Coulter Allegra X-30R or Fisher GS-6R 
centrifuge. In order to aid peptide dissolution, sonication of solutions was accomplished 
via a Bransonic 2510R-MTH or Fisher F5-14 ultrasonic cleaner. A Fisher 2052 Isotemp 
machine was used to heat test tubes in the Kaiser Test. Peptides were lyophilised using a 
Labconco FreeZone Freeze Dry System. Accurate weighing was carried out on a Mettler-
Toledo XP6 microbalance. UV traces were obtained with a Waters 2487 UV/Vis Dual λ 
Absorbance Detector (170-900 nm) and low-resolution mass spectra with a Micromass 
Quattro micro API mass spectrometer (ESI-LC-MS). Peptide purification was achieved 
through HPLC (MeCN + 0.1% TFA, H2O + 0.1% TFA solvent system). All peptides and 
small molecules obtained had a purity ≥ 95% as determined by HPLC or UHPLC 
analysis. A RP preparative C-18 column (SunFire OBD, 19 x 150 mm or Agilent Zorbax 
21.2 x 150 mm) was used for preparative HPLC, whilst a C-18 RP column (SunFire, 4.6 
x 150 mm or Agilent Zorbax, 4.6 x 150 mm) was used for analytical HPLC. Accurate 
mass spectrometry (HRMS) was carried out on a Finnigan MAT 8400 mass spectrometer 
(EI) for small molecules and on a Micromass LCT mass spectrometer (ESI-TOF) for 
peptides. 1H NMR and 13C NMR spectroscopy were performed on a Mercury VX 400 
machine at 400 and 100 MHz respectively. Chemical shifts are referenced to residual 
solvent, reported in ppm on a δ scale and all coupling constants quoted in hertz (Hz). 
3.4.2 Manual Fmoc-SPPS 
Rink amide MBHA resin (192 mg, 0.1 mmol, 1.0 equiv., 0.52 mmol g-1 loading) 
was vortexed in DCM (2.0 ml, 1 min.), allowed to swell (15 mins) and solvent removed. 
This was followed by addition of DMF (2.0 ml), vortexing (1 min.) and removal of 
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solvent. Deprotection of the Fmoc group was then performed. A solution of 20% 
piperidine/DMF (1.5 ml, v/v) was added to the resin and the subsequent mixture vortexed 
(2 mins) and solvent removed. This was then repeated a second time with vortexing for 
15 minutes. After solvent had been removed, the resin was washed of any unreacted by-
products with DMF six times (2.0 ml, vortex 30 s). The desired amino acid or small 
molecule (0.3 mmol, 3.0 equiv.) and coupling reagent (HCTU, 0.12 g, 0.3 mmol, 3.0 
equiv.) were then dissolved in DMF (1.5 ml) and added to the deprotected resin. After 
vortexing (30 s), DIPEA (111 μl, 0.6 mmol, 6.0 equiv.) was added and the final mixture 
vortexed (1-2 hrs). The resin was then washed with DMF (2.0 ml, 30 s vortex) a final 
four times. The deprotection/coupling cycle was then repeated unless the final amino acid 
in the sequence had been added, in which case the peptide was washed with DCM five 
times (2.0 ml, 30 s vortex) after washing with DMF and stored in a refrigerator. Removal 
of the N-terminal Fmoc-group was carried out in the same fashion as the deprotection 
cycle described previously, with resin washing occurring six times with DMF (2.0 ml, 30 
s vortex) and four times with DCM (2.0 ml, 30 s vortex). Successful synthesis of the 
desired peptide was then ascertained via a microcleave prior to full cleavage of the 
peptide from the solid-support. This was carried out as follows: a solution of 95% TFA: 
2.5% (iPr)3SiH: 2.5% H2O (300 μl) was added to a small number of resin beads (< 5 mg) 
and the subsequent mixture vortexed (3 hrs). The clear liquid was then evaporated under 
a stream of N2. Analytical HPLC was then performed to determine whether the correct 
peptide had been synthesised. If the correct peptide had been obtained, a full cleavage 
was performed using a mixture of 95% TFA: 2.5% (iPr)3SiH: 2.5% H2O (2.0 ml) for 5-7 
hrs. The subsequent solution was cooled in an ice-bath alongside tert-butyl methyl ether 
(TBMe, 40 ml). After 10 minutes, TBMe (20 ml) was added to the peptide solution, 
leading to the formation of a white precipitate. The precipitate was cooled further (10 
mins) and then centrifuged (7 mins). Decanting of the supernatant was followed by 
addition of a second aliquot of TBMe (20 ml), vortexing (30 s) and final centrifugation (7 
mins). After decanting, a white solid was obtained. This was then freeze-dried (20 mins) 
to furnish crude peptide. Preparative HPLC was then used to purify the product peptide. 
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3.4.3 Deprotection of the Alloc protecting group 
The resin-bound peptide was vortexed in DCM (4.5 ml, 30 s) and allowed to swell 
(10 mins). Deprotection was carried out under a blanket of N2. The swollen resin-bound 
peptide was stirred (5 mins) before addition of PhSiH3 (296 μl, 2.4 mmol, 24.0 equiv.). 
Further stirring (5 mins) ensued prior to treating with Pd(PPh3)4 (12 mg, 0.01 mmol, 0.1 
equiv.). After 5 minutes, the solution was vortexed (5 mins), solvent removed and the 
brown-coloured resin washed four times with DCM (2.0 ml, 30 s vortex). The procedure 
was then repeated ab initio, with final resin washing occurring in the following order: 
DCM, DMF, MeOH, DMF and DCM (all 2.0 ml, 30 s vortex). 
3.4.4 Kaiser Test 
A small number of resin beads (< 5 mg) were taken and treated with phenol: 
EtOH (200 μl, 8:2 v/v), 0.001 M KCN(aq.): pyridine (200 μl, 2:98 v/v, 0.001 M aqueous 
KCN) and ninhydrin in EtOH (200 μl, 5% w/v), respectively. Tentagel resin (< 5 mg) 
was used as a control. Both test tubes were heated to 70 °C. The presence of free amine 
was indicated by blue resin beads whilst yellow or clear resin beads indicated the 
presence of protected amino groups. 
3.4.5 Synthesis of peptidic- and peptidomimetic growth hormone secretagogues 
All peptidomimetics were synthesised by the same general procedure described 
previously unless otherwise noted. 
H-Aib-His-D-2-Nal-D-Phe-Lys-NH2: Ipamorelin (1) 
The product was purified by preparative HPLC (5-80% MeCN + 0.1% TFA). This 
furnished a white powder (20.5 mg, 19%): 1H-NMR (400 MHz, CD3OD); D-2-Nal, D-
Phe, His: δ 7.99 (s, 1H, ArH), 7.80-7.76 (m, 1H, ArH), 7.71 (d, J = 8.6 Hz, 2H, ArH), 
7.56 (s, 1H, ArH), 7.44-7.37 (m, 2H, ArH), 7.32-7.17 (m, 6H, ArH), 6.92 (s, 1H, His 
Hδ), 4.58 (m, 3H, Hα), 3.30-3.21 (m, 1H, D-2-Nal Hβ), 3.15-3.00 (m, 2H, Hβ), 2.96-
2.72 (m, 3H, Hβ), Lys: 4.11 (dd, J = 9.7, 4.2 Hz, 1H, Hα), 2.96-2.72 (m, 2H, Hε), 1.75-
1.64 (m, 1H, Hβ), 1.54-1.40 (m, 3H, Hβ, 2Hδ), 1.05-0.93 (m, 2H, Hγ), Aib: 1.48 (s, 
3H, CH3) 1.44 (s, 3H, CH3) ppm. ESI-LC-MS m/z 356.9 [M + 2H]2+; HRMS (ESI-MS) 
calcd. for C38H50N9O5 [M + H]+ 712.3935, found 712.3959. 
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H-Aib-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2: [Lys5(4-FB)]ipamorelin (2) 
Purification by preparative HPLC (20-70% MeCN + 0.1% TFA) yielded a white 
powder (15.4 mg, 15%): 1H-NMR (400 MHz, CD3OD); D-2-Nal, D-Phe, His, 4-FB: δ 
7.91 (s, 1H, ArH), 7.85-7.77 (m, 3H, ArH, 2F-ArH), 7.70 (d, J = 7.9 Hz, 2H, ArH), 
7.54 (s, 1H, ArH), 7.45-7.40 (m, 2H, ArH), 7.29-7.19 (m, 6H, ArH), 7.14-7.07 (m, 
2H, 2F-ArH), 6.93 (s, 1H, His Hδ), 4.65-4.52 (m, 3H, Hα), 3.30-3.27 (m, 1H, Hβ), 3.23 
(d, J = 4.0 Hz, 1H, Hβ), 3.10 (dd, J = 13.5, 7.8 Hz, 1H, Hβ), 3.04-2.74 (m, 3H, Hβ), 
Lys: 4.12 (dd, J = 9.8, 4.2 Hz, 1H, Hα), 3.04-2.74 (m, 2H, Hε), 1.77-1.67 (m, 1H, Hβ), 
1.58-1.42 (m, 3H, Hβ, 2Hδ), 1.14-1.03 (m, 2H, Hγ), Aib: 1.50 (s, 3H, CH3), 1.46 (s, 
3H, CH3) ppm. ESI-LC-MS m/z 418.0 [M + 2H]2+; HRMS (ESI-MS) calcd. for 
C45H53FN9O6 [M + H]+ 834.4103, found 834.4133. 
 
H-Aib-His-D-2-Nal-D-Phe-Lys(AEEA-4-FB)-NH2:[Lys5(AEEA-4-FB)]ipamorelin (3) 
Peptide purification by preparative HPLC (20-60% MeCN + 0.1% TFA) 
delivered an off-white powder (9.2 mg, 8%): 1H-NMR (400 MHz, CD3OD); His, D-2-
Nal, D-Phe, 4-FB: δ 7.93 (s, 1H, ArH), 7.86-7.77 (m, 3H, ArH, 2F-ArH), 7.71 (d, J = 
8.0 Hz, 2H, ArH), 7.55 (s, 1H, ArH), 7.46-7.41 (m, 2H, ArH), 7.31-7.18 (m, 6H, 
ArH), 7.17-7.10 (m, 2H, F-ArH), 6.94 (s, 1H, His Hδ), 4.65-4.58 (m, 2H, Hα), 4.55 (t, 
J = 7.5 Hz, 1H, Hα), 3.16-2.76 (m, 6H, Hβ), Lys: 4.10 (dd, J = 9.7, 4.2 Hz, 1H, Hα), 
3.16-2.76 (m, 2H, Hε), 1.72-1.62 (m, 1H, Hβ), 1.52-1.43 (m, 1H, Hβ), 1.41-1.30 (m, 
2H, Hδ), 1.07-0.97 (m, 2H, Hγ), AEEA linker: 3.93 (s, 2H, NHCOCH2O), 3.65-3.61 
(m, 6H, CH2), 3.53 (t, J = 5.6 Hz, 2H, CH2), Aib: 1.50 (s, 3H, CH3), 1.47 (s, 3H, 
CH3) ppm. ESI-LC-MS m/z 490.4 [M + 2H]2+; HRMS (ESI-MS) calcd. for 
C51H64FN10O9 [M + H]+ 979.4842, found 979.4868.  
 
H-Aib-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2: [D-2-Thi4,Lys5(4-FB)]ipamorelin (4) 
The title peptide was synthesized by automated peptide synthesis and purified by 
preparative HPLC (20-80% MeCN + 0.1% TFA). This furnished a white solid (4.20 mg, 
4%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.83 (s, 1H, ArH), 8.59 (d, J = 8.1 Hz, 1H, 
NH), 8.42 (t, J = 5.6 Hz, 1H, NH), 8.29 (d, J = 9.3 Hz, 1H, NH), 8.20 (d, J = 8.2 Hz, 
1H, NH), 8.09 (d, J = 8.9 Hz, 1H, NH), 7.99 (s, 2H, NH), 7.86-7.81 (m, 2H, F-ArH), 
7.79-7.75 (m, 1H, ArH), 7.72 (dd, J = 8.7, 3.7 Hz, 2H, ArH), 7.65 (s, 1H, ArH), 7.41-
7.37 (m, 2H, ArH), 7.35-7.31 (m, 2H, ArH, NH), 7.26 (dd, J = 4.8, 1.5 Hz, 1H, Thi-
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H), 7.22-7.16 (m, 2H, F-ArH), 7.05 (s, 2H, NH, ArH), 6.88-6.84 (m, 2H, Thi-H), 
4.73-4.66 (m, 1H, Hα), 4.62-4.51 (m, 2H, Hα), 4.19-4.12 (m, 1H, Lys-Hα), 3.21-3.12 
(m, 4H, 2Hε, 2Hβ), 3.06-2.96 (m, 1H, Hβ), 2.87-2.77 (m, 2H, Hβ), 2.62-2.49 (m, 1H, 
Hβ), 1.66-1.56 (m, 1H, Lys-Hβ), 1.50-1.36 (m, 3H, Lys-Hβ, 2Hδ), 1.26 (s, 3H, CH3), 
1.20-1.10 (m, 2H, Hγ), 1.16 (s, 3H, CH3), ppm. ESI-LC-MS m/z 420.8 [M + 2H]2+; 
HRMS (ESI-MS) calcd. for C43H51FN9O6S  [M + H]+ 840.3667 found 840.3693. 
 
H-Inp-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2: [Inp1,Lys5(4-FB)]ipamorelin (5) 
The title peptide was synthesized via automated peptide synthesis and purified by 
preparative HPLC (20-70% MeCN + 0.1% TFA). The title compound was acquired as a 
white solid (6.30 mg, 6%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.79 (s, 1H, His Hε), 8.72 
(s, 1H, NH), 8.44 (dd, J = 10.8, 6.4 Hz, 2H, NH), 8.19 (d, J = 7.8 Hz, 1H, NH), 8.17-
8.10 (m, 2H, NH), 7.87-7.81 (m, 2H, F-ArH), 7.80-7.76 (m, 1H, ArH), 7.71 (d, J = 
7.9 Hz, 2H, ArH), 7.63 (s, 1H, ArH), 7.42-7.35 (m, 2H, ArH), 7.33-7.29 (m, 2H, NH), 
7.22-7.18 (m, 6H, ArH), 7.17-7.11 (m, 2H, F-ArH), 7.06 (s, 1H, NH), 6.96 (s, 1H, His 
Hδ), 4.64-4.56 (m, 1H, Hα), 4.55-4.44 (m, 2H, Hα), 4.15-4.07 (m, 1H, Lys-Hα), 3.19-
3.07 (m, 5H, CH2), 2.94 (dd, J = 13.6, 5.9 Hz, 1H, CH2), 2.87-2.67 (m, 5H, CH2), 
2.58-2.48 (m, 1H, CH2), 2.38-2.29 (m, 1H, Hα), 1.67-1.34 (m, 8H, CH2), 1.15-1.00 
(m, 2H, CH2), ppm. ESI-LC-MS m/z 430.9 [M + 2H]2+; HRMS (ESI-MS) calcd. for 
C47H55FN9O6  [M + H]+ 860.4259 found 860.4284. 
 
H-Inp-His-D-2-Nal-D-2-Nal-Lys(4-FB)-NH2: [Inp1,D-2-Nal4,Lys5(4-FB)]ipamorelin 
(6) 
The title peptide was made by automated peptide synthesis and purified by 
preparative HPLC (20-80% MeCN + 0.1% TFA). This delivered a white solid (11.3 mg, 
10%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.77 (s, 1H, His Hε), 8.51 (d, J = 7.5 Hz, 2H, 
NH), 8.36 (t, J = 5.5 Hz, 1H, NH), 8.19-8.10 (m, 2H, NH), 8.05 (d, J = 8.7 Hz, 1H, 
NH), 7.85-7.79 (m, 3H, 2F-ArH, ArH), 7.79-7.74 (m, 3H, ArH), 7.73 (s, 1H, ArH), 
7.70 (s, 1H, ArH), 7.68 (d, J = 2.4 Hz, 2H, ArH), 7.59 (s, 1H, ArH), 7.43-7.35 (m, 
5H, ArH), 7.31-7.27 (m, 2H, NH), 7.20-7.13 (m, 2H, F-ArH), 7.05 (s, 1H, NH), 6.93 
(s, 1H, His Hδ), 4.67-4.60 (m, 2H, Hα), 4.52-4.44 (m, 1H, Hα), 4.16-4.08 (m, 1H, Lys-
Hα), 3.17-2.93 (m, 7H, CH2), 2.88-2.66 (m, 4H, CH2), 2.53-2.47 (m, 1H, CH2), 2.34-
2.25 (m, 1H, Hα), 1.63-1.34 (m, 6H, CH2), 1.32-1.23 (m, 2H, CH2), 1.07-0.95 (m, 2H, 
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CH2), ppm. ESI-LC-MS m/z 455.9 [M + 2H]2+; HRMS (ESI-MS) calcd. for 
C51H57FN9O6  [M + H]+ 910.4416 found 910.4400. 
 
H-Inp-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2: [Inp1,D-2-Thi4,Lys5(4-FB)]ipamorelin 
(7) 
The title peptide was prepared by automated peptide synthesis and purified by 
preparative HPLC (20-80% MeCN + 0.1% TFA). This furnished a white powder (14.0 
mg, 13%): 1H-NMR (400 MHz, CD3OD); His, D-2-Nal, D-2-Thi, 4-FB: δ 8.23 (s, 1H, 
His Hε), 7.86-7.81 (m, 2H, F-ArH), 7.80-7.77 (m, 1H, ArH), 7.73 (dd, J = 8.8, 3.3 Hz, 
2H, ArH), 7.59 (s, 1H, ArH), 7.45-7.39 (m, 2H, ArH), 7.27 (dd, J = 8.5, 1.6 Hz, 1H, 
ArH), 7.22 (dd, J = 5.0, 1.2 Hz, 1H, Thi-ArH), 7.15-7.08 (m, 2H, F-ArH), 6.92 (s, 1H, 
His Hδ), 6.91-6.85 (m, 2H, Thi-ArH), 4.61 (dd, J = 10.3, 4.4 Hz, 1H, Hα), 4.53-4.47 
(m, 2H, Hα), 4.22 (dd, J = 9.8, 4.2 Hz, 1H, Lys-Hα), 3.39-3.29 (m, 6H, CH2), 3.26-
3.22 (m, 1H, CH2), 3.01-2.80 (m, 5H, CH2), 2.53-2.44 (m, 1H, Inp-Hα), 1.87-1.50 (m, 
8H, CH2), 1.35-1.22 (m, 2H, CH2), ppm. ESI-LC-MS m/z 433.8 [M + 2H]2+; HRMS 
(ESI-MS) calcd. for C45H53FN9O6S  [M + H]+ 866.3824 found 866.3850. 
 
H-Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2: GHRP-1 (8) 
The product was purified by preparative HPLC (15-80% MeCN + 0.1% TFA). 
This yielded a white powder (26.4 mg, 19%): 1H-NMR (400 MHz, CD3OD); His, D-2-
Nal, Trp, D-Phe: δ 8.41 (s, 1H, His Hε), 7.81-7.71 (m, 3H, ArH), 7.65 (s, 1H, ArH), 7.49 
(d, J = 7.8 Hz, 1H, ArH), 7.46-7.40 (m, 2H, ArH), 7.35 (dd, J = 8.4, 1.7 Hz, 1H, ArH), 
7.31 (d, J = 8.1 Hz, 1H, ArH), 7.24-7.13 (m, 3H, ArH), 7.10-7.04 (m, 4H, ArH), 7.00 (t, J 
= 7.5 Hz, 1H, ArH), 6.89 (d, J = 0.8 Hz, 1H, His Hδ), 4.67-4.60 (m, 2H, Hα), 4.38 (t, J = 
7.4 Hz, 1H, Hα), 4.32 (t, J = 7.7 Hz, 1H, Hα), 3.25-2.68 (m, 8H, Hβ), Ala, Ala: 4.17-4.10 
(m, 1H, Hα), 3.94 (q, J = 7.0 Hz, 1H, Hα), 1.35 (d, J = 7.1 Hz, 3H, CH3), 1.10-1.01 (m, 
3H, CH3), Lys: 4.17-4.10 (m, 1H, Hα), 3.25-2.68 (m, 2H, Hε), 1.81-1.70 (m, 1H, Hβ), 
1.58-1.45 (3H, Hβ, 2Hδ), 1.10-1.01 (m, 2H, Hγ), ppm. ESI-LC-MS m/z 478.5 [M + 2H]2+; 
HRMS (ESI-MS) calcd. for C51H63N12O7 [M + H]+ 955.4943 found 955.4964.   
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H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2: GHRP-2 (9) 
Purification by preparative HPLC (25-70% MeCN + 0.1% TFA) delivered the 
title peptide as a white powder (19.7 mg, 17%): 1H-NMR (400 MHz, CD3OD); D-2-Nal, 
Trp, D-Phe: δ 7.76 (d, J = 9.2 Hz, 2H, ArH), 7.73 (s, 1H, ArH), 7.65 (s, 1H, ArH), 7.51-
7.47 (m, 1H, ArH), 7.44-7.37 (m, 2H, ArH), 7.35 (dd, J = 8.4, 1.7 Hz, 1H, ArH), 7.25-
7.14 (m, 4H, ArH), 7.09-7.01 (m, 4H, ArH), 7.00 (s, 1H, ArH), 4.77 (dd, J = 10.9, 4.6 
Hz, 1H, Hα), 4.49 (t, J = 6.8 Hz, 1H, Hα), 4.36 (t, J = 7.6 Hz, 1H, Hα), 3.11 (t, J = 6.7 Hz, 
2H, Hβ), 3.07 (d, J = 4.5 Hz, 1H, Hβ), 2.88-2.70 (m, 3H, Hβ), D-Ala, Ala: 4.23 (q, J = 7.1 
Hz, 1H, Hα), 3.79 (q, J = 7.0 Hz, 1H, Hα), 1.27 (d, J = 7.2 Hz, 3H, CH3), 1.00 (d, J = 7.1 
Hz, 3H, CH3), Lys: 4.16 (dd, J = 10.3, 4.1 Hz, 1H, Hα), 2.88-2.70 (m, 2H, Hε), 1.82-1.72 
(m, 1H, Hβ), 1.56-1.43 (m, 3H, Hβ, 2Hδ), 1.07-0.96 (m, 2H, Hγ), ppm. ESI-LC-MS m/z 
409.9 [M + 2H]2+; HRMS (ESI-MS) calcd. for C45H55N9O6Na [M + Na]+ 840.4204 found 
840.4173.  
 
H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2: GHRP-6 (10) 
Purification by preparative HPLC (15-80% MeCN + 0.1% TFA) gave a white 
powder (19.7 mg, 14%): 1H-NMR (400 MHz, CD3OD); His, D-Trp, Trp, D-Phe: δ 8.46 
(s, 1H, His Hε), 7.54 (d, J = 7.8 Hz, 1H, ArH), 7.46 (d, J = 7.8 Hz, 1H, ArH), 7.28 (t, J = 
7.7 Hz, 2H, ArH), 7.23-7.13 (m, 4H, ArH), 7.12-6.92 (m, 8H, 7ArH, His Hδ), 4.47 (t, J = 
7.4 Hz, 2H, Trp Hα), 4.35 (t, J = 6.7 Hz, 1H, Hα), 4.28 (t, J = 7.9 Hz, 1H, Hα), 3.22-3.14 
(m, 3H, Hβ), 3.14-3.02 (m, 3H, Hβ), 2.83 (d, J = 8.6 Hz, 2H, Hβ), Lys: 4.03 (dd, J = 10.3, 
3.9 Hz, 1H, Hα), 2.75 (t, J = 6.8 Hz, 2H, Hε), 1.76-1.63 (m, 1H, Hβ), 1.51-1.39 (m, 3H, 
Hβ, 2Hδ), 0.97-0.88 (m, 2H, Hγ), Ala: 3.91 (q, J = 7.2 Hz, 1H, Hα), 0.86 (d, J = 7.3 Hz, 
3H, CH3) ppm. ESI-LC-MS m/z 437.4 [M + 2H]2+; HRMS (ESI-MS) calcd. for 
C46H57N12O6 [M + H]+ 873.4524 found 873.4531. 
 
H-His-D-Trp-Ala-Trp-D-Phe-Lys(4-FB)-NH2: [Lys6(4-FB)]GHRP-6 (11) 
The product was purified by preparative HPLC (15-80% MeCN + 0.1% TFA). 
This yielded a white powder (9.60 mg, 7%): 1H-NMR (400 MHz, CD3OD); His, D-Trp, 
Trp, D-Phe, 4-FB: δ 8.50 (s, 1H, His Hε), 7.88-7.80 (m, 2H, F-ArH), 7.57 (d, J = 7.9 
Hz, 1H, ArH), 7.49 (d, J = 7.8 Hz, 1H, ArH), 7.30 (t, J = 8.2 Hz, 2H, ArH), 7.26-6.95 
(m, 14H, 13ArH, His Hδ), 4.53-4.46 (m, 2H, Hα), 4.37-4.30 (m, 2H, Hα), 3.26-3.04 
(m, 6H, Hβ), 2.87 (d, J = 8.0 Hz, 2H, Hβ), Lys: 4.04 (dd, J = 10.2, 4.0 Hz, 1H, Hα), 
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3.26-3.04 (m, 2H, Hε), 1.81-1.70 (m, 1H, Hβ), 1.58-1.43 (m, 3H, 2Hδ, Hβ), 1.06-0.97 
(m, 2H, Hγ), Ala: 3.94 (q, J = 7.3 Hz, 1H, Hα), 0.87 (d, J = 7.3 Hz, 3H, CH3) ppm. 
ESI-LC-MS m/z 498.4 [M + 2H]2+; HRMS (ESI-MS) calcd. for C53H59FN12O7Na [M + 
Na]+ 1017.4511 found 1017.4522. 
 
H-His-D-Trp-Ala-Trp-D-Phe-Dpr-NH2: [Dpr6]GHRP-6 (12) 
Purification by preparative HPLC (15-80% MeCN + 0.1% TFA) furnished the 
title peptide as a white powder (4.7 mg, 3 %): 1H-NMR (400 MHz, CD3OD); 8.49 (s, 1H 
His Hε), 7.55 (d, J = 7.9 Hz, 1H, ArH), 7.46 (d, J = 7.9 Hz, 1H, ArH), 7.30 (t, J = 8.6 Hz, 
2H, ArH), 7.21-7.12 (m, 3H, ArH), 7.11-7.04 (m, 3H, ArH), 7.02-6.92 (m, 5H, ArH), 
6.89 (d, J = 1.0 Hz, 1H, His Hδ), 4.62 (t, J = 6.8 Hz, 1H, Hα), 4.52 (t, J = 7.9 Hz, 1H, Hα), 
4.42-4.33 (m, 2H, Hα), 4.28 (t, J = 6.7 Hz, 1H, Dpr-Hα), 4.00 (q, J = 7.3 Hz, 1H, Ala-Hα), 
3.24-3.11 (m, 3H, CH2), 3.12-2.92 (m, 5H, CH2), 2.89-2.76 (m, 2H, CH2), 0.94 (d, J = 7.3 
Hz, 3H, Ala-CH3), ppm. ESI-LC-MS m/z 831.4 [M + H]+; HRMS (ESI-MS) calcd. for 
C43H51N12O6 [M + H]+ 831.4055 found 831.4070. 
 
H-His-D-Trp-Ala-Trp-D-Phe-Dpr(4-FB)-NH2: [Dpr6(4-FB)]GHRP-6 (13) 
Preparative HPLC (25-70% MeCN + 0.1% TFA) gave the title compound as a 
white solid (19.8 mg, 14%): 1H-NMR (400 MHz, CD3OD); His, D-Trp, Trp, D-Phe, 4-
FB: δ 8.58 (d, J = 1.3 Hz, 1H, His Hε), 7.82-7.75 (m, 2H, F-ArH), 7.52 (d, J = 7.9 Hz, 
1H, ArH), 7.40 (d, J  = 7.9 Hz, 1H, ArH), 7.27 (dd, J  = 8.6, 1.5 Hz, 2H, ArH), 7.15-
7.07 (m, 5H, ArH), 7.06-6.98 (m, 6H, ArH), 6.97-6.89 (m, 3H, 2ArH, His Hδ), 4.54-
4.45 (m, 1H, Hα), 4.44-4.30 (m, 3H, Hα), 3.22-2.98 (m, 6H, Hβ), 2.93-2.74 (m, 2H, 
Hβ), Dpr: 4.54-4.45 (m, 1H, Hα), 3.67 (dd, J = 13.8, 5.6 Hz, 1H, Hβ), 3.54 (dd, J = 
13.8, 7.8 Hz, 1H, Hβ), Ala: 3.93 (q, J = 7.3 Hz, 1H, Hα), 0.86 (d, J = 7.3 Hz, 3H, CH3) 
ppm. ESI-LC-MS m/z 477.4 [M + 2H]2+; HRMS (ESI-MS) calcd. for C50H54FN12O7 [M 
+ H]+ 953.4223 found 953.4237. 
 
H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2: G7039* (14) 
Purification of the peptide proceeded through preparative HPLC (25-80% MeCN 
+ 0.1% TFA). The title compound was obtained as a white powder (6.70 mg, 7%): 1H-
NMR (400 MHz, CD3OD); 7.80-7.76 (m, 1H, ArH), 7.74 (dd, J = 6.1, 2.2 Hz, 2H, ArH), 
7.70 (dd, J = 8.5, 3.5 Hz, 3H, ArH), 7.56 (s, 1H, ArH), 7.50 (s, 1H, ArH), 7.46-7.35 (m, 
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4H, ArH), 7.26 (dd, J = 8.5, 1.5 Hz, 1H, ArH), 7.20-7.10 (m, 6H, ArH), 4.66-4.56 (m, 
2H, Hα), 4.50 (dd, J = 9.3, 5.4 Hz, 1H, Hα), 4.30 (dd, J = 9.5, 4.7 Hz, 1H, Lys-Hα), 3.20-
2.80 (m, 10H, CH2), 2.78-2.64 (m, 2H, CH2), 2.33-2.24 (m, 1H, Inp-Hα), 1.92-1.82 (m, 
1H, CH2), 1.74-1.65 (m, 1H, CH2), 1.64-1.44 (m, 5H, CH2), 1.44-1.24 (m, 3H, CH2), 
ppm. ESI-LC-MS m/z 399.8 [M + 2H]2+; HRMS (ESI-MS) calcd. for C47H56N7O5 [M + 
H]+ 798.4343 found 798.4339. HRMS data and yield has been reported previously[35], 
whereas the 1H-NMR data has not. 
 
H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(4-FB)-NH2: [Lys5(4-FB)]G7039 (15) 
Preparative HPLC (35-80% MeCN + 0.1% TFA) furnished the title compound as 
a white solid (5.90 mg, 6%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.50 (d, J = 8.2 Hz, 1H, 
NH), 8.45 (t, J = 5.5 Hz, 1H, NH), 8.39 (s, 1H, NH), 8.15-8.09 (m, 2H, NH), 8.04 (d, 
J = 8.4 Hz, 1H, NH), 7.86-7.82 (m, 2H, F-ArH), 7.82-7.76 (m, 2H, ArH), 7.75-7.66 
(m, 4H, ArH), 7.58 (s, 1H, ArH), 7.48 (s, 1H, ArH), 7.45-7.38 (m, 4H, ArH), 7.31 
(dd, J = 8.5, 1.5 Hz, 1H, ArH), 7.28 (s, 1H, ArH), 7.26 (s, 1H, NH), 7.24-7.17 (m, 5H, 
ArH), 7.15-7.08 (m, 2H, ArH), 7.04 (s, 1H, NH), 4.66-4.60 (m, 1H, Hα), 4.60-4.53 
(m, 2H, Hα), 4.20-4.14 (m, 1H, Lys-Hα), 3.25-3.14 (m, 2H, CH2), 3.13-3.02 (m, 3H, 
CH2), 2.98-2.91 (m, 1H, CH2), 2.90-2.83 (m, 1H, CH2), 2.81-2.56 (m, 5H, CH2), 2.30-
2.22 (m, 1H, Inp-Hα), 1.75-1.65 (m, 1H, CH2), 1.62-1.55 (m, 1H, CH2), 1.54-1.43 (m, 
6H, CH2), 1.38-1.19 (m, 2H, CH2), ppm. ESI-LC-MS m/z 452.5 [M + 4H - F]2+; HRMS 
(ESI-MS) calcd. for C54H59FN7O6 [M + H]+ 920.4511 found 920.4529. 
 
H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2: [1-Nal4]G7039 (16) 
Peptide purification by preparative HPLC (25-80% MeCN + 0.1% TFA) 
delivered a white powder (24.9 mg, 23%): 1H-NMR (400 MHz, CD3OD); δ 8.12 (d, J = 
8.4 Hz, 1H, ArH), 7.84 (d, J = 7.8 Hz, 1H, ArH), 7.78-7.72 (m, 2H, ArH), 7.68 (d, J = 
8.5 Hz, 3H, ArH), 7.62-7.46 (m, 5H, ArH), 7.43-7.35 (m, 5H, ArH), 7.30 (d, J = 6.4 
Hz, 1H, ArH), 7.27-7.21 (m, 2H, ArH), 7.02 (dd, J = 8.4, 1.5 Hz, 1H, ArH), 4.69 (dd, 
J = 9.4, 5.4 Hz, 1H, Hα), 4.65-4.55 (m, 2H, Hα), 4.32 (dd, J = 9.4, 4.8 Hz, 1H, Lys-
Hα), 3.65 (dd, J = 14.4, 5.4 Hz, 1H, CH2), 3.20-3.10 (m, 2H, CH2), 3.05-2.94 (m, 3H, 
CH2), 2.92-2.80 (m, 5H, CH2), 2.76-2.62 (m, 2H, CH2), 2.30-2.23 (m, 1H, Inp-Hα), 
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1.92-1.81 (m, 1H, CH2), 1.75-1.29 (m, 9H, CH2), ppm. ESI-LC-MS m/z 424.8 [M + 
2H]2+; HRMS (ESI-MS) calcd. for C51H58N7O5 [M + H]+ 848.4499, found 848.4501.       
 
H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(4-FB)-NH2: [1-Nal4,Lys5(4-FB)]G7039 (17) 
The product was purified by preparative HPLC (25-90% MeCN + 0.1% TFA) 
which yielded a white powder (9.80 mg, 9%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.64 (d, 
J = 8.3 Hz, 1H, NH), 8.46 (t, J = 5.5 Hz, 1H, NH), 8.33 (s, 1H, NH), 8.25 (d, J = 8.4 
Hz, 1H, ArH), 8.13 (d, J = 8.0 Hz, 1H, NH), 8.09 (d, J = 7.5 Hz, 1H, NH), 8.03 (d, J 
= 8.5 Hz, 1H, NH), 8.01-7.97 (m, 1H, NH), 7.89 (d, J = 8.2 Hz, 1H, ArH), 7.86-7.80 
(m, 2H, F-ArH), 7.79-7.72 (m, 3H, ArH), 7.71-7.66 (m, 2H, ArH), 7.58-7.50 (m, 4H, 
ArH), 7.44 (d, J = 6.9 Hz, 1H, ArH), 7.42-7.34 (m, 5H, ArH), 7.31-7.25 (m, 2H, 
ArH), 7.21-7.15 (m, 3H, 2F-ArH, ArH), 7.07 (s, 1H, NH), 7.02 (d, J = 8.4 Hz, 1H, 
ArH), 4.72-4.65 (m, 1H, Hα), 4.62-4.50 (m, 2H, Hα), 4.19 (dd, J = 13.3, 8.4 Hz, 1H, 
Lys-Hα), 3.61 (dd, J = 14.3, 3.9, 1H, CH2), 3.24-3.00 (m, 5H, CH2), 2.97-2.89 (m, 1H, 
CH2), 2.82-2.49 (m, 5H, CH2), 2.29-2.19 (m, 1H, Inp-Hα), 1.78-1.66 (m, 1H, CH2), 
1.66-1.54 (m, 1H, CH2), 1.53-1.40 (m, 5H, CH2), 1.40-1.16 (m, 2H, CH2), ppm. ESI-
LC-MS m/z 477.4 [M + 4H - F]2+; HRMS (ESI-MS) calcd. for C58H61FN7O6 [M + H]+ 
970.4667 found 970.4693. 
3.4.6 Synthesis of 4-(tert-butoxycarbonyl)-N,N,N-trimethylbenzenammonium triflate 
(20) 
4-dimethylaminobenzoic acid (1.00 g, 6.05 mmol, 1.0 equiv.) was added to THF 
(50 ml) and the resultant mixture stirred and cooled to 0°C. After 15 minutes, 
trifluoroacetic anhydride (1.85 ml, 13.3 mmol, 2.2 equiv.) was added dropwise and the 
consequent blue solution stirred (35 mins). Addition of tBuOH (11.4 ml, 119 mmol, 19.7 
equiv.) was followed by further stirring at room temperature (2 hrs). The solution was 
then poured into saturated NaHCO3 (250 ml) and extracted with DCM (3x 100 ml, 3x 50 
ml). The combined organic layers were dried (MgSO4), filtered by gravity and residual 
solvent removed by rotary evaporation. This delivered a black oil which was eluted 
through a silica pad (DCM, 60 ml) and solvent removed by concentration in vacuo. The 
final yellow oil (1.12 g, crude) was then re-dissolved in DCM (dry, 30 ml) and cooled to 
0°C under a blanket of N2. This was followed by the addition of MeOTf (0.86 ml, 7.61 
mmol, 1.5 equiv.) and stirring at 0°C (1 hr). The reaction mixture was then poured into an 
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ice-cold solution of Et2O (200 ml) which caused instant precipitation of the product salt 
as a white crystalline solid (740 mg, 38%): 1H-NMR (400 MHz, CD3COCD3); δ 8.24 
(d, J = 9.3 Hz, 2H), 8.18 (d, J = 9.3 Hz, 2H), 3.91 (s, 9H, NMe3), 1.60 (s, 9H, 
OC(CH3)3); 13C-NMR (100 MHz, CD3COCD3); δ 205.5 (CO) 163.6 (ArC), 133.7 
(ArC), 131.0 (ArC), 120.9 (ArC), 81.7, 56.9, 27.3 (CH3CO) ppm. ESI-MS m/z 165.1 
[C10H13O2]+; HRMS (ESI-MS) calcd for C14H22NO2 [M-CF3O3S]+ 236.1651, found 
236.1658. 
3.4.7 Receptor-ligand binding assay 
Competitive binding assays were carried out using HEK293/GHS-R1a cells with 
[125I]ghrelin as the competitive radioligand. A solution of binding buffer (50 ml, pH 7.4) 
was made up by adding 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES, 0.3 
g, 25 mM), MgCl2 (0.051 g, 5 mM), CaCl2 (7.4 x 10-3 g, 1 mM), EDTA (0.015 g, 2.5 
mM) and BSA (0.2 g, 0.4%) to distilled water. pH adjusted with 5 M HCl. The resultant 
solution was filtered through a 0.22 μm syringe filter and kept on ice.  
An aliquot of frozen cells (HEK293T cells transiently transfected with GHS-R1a 
by means of calcium phosphate transfection for 48 hours before being harvested and 
fragmented by 50, 000 g centrifugation and frozen to 2 million cells per vial in 10 % 
DMSO in FBS) was thawed to room temperature (1.5 x 106 cells/pellet), centrifuged 
(3000 rpm, 10 mins, room temperature) and the subsequent cell pellet re-suspended in 
binding buffer (2 ml) and placed on ice. A stock solution of peptide/peptidomimetic was 
diluted in binding buffer to acquire final concentrations between 10-5 to 10-11 M and 
added (30 µl) to these cells (50 µl) in triplicate. 
[125I]-ghrelin (10 µl) was added to binding buffer (3 ml) and vortexed. An aliquot 
of this [125I]-ghrelin solution (20 µl) was counted on a Cobra II Auto-Gamma gamma 
counter and initial volume adjusted to obtain 14000-17000 counts per minute (cpm) per 
20 µl aliquot. [125I]-ghrelin (20 µl) was added to each peptide/peptidomimetic-cell 
mixture, to give a final volume of 300 µl in binding buffer. Each solution concentration 
was vortexed, followed by agitation (550 rpm, 20 mins, 37 °C). After 20 minutes, samples 
were spun (13 000 rpm, 5 mins, 4 °C) and placed on ice. The supernatant was removed 
and the cell pellet rinsed with ice-cold Tris-HCl (200 µl, 50 mM, pH 7.4). The samples 
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were spun again (13,000 rpm, 5 mins, 4 °C), cooled on ice, supernatant removed and cell 
pellet counted using a Cobra II Auto-Gamma gamma counter.  
All binding assays were performed in triplicate for each concentration of 
peptide/peptidomimetic. Binding buffer (300 µl) and [125I]-ghrelin (20 µl) alone were 
used as background controls. [125I]-ghrelin (20 µl) and cells (50 µl) in binding buffer (230 
µl) were used to calculate the percentage of bound [125I]-ghrelin displaced by each 
concentration of peptide/peptidomimetic. 
3.4.8 Computation of partition coefficients (LogP) for peptides and peptidomimetics 
The n-octanol/water partition coefficients for all peptides and peptidomimetics 
were calculated using ACD/LogP prediction software from ACD/ChemSketch 
(Freeware) 2017.2.1.  
3.4.9 Calcium flux dose-response assay 
This assay was used to determine the EC50 value for [1-Nal4,Lys5(4-FB)]G7039 in 
terms of intracellular Ca2+ release, with ghrelin used as the control ligand. The 
peptidomimetic compound was dissolved in DMSO (1 ml) at a concentration of 250 μM 
and solubility tested in Hank’s balanced salt solution (HBSS): 1.26 mM CaCl2, 0.493 
mM MgCl2·6H2O, 0.407 mM MgSO4·7H2O, 5.33 mM KCl, 0.441 mM KH2PO4, 4.17 
mM NaHCO3, 137.9 mM NaCl, 0.338 mM Na2HPO4, 5.56 mM D-Glucose, 20 mM 
HEPES, pH 7.4 with a final concentration of 1.2 % DMSO. Following successful 
solubility, human recombinant GHS-R1a calcium-optimised stable cell lines (chem-1 
cells) were loaded with a fluorescent calcium dye (Fluo-8 NW from ABD Bioquest 
21080) and calcium flux detected in response to the agonist by a Molecular Devices 
FLIPRTETRA instrument in a modified HBSS buffer (20 mM HEPES, 2.5 mM Probenecid, 
pH 7.4). Fluorescence values underwent baseline correction and the percentage activation 
was normalised to the maximum response (Emax) of the control ligand ghrelin. The 
agonist assay was performed for a total of 180 seconds and each assay concentration was 
performed in duplicate. 
3.4.10 Serum stability study 
A Waters Oasis HLB plate was used for both collection and extraction. The 
peptidomimetic [1-Nal4,Lys5(4-FB)]G7039 was incubated in a solution of 25% human 
serum in PBS for 24 hours. Aliquots were removed at 0, 20, 60, 240, 420, and 1440 
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minutes, with each time-point performed in triplicate. These aliquots were then mixed 
with 4% (v/v) ammonium hydroxide (NH4OH) in water to denature peptidomimetic-
serum (albumin) interactions. [1-Nal4,Lys5(4-FB)]G7039 was then extracted from human 
serum using 20% MeOH/2% HCO2H in water and quantified by UHPLC-MS. The 
amount was then expressed as the percentage of the area under the curve (AUC) in the 
UV chromatogram relative to time 0, plotted against time (minutes) and data fitted to a 
curve of exponential decay to determine the serum half-life (t1/2).   
3.4.11 Radiochemistry 
 
General information  
All reagents and solvents used for radiosynthesis were purchased from Sigma-
Aldrich unless otherwise specified. 18F-fluoride was produced via the 18O(p,n) 18F 
reaction in a GE PETtrace 880 cyclotron (Lawson Health Research Institute, London, 
Ontario, Canada). A Biotage V-10 evaporator was used to remove solvent. A Waters 
HPLC with a 1525 binary pump system (solvent A = MeCN + 0.1% TFA, solvent B = 
H2O + 0.1% TFA) and two detectors (Waters 2487 Dual λ absorbance detector set at 254 
nm and a radioactive flow count detector) were utilised for product analysis and 
purification. An analytical column (Agilent Eclipse XDB-C18, 4.6 × 150 mm, 5 μm) was 
used for determining radiochemical purity and molar activity of [1-Nal4,Lys5(4-[18F]-
FB)]G7039. A semi-preparative column (Agilent Zorbax SB-C18, 9.4 × 150 mm, 5 μm) 
was used for the purification of [18F]SFB and [1-Nal4,Lys5(4-[18F]-FB)]G7039.  
 
Synthesis of [18F]FBA 
Scheme 1 shows the synthetic pathway to [18F]FBA. Aqueous [18F]fluoride was 
trapped on a Waters Sep-Pak Accell Plus Light (46 mg) QMA Carbonate cartridge pre-
activated with MilliQ water (10 ml). The initial radioactivity of the cartridge was 
measured using a dose calibrator (980-1300 MBq) A solution of acetonitrile/H2O (1 ml, 
25:75, v/v) containing potassium carbonate (2.1 mg, 0.015 mmol, 2.6 eq.) and 
4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (6.0 mg, 0.016 mmol, 2.8 
eq.) was used to elute [18F]fluoride into the reaction vial. The solvent was removed 
azeotropically under vacuum at 50 °C. [18F]fluoride was then dried a further two times 
under the aforementioned conditions by adding anhydrous acetonitrile (1 ml). 4-Tert-
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butoxycarbonyl)-N,N,N-trimethylbenzenammonium triflate (2.0 mg, 0.0057 mmol, 1.0 
eq.) in anhydrous DMSO (400 μl) was added to dried [18F]F- and the subsequent solution 
heated for 10 mins at 120 °C. Aqueous HCl (1 ml, 6 M) was added and the resultant 
mixture heated further (10 mins, 120 °C). Water (2 ml) was added to dilute the reaction 
mixture containing crude [18F]FBA. This solution was then trapped on two inter-
connected Waters Sep-Pak C-18 light cartridges sequentially pre-treated with ethanol (15 
ml) and water (15 ml). Elution of product then occurred using anhydrous acetonitrile (800 
μl) to deliver the title compound [18F]FBA in an average d.c. radiochemical yield of 82% 
(n = 3). This compound was used in the next step without further purification. To confirm 
that the correct product had been acquired, a co-injection of 4-[19F]-FBA and [18F]-FBA 
in water was performed (20 μl, 30-70% MeCN + 0.1% TFA gradient system, see Figure 
4.S3 supporting information).  
 
Synthesis of [18F]SFB 
[18F]FBA was trapped onto two inter-connected Waters Sep-Pak C-18 light 
cartridges sequentially pre-treated with ethanol (15 ml) and water (15 ml) and eluted with 
acetonitrile (800 μl) into a vial charged with NHS (29 mg, 0.25 mmol.) and EDC (71 mg, 
0.46 mmol.). The resultant solution was allowed to stand at room temperature for 15-20 
minutes before being diluted with water + 0.1% TFA (1.2 ml) and purified by semi-
preparative HPLC (30-70% MeCN + 0.1% TFA gradient system). After solvent removal 
(V-10 evaporator, 36 °C) dry [18F]SFB was obtained in an average d.c. radiochemical 
yield of 71% (n = 3) and ³ 99% radiochemical purity. 
 
Synthesis of [1-Nal4, Lys5(4-[18F]-FB)]G7039 
A solution of [1-Nal4]G7039 (2.0 mg, 1.86 x 10-3 mmol.) in acetonitrile (100 μl) 
and H2O (100 μl) was added to the [18F]SFB, followed by DIPEA (10 μl) and the 
resultant solution heated to 65 °C for 15-20 minutes. Crude [1-Nal4, Lys5(4-[18F]-
FB)]G7039 began to precipitate out of solution as a white solid. The solvent was 
subsequently removed and the solid re-dissolved stepwise with DMF (300 μl), H2O (500 
μl) and MeCN (200 μl). This solution was purified by preparative HPLC (30-70% MeCN 
+ 0.1% TFA gradient system) and delivered the title [18F]radiolabelled peptidomimetic 
[1-Nal4,Lys5(4-[18F]-FB)]G7039 in an average d.c. radiochemical yield of 81% (n = 3), 
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an overall average d.c. radiochemical yield of 48% (n = 3), a radiochemical purity ≥ 99% 
and an average molar activity of 34 GBq/μmol (n = 3). 
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Amino acid sequences, lipophilicity data, HPLC chromatograms, 1H-NMR 
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Chapter 3 Supplementary Information 
 
 
Supplementary Table 3.1 - Synthesised peptides and peptidomimetics. 4-FB, 4-
fluorobenzoyl; AEEA, 2-(2-(2-aminoethoxy)ethoxy)acetic acid; D-2-Nal, D-2-
naphthylalanine; D-2-Thi, D-2-thienylalanine; Dpr, 2,3-diaminopropionic acid; Inp, 
isonipecotic acid 
 
Peptide/Peptidomimetic Amino Acid Sequence 
Ipamorelin H-Aib-His-D-2-Nal-D-Phe-Lys-NH2 
[Lys5(4-FB)]ipamorelin H-Aib-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 
[Lys5(AEEA-4-FB)]ipamorelin H-Aib-His-D-2-Nal-D-Phe-Lys(AEEA-4-FB)-NH2 
[D-2-Thi4,Lys5(4-FB)]ipamorelin H-Aib-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 
[Inp1,Lys5(4-FB)]ipamorelin H-Inp-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 
[Inp1,D-2-Nal4,Lys5(4-
FB)]ipamorelin 
H-Inp-His-D-2-Nal-D-2-Nal-Lys(4-FB)-NH2 
[Inp1,D-2-Thi4,Lys5(4-
FB)]ipamorelin 
H-Inp-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 
GHRP-1 H-Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 
GHRP-2 H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 
GHRP-6 H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 
[Lys6(4-FB)]GHRP-6 H-His-D-Trp-Ala-Trp-D-Phe-Lys(4-FB)-NH2 
[Dpr6]GHRP-6 H-His-D-Trp-Ala-Trp-D-Phe-Dpr-NH2 
[Dpr6(4-FB)]GHRP-6 H-His-D-Trp-Ala-Trp-D-Phe-Dpr(4-FB)-NH2 
G7039 H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2 
[Lys5(4-FB)]G7039 H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(4-FB)-NH2 
[1-Nal4]G7039 H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2 
[1-Nal4,Lys5(4-FB)]G7039 H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(4-FB)-NH2 
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Supplementary Figure 3.1 - Displacement curve for the endogenous ligand ghrelin 
 
 
 
 
 
Supplementary Table 3.2 - LogP values for peptides and peptidomimetics. These 
values were computed using ACD/LogP prediction software from ACD/Labs 
 
Peptidomimetic LogP 
Ipamorelin 1.72 ± 0.85 
[Lys5(4-FB)]ipamorelin 3.97 ± 0.89 
[Lys5(AEEA-4-FB)]ipamorelin 2.80 ± 0.93 
[D-2-Thi4,Lys5(4-FB)]ipamorelin 3.65 ± 0.90 
[Inp1,Lys5(4-FB)]ipamorelin 3.92 ± 0.89 
[Inp1,D-2-Nal4,Lys5(4-FB)]ipamorelin 5.15 ± 0.89 
[Inp1,D-2-Thi4,Lys5(4-FB)]ipamorelin 3.60 ± 0.89 
GHRP-1 2.60 ± 0.90 
GHRP-2 3.41 ± 0.86 
GHRP-6 1.51 ± 0.88 
[Lys6(4-FB)]GHRP-6 3.76 ± 0.92 
[Dpr6]GHRP-6 1.61 ± 0.89 
[Dpr6(4-FB)]GHRP-6 3.86 ± 0.93 
G7039 5.28 ± 0.82 
[Lys5(4-FB)]G7039 7.53 ± 0.88 
[1-Nal4]G7039 6.51 ± 0.82 
[1-Nal4,Lys5(4-FB)]G7039 8.76 ± 0.88 
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Supplementary Figure 3.2 - Decay-curve for the lead peptidomimetic [1-Nal4,Lys5(4-
FB)]G7039 in human serum. The amount of peptidomimetic is expressed as the 
percentage of the area under the curve (AUC) from time = 0 (T0) in the UV 
chromatogram. Each time point was performed in triplicate 
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Supplementary Figure 3.3 - Radiochromatogram of [19F]FBA and [18F]FBA co-
injection 
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Supplementary Figure 3.4 - Radiochromatogram of [18F]SFB 
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Peptidic and peptidomimetic HPLC chromatograms 
 
Ipamorelin: H-Aib-His-D-2-Nal-D-Phe-Lys-NH2 (1) 
 
 
 
 
 
[Lys5(4-FB)]ipamorelin: H-Aib-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2  (2) 
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[Lys5(AEEA-4-FB)]ipamorelin: H-Aib-His-D-2-Nal-D-Phe-Lys(AEEA-4-FB)-NH2 (3) 
 
 
 
 
 
 
[D-2-Thi4,Lys5(4-FB)]ipamorelin: H-Aib-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 (4) 
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[Inp1,Lys5(4-FB)]ipamorelin: H-Inp-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 (5) 
 
 
 
 
 
 
[Inp1,D-2-Nal4,Lys5(4-FB)]ipamorelin: H-Inp-His-D-2-Nal-D-2-Nal-Lys(4-FB)-NH2 (6) 
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[Inp1,D-2-Thi4,Lys5(4-FB)]ipamorelin: H-Inp-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2  (7) 
 
 
 
 
 
 
GHRP-1: H-Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (8) 
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GHRP-2: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (9) 
 
 
 
 
 
GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (10) 
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[Lys6(4-FB)]GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Lys(4-FB)-NH2 (11) 
 
 
 
 
 
 
[Dpr6]GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Dpr-NH2 (12) 
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[Dpr6(4-FB)]GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Dpr(4-FB)-NH2 (13) 
 
 
 
 
 
 
G7039: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2 (14) 
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[Lys5(4-FB)]G7039: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(4-FB)-NH2 (15) 
 
 
 
 
 
 
 
[1-Nal4]G7039: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2 (16) 
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[1-Nal4,Lys5(4-FB)]G7039: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(4-FB)-NH2 (17) 
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Peptidic- and peptidomimetic 1H-NMR spectra 
 
Ipamorelin: H-Aib-His-D-2-Nal-D-Phe-Lys-NH2 (1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
160 
[Lys5(4-FB)]ipamorelin: H-Aib-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 (2) 
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[Lys5(AEEA-4-FB)]ipamorelin: H-Aib-His-D-2-Nal-D-Phe-Lys(AEEA-4-FB)-NH2 (3) 
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[D-2-Thi4,Lys5(4-FB)]ipamorelin: H-Aib-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 (4) 
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[Inp1,Lys5(4-FB)]ipamorelin: H-Inp-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 (5) 
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[Inp1,D-2-Nal4,Lys5(4-FB)]ipamorelin: H-Inp-His-D-2-Nal-D-2-Nal-Lys(4-FB)-NH2 (6) 
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[Inp1,D-2-Thi4,Lys5(4-FB)]ipamorelin: H-Inp-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 (7) 
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GHRP-1: H-Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (8) 
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GHRP-2: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (9) 
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GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (10) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
169 
[Lys6(4-FB)]GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Lys(4-FB)-NH2 (11) 
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[Dpr6]GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Dpr-NH2 (12) 
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[Dpr6(4-FB)]GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Dpr(4-FB)-NH2 (13) 
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G7039: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2 (14) 
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[Lys5(4-FB)]G7039: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(4-FB)-NH2 (15) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
174 
[1-Nal4]G7039: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2 (16) 
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[1-Nal4,Lys5(4-FB)]G7039: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(4-FB)-NH2 (17) 
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Peptidic- and peptidomimetic displacement curves 
 
Ipamorelin (1) 
 
[Lys5(4-FB)]ipamorelin (2)
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[Lys5(AEEA-4-FB)]ipamorelin (3)
 
 
 
[D-2-Thi4,Lys5(4-FB)]ipamorelin (4)
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[Inp1,Lys5(4-FB)]ipamorelin (5)
 
 
 
[Inp1,D-2-Nal4,Lys5(4-FB)]ipamorelin (6)
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[Inp1,D-2-Thi4,Lys5(4-FB)]ipamorelin (7)
 
 
GHRP-1 (8) 
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GHRP-2 (9) 
 
 
GHRP-6 (10) 
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[Lys6(4-FB)]GHRP-6 (11)
 
 
 
[Dpr6]GHRP-6 (12) 
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[Dpr6(4-FB)]GHRP-6 (13)
 
 
G7039* (14) 
 
* Please note that this data has already been published1, but is presented here for 
completeness. 
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[Lys5(4-FB)]G7039 (15) 
 
[1-Nal4]G7039 (16) 
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[1-Nal4,Lys5(4-FB)]G7039 (17) 
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UHPLC chromatogram of 4-(tert-butoxycarbonyl)-N,N,N-
trimethylbenzenammonium triflate (20) 
 
 
1H-NMR spectrum of 4-(tert-butoxycarbonyl)-N,N,N-trimethylbenzenammonium 
triflate (20) 
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13C-NMR spectrum of 4-(tert-butoxycarbonyl)-N,N,N-trimethylbenzenammonium 
triflate (20) 
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Chapter 43 
 
Single Amino Acid Replacement in G7039 Leads to a 70-Fold Increase in Binding 
Towards GHS-R1a 
4.1 Introduction 
Ghrelin is a hormone produced mainly by the stomach that was first discovered in 
1999 by Kojima et al1. Ghrelin actions are mediated via activation of the G Protein 
Coupled Receptor (GPCR) growth hormone secretagogue receptor type 1a (GHS-R1a)1,2. 
It was originally reported that GHS-R1a was found within the pituitary gland and 
hypothalamus2 but recent work has revealed a more widespread expression in other 
tissues, including other regions of the brain and heart3,4. GHS-R1a is also reported to be 
differentially expressed in certain cancer cells. For example, GHS-R1a activation 
increases cellular proliferation in prostate cancer through activation of the p44/42 MAPK 
signalling pathway5-7. Overexpression of GHS-R1a increases the motile phenotype in 
astrocytomas, in which increased GHS-R1a expression is correlated with a higher tumor 
grade8. Overexpression of GHS-R1a has more recently been demonstrated in some 
ovarian epithelial carcinomas, a disease with poor prognosis due to the late stages in 
which this cancer is usually diagnosed9-14.  
A number of synthetic peptides acting as GHS-R1a agonists have been described. 
In 1977 Bowers et al, while undertaking structure-activity relationship (SAR) on 
enkephalin analogues, discovered that some of these derivatives were involved in the 
release of growth hormone (GH) from the pituitary gland in the female rats15-17.The 
hexamer H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 was identified as the first synthetic 
peptide to release GH both in vitro and in vivo through the activation of GHS-R1a. From 
this point on, researchers began to develop peptides that had the ability to release growth 
hormone through the activation of GHS-R1a, generating the class of compounds known 
as growth hormone secretagogues (GHSs)18. They are uniquely classified based on their 
function of secreting GH from the pituitary by activation of GHS-R1a, instead of the 
                                               
3 Lalonde, T.; Fowkes, M.; Hou, J.; Thibeault, P.; Milan, M.; Dhanvantari, S.; 
Ramachandran, R.; Luyt, L.G. Single Amino Acid Replacement in G-7039 Leads to a 70-
Fold Increase in Binding Towards GHS-R1a. Chem. Med. Chem, 2019, DOI: 
10.1002/cmdc.201900466. 
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through secondary release stimulated by the action of GH releasing hormone from the 
hypothalamus18-19.  
GHSs allow for a more rapid synthesis (5 to 6-mer peptides) compared to the full-
length ghrelin peptide and act as a small molecule when targeting the receptor20. Our 
development of these agonists was guided by work from Feighner et al. who utilized site 
directed mutagenesis to determine the key residues in GHS-R1a that interacted with the 
GHSs (GHRP-6, MK-0677, and L-692,585) they studied20. 
The starting peptidomimetic for this project was G7039 (H-Inp-D2Nal-D2Nal-
1Nal-Lys-NH2 or [1-Nal4]G7039). Previously, we reported on the evaluation of a 
fluorine-containing G7039 peptidomimetic ([1-Nal4, Lys5 (4-fluorobenzoyl-4-
FB)]G7039) as a positron emission tomography (PET) tracer, through addition of a 4-
fluorobenzoic acid (4-FBA) group on the C-terminal lysine, allowing for radiolabeling 
with fluorine-18 (18F) (panel B Figure 4.1)21.  
 
Figure 4.1 - (A) Starting peptidomimetic ([1-Nal4]G7039) to perform SAR. (B) 
Previously reported fluorine-containing G7039 peptidomimetic ([1-Nal4, Lys5 (4-
FB)]G7039)21. (C) Current peptidomimetics being studied with changes in the 
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fourth position to either Ser and/or Phe, and Tyr (indicated by red X), and 
modification of prosthetic group from 4-FB to 2-FP (seen in blue) 
 
This led to a compound that had moderate affinity for GHS-R1a (IC50 = 69 nM compared 
to ghrelin IC50 = 3 to 5 nM) in addition to high lipophilicity (cLogP of 6.51 ± 0.82)21. 
This lead candidate was assessed in a healthy mouse model (C57BL/6) and showed 
significant uptake in off target tissues (e.g. liver, spleen, kidneys, and lungs), as expected 
due to the high lipohphilicity22. However, it was noted that the first 3 amino acids were 
important for binding and activating the receptor, therefore, to improve receptor affinity, 
modifications of only the fourth position were proposed, leaving the C-terminal lysine 
free for the attachment of a different prosthetic group21. The main goal of this current 
work was to evaluate different amino acids in the fourth position in order to reduce the 
cLogP and improve the binding affinity towards GHS-R1a. An additional goal was to 
switch from the 4-FB group to a 2-fluoropropionyl group (2-FP), appended to the side-
chain of the C-terminal lysine. This change in prosthetic group was expected to decrease 
the hydrophobicity, but still provide a facile radiolabelling route to the  
synthesis of a PET probe23.  These proposed structural modifications can be seen in panel 
C, Figure 4.1. In total seven G7039 analogues were synthesized and evaluated for GHS-
R1a affinity by a competitive binding assay (IC50), a β-arrestin-1 and β-arrestin-2 
recruitment assay (EC50), and a computational docking study. This led to the discovery of 
novel peptides with high affinity and potency that have potential to be used as 
therapeutics and/or imaging agents when targeting GHS-R1a. 
4.2 Results and Discussion 
As an initial step, the previously used prosthetic group 4-FB located off the ε-
amine of the C-terminal lysine, was replaced with the smaller 2-FP group to give 
compound 2. This analogue maintained moderate GHS-R1a affinity while maintaining 
relatively high cLogP value (Table 4.1). Further structure activity relationship studies 
were undertaken to change the fourth position in order to improve both the affinity and 
cLogP of this class of peptidomimetics. 
 
Table 4.1 - Peptidomimetics with calculated binding numbers (IC50) and predicted 
lipophilicity (cLogP). Only the fourth position was changed and evaluated with the 
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exception of compound 3 and 4. The 2-fluoropropionic acid group was added to Lys 
5 in all cases except compounds 1 and 7 
 
All peptides in Table 4.1 were synthesized using Fmoc solid-phase peptide chemistry, 
purified using reverse-phase high performance liquid chromatography (RP-HPLC) and 
analyzed by ESI-MS. To allow the addition of the fluorine-containing entity, peptides 
required an orthogonal Alloc protecting group on the C-terminal lysine to allow for 
selective deprotection and coupling to the 2-fluoropropionic acid (2-FPA) prosthetic 
group. Purity for each peptide was greater than 98% as determined by UHPLC (Table 
4.S1).  
To test the affinity of these peptides towards GHS-R1a, a competitive binding 
assay was performed with [125I] human ghrelin as the competitor (Table 4.1). When a 
non-aromatic amino acid was present in the fourth position, affinity towards GHS-R1a is 
diminished. Compound 3 and 6, with Ser in position 4, have IC50 values of 62.9 nM and 
60.3 nM respectively. If an aromatic group is in the fourth position, as per Phe for 
compound 4, the affinity improves to 4.35 nM. Moreover, when incorporating Tyr in the 
fourth position the binding substantially improves to 0.28 nM (compound 5). The 2-FP 
group was removed from compound 5 in order to confirm that the increase in binding was 
due to the Tyr in the 4th position. With no 2-FP prosthetic group compound 7 was found 
to maintain this sub-nanomolar affinity with an IC50 of 0.70 nM.  
As modifications were made to the C-terminal amino acids of the peptidomimetic, 
it was noted that when Phe remains in either the fourth or fifth position (compound 4 and 
Compound 
Number 
Peptide Sequence IC50 
(nM) 
cLogP 
(ACD/Labs) 
1 H-Inp-D2Nal-D2Nal-Phe-Lys-NH2 5.2 5.28 ± 0.82 
2 H-Inp-D2Nal-D2Nal-Phe-Lys(2-FP)-NH2 19 4.34 ± 0.90 
3 H-Inp-D2Nal-D2Nal-Ser-Phe-Lys(2-FP)-NH2 62.9 4.33 ± 0.90 
4 H-Inp-D2Nal-D2Nal-Phe-Ser-Lys(2-FP)-NH2 4.35 4.33 ± 0.90 
5 H-Inp-D2Nal-D2Nal-Tyr-Lys(2-FP)-NH2 0.28 2.77 ± 0.87 
6 H-Inp-D2Nal-D2Nal-Ser-Lys(2-FP)-NH2 60.3 2.77 ± 0.87 
7 H-Inp-D2Nal-D2Nal-Tyr-Lys-NH2 0.70 2.69 ± 0.89 
 
 
191 
3 respectively in Table 4.1) the cLogP remains above 4. However, when the fourth 
position is a Tyr or Ser, cLogP drops below 3. This lowered cLogP is desirable and could 
help with improving pharmacokinetic behavior in vivo. Tyrosine in the fourth position 
was the optimal amino acid change, dramatically decreasing the cLogP (comparing 
compounds 1-4 vs. compound 5 and 7). The addition or absence of the 2-FP prosthetic 
group doesn’t drastically change the cLogP values (compound 5 vs. 7).  
  Next, we wanted to assess the potency of the peptides through monitoring the 
recruitment of β-arrestin-1 and β-arrestin-2 to GHS-R1a to obtain EC50 values for the 
peptides. Both of these intracellular proteins are normally recruited by the activation of 
GHS-R1a leading to its internalization and recyclization. In all cases, compounds 1 
through 7 were agonists for the receptor, with EC50 values in the sub-picomolar range. 
Based on the concentration-effect curves (Figure 4.2), some compounds were more 
potent and efficacious than others. From Table 4.2 the most potent peptide is compound 
2 (EC50 of 15.8 pM and 72.8 pM for β-arrestin-1 and β-arrestin-2, respectively), while 
compounds 3 (EC50 of 202.4 pM and 178.1 pM for β-Arrestin-1 and β-Arrestin-2 
respectively) and 7 (EC50 of 178.7 pM and 262.5 pM for β-Arrestin-1 and β-Arrestin-2 
respectively) were the least potent. The Emax for compound 3 is 0.0780 and 0.1106 for β-
Arrestin-1 and β-Arrestin-2 respectively and the Emax for compound 6 is 0.0740 and 
0.1295 for β-Arrestin-1 and β-Arrestin-2 respectively. Compound 3 and 6 have a 1.5 – 2x 
reduction in Emax  compared to the other peptides in this series.  This indicates that 
compounds 3 and 6 are acting as a partial agonist when binding to GHS-R1a. 
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Figure 4.2 - β-Arrestin-1 and β-Arrestin-2 recruitment concentration curves 
measuring the EC50 of the 7 peptides in HEK293T cells co-transfected with GHS-
R1a-eYFP and GHS-R1a-Rluc constructs. Data are shown as net BRET (eYFP/rluc) 
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Table 4.2 - Potency measured by the recruitment of β-Arrestin-1 and β-Arrestin-2 
upon binding of an agonist to GHS-R1a 
 
To understand the molecular basis for the experimental observation that Tyr 
incorporation in the fourth position improves the binding affinity for this series, a 
molecular docking study was performed on compound 7 using a homology model for 
GHS-R1a recently developed by our lab23. Our previous molecular dynamics (MD) 
simulation revealed that the N-terminal end of compound 1 (G7039) is situated at the 
bottom of the orthosteric site engaging in a salt bridge interaction with Glu124, and the 
2nd and 3rd residue D2Nal binds to the other two hydrophobic sub-pockets (Figure 
4.3A)23.  The molecular docking study on compound 7 suggested a very similar binding 
pattern except that the fourth residue Tyr is H-bonding with Arg283 (Figure 4.3B). Our 
previous model also showed that the 4th residue Phe of G-7039 is surrounded by 
hydrophobic residues suggesting switching it to a hydrophilic residue Ser would reduce 
the binding affinity, which is consistent with the experimental data (compound 2 vs 6) . 
The computational studies showed that the aromatic ring of the Tyr retains the interaction 
with the surrounding hydrophobic residues such as Phe 286 in the receptor (Figure 4.3), 
Compound 
Number 
Peptide Sequence b-Arr-
1 
b-Arr-
2 
b-Arr-
1 
b-Arr-
2 
  EC50 
(pM) 
EC50 
(pM) 
Emax 
(Net 
BRET 
Ratio) 
Emax 
(Net 
BRET 
Ratio) 
1 H-Inp-D2Nal-D2Nal-Phe-Lys-NH2 59.9 61.7 0.1159 0.1889 
2 H-Inp-D2Nal-D2Nal-Phe-Lys(2-FP)-NH2 15.8 72.8 0.1072 0.1819 
3 H-Inp-D2Nal-D2Nal-Ser-Phe-Lys(2-FP)-NH2 202.4 178.1 0.0780 0.1106 
4 H-Inp-D2Nal-D2Nal-Phe-Ser-Lys(2-FP)-NH2 90.9 81.7 0.1307 0.1748 
5 H-Inp-D2Nal-D2Nal-Tyr-Lys(2-FP)-NH2 125.7 121.1 0.1194 0.1616 
6 H-Inp-D2Nal-D2Nal-Ser-Lys(2-FP)-NH2 135.6 207.8 0.0740 0.1295 
7 H-Inp-D2Nal-D2Nal-Tyr-Lys-NH2 178.7 262.5 0.1176 0.1687 
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and the additional H-bonding interaction with Arg 283 contributes to the improved 
binding affinity.  
 
 
 
Figure 4.3 - The structure of compound 1 (G7039) in complex with GHS-R1a 
obtained from our previous computational study24. Compound 1 is situated at the 
bottom of orthosteric site engaging a salt bridge interaction with Glu124, and the 2nd 
and 3rd residues D2Nal binds to the other two hydrophobic sub-pockets. (B) The 
structure of compound 7 in complex with GHS-R1a from molecular docking study 
suggested a very similar binding pattern except that the 4th residue Tyr is H-
bonding with Arg283 
 
4.3 Conclusion 
The goal of the current work was to improve the binding affinity and decrease 
lipophilicity of a previously reported GHS-R1a targeting peptidomimetic21. Changes 
were made to both the fourth position and prosthetic group conjugated from the C-
terminal Lys of ([1-Nal4, Lys5 (4-FB)]G7039), followed by assessing the binding affinity, 
cLogP, potency, and molecular docking to confirm the outcomes of the amino acid 
changes. In total, seven novel ghrelin agonists were synthesized and assessed for their 
binding affinity and potency towards GHS-R1a. Compound 5 showed the greatest 
binding affinity (IC50 = 0.28 nM) with Tyr in the fourth position and it was noted that an 
aromatic amino acid is required in the fourth position in order to retain binding affinity 
towards the receptor. Compound 3 and 6 were identified as partial agonists and this class 
of molecule can be useful in terms of regulating the GHS-R1a signalling in a differential 
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fashion.  Molecular docking confirmed an additional H-bond interaction with Tyr in 
compound 5 explaining the increase in binding. Compound 5 could be used as an 
imaging agent since there is an available fluorine atom (the 2-FP moiety on Lys five) that 
can be replaced by fluorine-18 through established prosthetic radiochemistry methods24. 
Compound 5 is currently the most potent fluorine-containing peptidomimetic reported for 
GHS-R1a (based upon β-arrestin recruitment) and uniquely has the potential to be used as 
an imaging agent for the diagnosis of human diseases associated with GHS-R1a. 
4.4 Materials and Methods 
4.4.1 General Information 
All reagents were obtained from the commercial suppliers and used without any 
further purification. All Fmoc-protected amino acids were obtained from ChemImpex. 
HCTU, HATU, and Rink Amide MBHA Resin (4-(2’,4’-dimethoxyphenyl-(9-
fluorenylmethoxycarbonyl)-aminomethyl)-phenoxy-acetamidonorleucyl-4-methyl 
benzhydrylamine resin) were obtained from ChemImpex. 
Tetrakis(triphenylphosphine)palladium(0), and phenylsilane. All other solvents were 
obtained from Fischer Thermo-Scientific.  
4.4.2 Solid-Phase Peptide Synthesis 
Automated Fmoc-based solid-phase synthesis was carried out using a Biotage® 
Syro Wave™ automated peptide synthesizer. Synthesis was done on a 0.1 mmol scale 
with 0.52 mmol/g Fmoc-Rink amide MBHA resin and a 3-fold excess of the protected 
amino acids. The resin was allowed to swell in DCM (2.0 mL, 15 min) and then solvent 
was removed. The resin was then rinsed with DMF (1.0 mL, 1min), and after removal of 
the solvent, deprotection of the Fmoc group was performed by adding a solution of 20% 
piperidine/DMF (1.5 mL) to the resin and was allowed to vortex for 5 minutes. The resin 
was then washed three times with DMF (2.0 mL, vortex 30 sec) and then the resin was 
vortexed for 15 min with 20% piperidine/DMF (1.5 mL). The resin was then washed with 
DMF six times to remove any unreacted products (2.0 m, vortex 30 sec). A Kaiser test 
was performed after the Fmoc removal to verify the presence of a free primary amino 
group. The desired Fmoc-protected amino acid (0.3 mmol) and the coupling reagent 
HCTU (0.3 mmol) was dissolved in DMF (1.5 mL) and added to the resin. The mixture 
was allowed to vortex for 30 seconds and then DIPEA (0.6 mmol) was added to the 
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mixture and was allowed to vortex for 1 hour. This deprotection/amino acid coupling 
cycle was repeated until the desired amino acid sequence was obtained. After the final 
amino acid was coupled, the resin was washed 3 times with DMF (2.0 mL, vortex 30 sec) 
and then 3 times with DCM (2.0 mL, vortex 30 sec) and then dried under vacuum and 
stored in the freezer. The removal of the final Fmoc protecting group on the N-terminus 
is achieved using the same procedure for the other deprotections as previously described. 
To determine if the correct peptide has been synthesized, a microcleave was performed 
before full cleavage off the resin. A small amount of resin (<5 mg) is added to a small 
peptide vessel and 95% trifluoroacetic acid/2.5% triisopropylsilane/2.5% water (500 μL) 
was added. The mixture was allowed to vortex for 3-4 hours, and the resulting liquid was 
precipitated with cold tert-butyl methyl ether (TBMe) (2 mL). The precipitate was 
centrifuged, the mother liquor was decanted off, the pellet was dissolved in water (2 mL), 
frozen and then lyophilized. If the correct peptide was synthesized as determined by 
analytical UHPLC/ESI-MS, then a full cleavage of all of the resin was performed. The 
procedure for full cleaves is the same as a microcleave, a solution of 95% trifluoroacetic 
acid/2.5% triisopropylsilane/2.5% water (3 mL) was added to the resin and vortexed for 
4-6 hours. The solution is drained, precipitated in TBMe (20 mL) and centrifuged. The 
mother liquor is decanted, the pellet is dissolved in water (20 mL) and lyophilized to 
obtain the crude fully deprotected peptide. 
4.4.3 Kiaser Test 
To qualitatively test if there is presence of a free amine present (after a Fmoc-
deprotection, amino acid coupling, or alloc deprotection), a Kaiser test is performed. A 
small amount of resin (<5 mg) is taken and placed in a small test tube. To the test tube, 
solutions of: Phenol:EtOH (8:2 v/v), 0.001M KCN: pyridine (2:98 v/v) and ninhydrin in 
EtOH (5% w/v) were added. The test tube was heated to 70°C and the presence of a free 
amine was indicated by the resin beads turning blue. The indication of no free amine was 
determined by the presence of clear/yellow resin beads.  
4.4.4 Deprotection of Allyloxycarbonyl (Alloc)  
Selective deprotection of the allyloxycarbonyl protecting group was accomplished 
by adding DCM (4.5 mL) to the resin-bound peptide and shaking gently for 10 minutes. 
After addition of phenylsilane (24 equiv.), the peptide vessel was flushed with nitrogen 
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and allowed to react for 5 minutes. Then, tetrakis(triphenylphosphine) palladium (0) (0.1 
equiv.) was added to the mixture and the peptide vessel was again flushed with nitrogen, 
and the reaction was allowed to proceed for 10 minutes. Next, the peptide-resin was 
washed with DCM (4 x 30 s), followed by a series of washings with DCM, DMF, MeOH, 
DMF, DCM (30 s each).  
4.4.5 Coupling of 2-Fluoropropionic Acid Group 
Following removal of Alloc, 2-fluoropropionic acid (2-FPA) is coupled onto Lys 
adding 2-FP (0.3 mmol) and the coupling reagent HATU (0.3 mmol) dissolved in DMF 
(1.5 mL) and then added to the resin. This mixture was allowed to vortex for 2 hours, and 
the resin was then washed 3 times with DMF (2.0 mL, vortex 30 sec) and then 3 times 
with DCM (2.0 mL, vortex 30 sec) and then dried under vacuum. 
4.4.6 Purification of RP-HPLC/ESI-MS 
Peptides were analyzed using a reverse-phase analytical HPLC column (Agilent 
Zorbax SB-C8 column 4.6 x 150 mm, 3.5 μm). This system was equipped with a Waters 
600 136 controller, Waters Prep degasser, and Waters Masslynx software (version 4.1). 
Employed mobile phases were 0.1% TFA in deionized water (eluent A) and 0.1% TFA in 
acetonitrile (eluent B). The flow rate was set at 1.5mLmin-1 over 15 minutes. The column 
eluate was monitored using a Waters 2998 Photodiode array detector set at 220 nm, 254 
nm and 400 nm. Peptides were purified using a reverse-phase preparative HPLC column 
(Agilent Zorbax SB-C18 column 21.2 x 150 mm, 5 μm) on the same system mentioned 
above. The detection method and eluents were the same was mentioned above for the 
analytical system and the flow rate was set at 20 mLmin-1. The collected fractions were 
then lyophilized to a solid. For analytical UHPLC-MS, studies were performed on a 
Waters, Inc. Acquity UHPLC H-Class system, combined with a Xevo QTof mass 
spectrometer (ESI+, cone voltage = 30 V). A Waters Acquity UHPLC BEH C18 2.1 x 50 
mm, 1.7 μm column was used with a gradient solvent system consisting of 0.1% formic 
acid in acetonitrile and 0.1% formic acid in water. 
4.4.7 Receptor Ligand Binding Assay 
Competitive ligand binding assays were performed in triplicate using 
HEK293/GHS-R1a cells and [125I]Ghrelin as the competitive ligand, as previously 
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described21. Receptor binding affinities were calculated as IC50 values as previously 
described21. 
4.4.8 Molecular cloning and constructs  
YFP tagged human GHS-R1a from Addgene (hGHS-R1a) was made by replacing 
PAR4 in the previously published PAR4-YFP (Ramachandran et al., 2017) construct25 
with GHS-R1a using restriction enzymes digestion with EcoRI and Xhol and ligation. 
Constructs was verified by direct sequencing (University of Western Ontario, Robarts 
DNA sequencing facility). 
4.4.9 b-Arrestin Recruitment Assay 
Bioluminescent resonance energy transfer was measured between c-terminally 
YFP tagged GHS-R1a and Renilla Luciferase (Rluc) tagged b-arrestin 1 (b-Arr-1) or b-
arrestin 2 (b-Arr-2), following 20 minutes of receptor activation in the presence of 
agonist compounds in HEK293 cells. HEK293 cells are maintained in Dulbecco’s 
Modified Eagle’s medium (DMEM) from Sigma-Aldrich (D5796) with added 5% sodium 
pyruvate, 5% penicillin streptomycin, and 10% fetal bovine serum (FBS) at 37°C with 
5% CO2. Cells were cultured in a T-75 flask to 95% confluency then lifted by trypsin-
ETDA (0.25%). Once cells were counted and spun down at 1000 rpm they were 
resuspended and then re-plated in 10 cm culture dishes at 1 million cells per plate. 
Seeding was then accomplished for 24 hrs at 37°C with 5% CO2. GHS-R1a-YFP (2 μg) 
and b-arrestin-1-rluc/ -2-luc (0.2 µg; a kind gift from Dr. Michel Bouvier) were 
transiently transfected for 24 hours. At 24 hours transfection, cells were re-plated into 
white 96-well culture plates (Brand Tech.) and cultured for an additional 24 hours. 
Interactions between GHS-R1a and b-arrestin-1/2 were detected by measuring BRET 
ratios (eYFP/rluc) at 20 min of agonist stimulation, following the addition of 5 μM 
coelenterazine (Nanolight Technology, Pinetop, AZ) 10 min prior to quantification on a 
Mithras fluorescence plate reader (Berthold) using the appropriate filters. All drugs being 
tested were dissolved in Hanks’ Balanced Salt Solution (HBSS) with 0.1% DMSO. The 
highest drug concentration of 10-5 M was first prepared, and each full log concertation 
was prepared by serial dilution thereafter. The control well contained just HBSS with 
0.1% DMSO. The serum media was removed from the plate before then addition of the 
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drug at varying concentrations (10-5 M to 10-17 M). Data are shown as net BRET ratios 
(eYFP/rluc – baseline ratio in no agonist control). Concentration effect curves were 
calculated using 3 parameter non-linear regression curve fitting, as this was most 
appropriate based on the R squared value (Prism 7).  
4.4.10 Molecular docking studies  
The homology model of GHS-R1a previously developed by our lab was used to 
study the interactions between compound 7 and GHS-R1a26. The structure of compound 7 
was generated from modification of compound 1, thus both compound 1 and 7 have 
identical conformation. To investigate the effort of Tyr replacement in the fourth position 
on the binding pattern, the residues of GHS-R1a (Phe289, Arg283, Phe279) surrounding 
the Tyr in the fourth position were set to be flexible while the conformation of the 
compound 7 remains unchanged during the docking calculation. Docking studies were 
performed using the AUTODOCK 4.2 program26. The dimensions of the active site box 
were chosen to be large enough to encompass the entire orthosteric site in the receptor. 
Docking calculations were carried out using the Local Search Algorithm. The docking 
experiment was consisted of 200 independent runs. Default values were used for other 
parameters. All the calculations were performed on high-performance computing (HPC) 
facilities within the Compute Canada network27. The graphics were generated using DS 
Visualizer (BIOVIA). 
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Chapter 4 Supplementary Information 
 
Half-Maximal Inhibitory Concentration (IC50) Curves 
 
*Compound 1 previously published in reference 21* 
 
Compound 2  
 
 
 
Compound 3  
 
 
 
 
 
 
 
10-12 10-10 10-8 10-6 10-4 10-2
0
20
40
60
80
100
120
Concentration (M)
%
 R
ad
io
lig
an
d 
Bo
un
d 
19 nM 
10-14 10-12 10-10 10-8 10-6 10-4
0
20
40
60
80
100
120
Concentration (M)
%
 R
ad
io
lig
an
d 
Bo
un
d 
62.9 nM
 
 
204 
Compound 4  
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Compound 6 
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UHPLC-MS Traces 
 
 
Supplementary Table  4.1 – Analytical Data for Compounds 1 to 7 
 
 
 
Compound 1  
 
 
 
 
 
 
 
 
 
 
 
 
Compound Number Calculated Mass 
([M+H]+) 
Found Mass 
([M+H]+) 
Purity (%) 
1 872.4521 872.4536 >96 
2 798.4243 
399.7016 ([M+2H]2+) 
798.4266 
399.6943 ([M+2H]2+) 
>98 
3 812.4136 812.4056 >98 
4 959.4831 959.4967 >98 
5  959.4831  959.4967 >96 
6 888.4460 888.4614 >98 
7 814.4292 
407.7284 ([M+2H]2+) 
814.4487 
407.7061 ([M+2H]2+) 
>98 
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Compound 2  
 
 
 
 
Compound 3  
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Compound 4  
 
 
 
Compound 5 
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Compound 6  
 
 
 
Compound 7  
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Chapter 5 
 
Trifluoroborate Containing Peptidomimetic GHS-R1a Agonist for PET Imaging of 
Prostate Cancer 
5.1 Introduction 
Growth hormone secretagogues (GHSs) are a class of peptides and small 
molecules that stimulate the secretion of growth hormone (GH) by acting on the growth 
hormone secretagogue receptor type-1a (GHS-R1a)1. This receptor is predominantly 
expressed in the hypothalamus and pituitary gland1. When GHS-R1a is activated it causes 
the release of GH by a route that is different the normal route, the growth hormone-
releasing hormone (GHRH)2. Bowers and co-workers were the first to develop a series of 
GHSs based on the natural ligands Met-enkephalin and Leu-enkephalin and performed in 
vitro analysis to prove that these analogues could still cause GH release3. Most of these 
ligands had the initial purpose to treat patients who have GH abnormalities4-6. Examples 
of some of these compounds include the growth hormone-releasing peptide-6 (GHRP-6), 
GHRP-17, hexarelin8, GHRP-29, peptidomimetics (e.g. G703910, [1-Nal]4G703911and 
ipamorelin12) and small-molecules (e.g. L-692,42913and MK-067714). These various 
GHSs can be visualized in Figure 5.1. Human ghrelin is the natural ligand for GHS-R1a 
first identified by Kojima et al. in 199915. Ghrelin is a 28-amino acid peptide with an 
octanoylation on Ser-3. This octanoylation is performed by ghrelin O-acyl transferase 
(GOAT) to produce the active form of the ligand. The activation of GHS-R1a has a 
multitude of biological activities, such as the regulation of food intake, glucose 
metabolism, cardiovascular and neuroprotective effects15-17.  
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Figure 5.1 - Peptidic, peptidomimetic and small-molecule growth hormone 
secretagogues that have been designed to target GHS-R1a leading to its activation. 
All amino acids are designated by the standard three-letter code (D2Nal, D2-
naphthylalanine; Inp, isonipecotic acid; D-Trp(2-Me); D-2-methyltryptophan) 
 
The GHS-R1a is over expressed and dysregulated in a number of human 
malignancies, including prostate cancer18-19, breast cancer21, testicular cancer22, ovarian 
and lung cancer23. The expression of this receptor continues to appear in several other 
cancers as more examples become apparent in the literature and cBioPortal. It also has 
been shown to be upregulated in a number of other human diseases such as protective 
effects in atherosclerosis and chronic heart failure24-25. This makes GHS-R1a a highly 
favourable target in terms of designing novel imaging agents in order to perform 
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diagnosis and monitor the variety of human diseases in which it is overexpressed. The 
imaging modality within this work that was chosen is positron emission tomography 
(PET). This is because PET combines a relatively high spatial resolution (5 to 7 mm) 
with high sensitivity (in the femtomolar range) and is among the widely used imaging 
modalities in the clinic today26. A number of recent publications describe PET 
radiotracers to monitor GHS-R1a in human disease27-30. Hou et al. synthesized 
radiolabelled quinazolinone derivatives as a small molecule capable of targeting GHS-
R1a30. Also, a [11C]radiotracer revealed a higher specific uptake in the pancreas 
compared to other organs in a mouse model were the tumour cells over expressed GHS-
R1a28. However, these studies27-29 and others30-31 have primarily focused on either small-
molecule quinazolinones27-31 or ghrelin-derived compounds29,30,31. Peptidic and 
peptidomimetic GHSs would result in a clinically translatable PET agent because of their 
high target specificity, in vivo stability and favourable pharmacokinetic properties. 
Fluorine-18 (18F) was our preferred choice of radioisotope as it is a small innocuous unit 
that can be easily installed in the absence of a bulky chelator that potentially can reduce 
the affinity towards a given target. Also, 18F can be easily installed to the desired ligand 
in a direct labelling manor.  
Perrin and co-workers synthesized a novel prosthetic group for 18F chemistry that 
is able to directly label a peptide in one step with no HPLC purification, based upon the 
precursor alkyne containing ammonium methyltrifluoroborate (AMBF3 – seen in blue in 
Figure 5.2). This prosthetic group can easily be installed onto a lysine azide of a desired 
peptide by copper catalyzed click chemistry in high purity and yields. Once on the 
peptide, direct labelling is accomplished in buffered conditions (aqueous) with high 
radiochemical purity (>98%), highly specific molar activity (40 – 111 GBq/µmol), and 
high radiochemical yields (20 to 35%). This is data that has been collected over 20 
trials32. This particular prosthetic group has been proven to be a beneficial and efficient 
way to label biologically relevant peptides in the past such as a bombesin derivative for 
prostate cancer imaging and a Des-Ar(10)]Kallidin derivative for imaging Bradykinin B1 
receptor expression33. In the cases of imaging gastrin-releasing peptide receptor (GRPR)-
expressing pancreatic and PC-3 prostate cancer tumours in xenograft models with the 
radiofluorinated bombesin derivative there was excellent tumour visualization and low 
 
 
213 
background uptake in other organs. This exact same result was seen when visualizing the 
Bradykinin B1 receptor expression in a xenograft model33-34.  
The peptidomimetic G7039 (Figure 5.1) has undergone substantial structure-
activity relationship (SAR) studies in order to both improve binding towards the receptor, 
as well as enhance the hydrophilicity35. Fowkes and co-workers made several changes 
with respect to the prosthetic group as well as changes to the fourth position of the 
peptide. The first three amino acids (piperidine-4-carboxylic acid (Inp), D-2-
napthylalanine (D2Nal), and D-1-napthylalanine (D1Nal)) are highly vulnerable to 
change and have been shown necessary to bind and activate GHS-R1a35. A follow up 
study by Lalonde and co-workers (Chapter 4) determined that Tyr in the fourth position 
caused an 18-fold increase in binding towards GHS-R1a compared to the parent G7039 
molecule (5.2 nM versus 0.70 nM measure by a competitive radioligand assay (half 
maximal inhibitory concentration-IC50)). This increase in binding is believed to be due to 
an additional H-bond interaction with Arg 283 in the binding pocket of the GHS-R1a 
homology model (determined by docking analysis). The addition of a 2-fluoropropionic 
acid (2-FPA) group to the C-terminal lysine of ([Tyr4, Lys5(2-fluoropropionyl-2-
FP)]G7039) caused a slight improvement in binding to 0.28 nM and provided a potential 
site to radiolabel the peptide with 18F in order to have the respective PET imaging probe. 
However, the 2-FP group proved to be a lengthy four-step labelling with very low yields. 
This is because the exchange of a leaving group on the two position of 2-FP for 18F 
caused an elimination product over the desired substitution product.  
By conjugating AMBF3 to a lysine azide group of ([Tyr4, Lys5(N3)]G7039) the 
peptidomimetic ([Tyr4, Lys5(AMBF3)]G7039) was synthesized. This peptide still 
maintained binding towards the receptor but can now be labelled in a single step by 
isotopic exchange (IEX) of 19F for 18F. This work provides a method to prepare a sub-
nanomolar PET agent for the GHS-R1a with rapid and high yielding radiochemistry in 
order to image the receptor by PET.  
5.2 Results and Discussion 
 The azide peptide ([Tyr4, Lys5(N3)]G7039) was synthesized using 
fluorenylmethyloxycarbonyl (Fmoc) solid-phase peptide chemistry, purified using 
reverse-phase high performance liquid chromatography (RP-HPLC) and analyzed by 
 
 
214 
electronspray ionization-mass spectrometry (ESI-MS). In a single step, AMBF3 was 
conjugated onto the lysine azide utilizing copper click chemistry in an 89% chemical 
yield to furnish ([Tyr4, Lys5(AMBF3)]G7039) (Scheme 5.1), followed by purification by 
RP-HPLC and analysis by ESI-MS.   
 
 
Scheme 5.1 - Chemical synthesis ([Tyr4, Lys5(AMBF3)]G7039) using copper click 
chemistry. The Tyr in position four is highlighted in pink and is a significant 
contributor to improved GHS-R1a affinity. AMBF3 is highlighted in blue and is the 
prosthetic group required for IEX 
 
Previously the peptide ([1-Nal4, Lys5(4-fluorobenzoyl - 4-FB)]G7039) determined to 
have an IC50 of 69 nM and a cLogP of 8.76 ± 0.8835. The lower binding affinity and high 
cLogP of the peptide led to poorer in vivo PET images in a cancer mouse model35. In 
Chapter 4 Lalonde and co-workers improved on both the binding affinity (IC50 of 0.28 
nM) and cLogP (2.77 ± 0.87) by altering the Tyr in the fourth position and the 4-FB 
prosthetic group to 2-FP ([Tyr4, Lys5(2-FP)]G7039). This prosthetic group proved to be 
low yielding during radiosynthesis with 18F. Finally, in this current work the prosthetic 
group was changed one additional time to AMBF3. The addition of the AMBF3 caused no 
drastic change in binding affinity with a determined IC50 value of 0.85 nM (Figure 5.2). 
This was done by a competitive radioligand assay with [125I]-human ghrelin as the 
competitor. It can also be noted that the cLogP of this compound was calculated to be 
2.54 ± 0.85, which in terms of hydrophobicity is in an acceptable range to have good 
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pharmacokinetics. This lead compound has improved on both the binding and cLogP 
from the first generation35.  
 
Figure 5.2 - IC50 curve for ([Tyr4, Lys5(AMBF3)]G7039) as determined by 
competitive radioligand assay 
 
([Tyr4, Lys5(AMBF3)]G7039 was then radiolabelled with 18F by isotopic 
exchange (IEX) with 19F. This was done in a pyridazine-HCL buffer followed by 
purification with a C-18 Sep-Pak. Over the course of four trials a decay corrected 
radiochemical yield was between 17 and 35%, a radiochemical purity >99%, and a molar 
activity of 12 to 15 GBq/μmol. The retention times of the cold standard and “hot” peptide 
are almost identical ([Tyr4, Lys5(AMB19F3)], tR = 5.50 mins compared to tR = 5.48 mins 
for the “hot” peptide ([Tyr4, Lys5(AMB18F3)]), indicating that the precursor ([Tyr4, 
Lys5(AMB19F3)] has been selectively radiolabelled by IEX (Figure 5.3). In terms of the 
radiolabelling performed with ([1-Nal4, Lys5(4-FB)]G7039) this is a drastic improvement 
in the number of steps to the final product (four versus one step). Radiosynthetic data is 
similar in terms of purity, yield, and molar activity35. 
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Figure 5.3 - (A) Synthesis scheme for 18F labelling; (B) Overlaid HPLC 
chromatograms for ([Tyr4, Lys5(AMB18F3)] and ([Tyr4, Lys5(AMB19F3)] (both λ = 
254 nm); (C) Radiochemical yields, purity and molar activity 
 
To demonstrate that ([Tyr4, Lys5(AMB18F3)] was still able to bind to GHS-R1a 
after being radiolabelled, a radioligand cellular assay was performed with LNCaP cells 
that stably express GHS-R1a. As a control, blocking the radioligand signal coming from 
Tyr4, Lys5(AMB18F3) was performed with a 10 mM concentration of Tyr4, 
Lys5(AMB19F3). There was on average 10% cellular uptake of the PET agent, which was 
significantly different than the blocking study (< 1% uptake). This demonstrates that the 
imaging agent is targeting the receptor specifically when using the ([Tyr4, 
Lys5(AMB18F3)] PET probe (Figure 5.4).  
 
 
217 
 
Figure 5.4 – Cellular uptake of ([Tyr4, Lys5(AMB18F3)] in LNCaP cells stably 
expressing GHS-R1a blocked with a 10 times conc of ([Tyr4, Lys5(AMB19F3)]  
 
5.3 Conclusion 
This work has highlighted the development of a sub-nanomolar PET probe with 
excellent radiochemical data that specifically targets GHS-R1a. The ([Tyr4, 
Lys5(AMB18F3)] analogue of G7039 in terms of the changes made to the fourth position 
(Phe to Tyr) and the addition of the AMBF3 improved both binding affinity (0.85 nM) 
and cLogP (2.54 ± 0.85).  The new prosthetic group allowed for a single step 
radiosynthesis route with no HPLC purification. Cellular uptake was demonstrated (10 to 
12%), compared to almost none when blocked with ([Tyr4, Lys5(AMB19F3)]. Over the 
course of four trials a decay corrected radiochemical yield was between 17 and 35%, a 
radiochemical purity >99%, and a radiochemical molar activity of 12 to 15 GBq/μmol. 
This demonstrates consistency in radiolabelling with 18F and will facilitate the use of this 
PET agent for in vivo imaging experiments. This tracer has the advantage of being 
labelled in only one step with no HPLC purification required (32 min to end of synthesis) 
making it very attractive to be driven towards a clinical setting.  
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5.4 Materials and Methods 
5.4.1 General Information  
All reagents were obtained from commercial suppliers and used without further 
purification. Peptides were either synthesised manually or through the use of a 
Biotage SyroWave automated peptide synthesizer. Peptide vessels were shaken using an 
IKA Vibrax VXR basic shaker with centrifugation performed on a Beckman Coulter 
Allegra X-30R or Fisher GS-6R centrifuge. In order to aid peptide dissolution, sonication 
of solutions was accomplished via a Bransonic 2510R-MTH or Fisher F5-14 ultrasonic 
cleaner. A Fisher 2052 Isotemp machine was used to heat test tubes in the Kaiser Test. 
Peptides were lyophilised using a Labconco FreeZone Freeze Dry System. Accurate 
weighing was carried out on a Mettler-Toledo XP6 microbalance. UV traces were 
obtained with a Waters 2487 UV/Vis Dual λ Absorbance Detector (170-900 nm) and 
low-resolution mass spectra with a Micromass Quattro micro API mass spectrometer 
(ESI-LC-MS). Peptide purification was achieved through HPLC (MeCN + 0.1% TFA, 
H2O + 0.1% TFA solvent system). All peptides obtained had a purity ≥ 95% as 
determined by HPLC or UHPLC analysis. A RP preparative C-18 column (SunFire OBD, 
19 x 150 mm or Agilent Zorbax 21.2 x 150 mm) was used for preparative HPLC, whilst a 
C-18 RP column (SunFire, 4.6 x 150 mm or Agilent Zorbax, 4.6 x 150 mm) was used for 
analytical HPLC. 
5.4.2 Solid-Phase Peptide Synthesis 
Fmoc-based solid-phase synthesis was carried out manually and automatically 
using a Biotage® Syro Wave™ automated peptide synthesizer. Synthesis was done on a 
0.1 mmol scale with 0.52 mmol/g Fmoc-Rink amide MBHA resin and a 3-fold excess of 
the protected amino acids. The resin was allowed to swell in DCM (2.0 mL, 15 min) and 
then solvent was removed. The resin was then rinsed with DMF (1.0 mL, 1 min); after 
removal of the solvent, Fmoc deprotection was performed by adding a solution of 20% 
piperidine/DMF (1.5 mL) to the resin and vortexing for 5 minutes. The resin was then 
washed with three times with DMF (2.0 mL, vortex 30 sec) and the resin was vortexed 
for 15 min with 20% piperidine/DMF (1.5 mL). The resin was then washed with DMF 
six times to remove any unreacted products (2.0 mL, vortex 30 sec). A Kaiser test was 
performed after the Fmoc removal to verify the presence of a free primary amino group. 
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The desired Fmoc-protected amino acid (0.3 mmol) and the coupling reagent HCTU (0.3 
mmol) was dissolved in DMF (1.5 mL) and added to the resin. The mixture was vortexed 
for 30 seconds and then DIPEA (0.6 mmol) was added to the mixture and was vortexed 
for 1 hour. This deprotection/amino acid coupling cycle was repeated until the desired 
amino acid sequence was obtained. After the final amino acid was coupled, the resin was 
washed 3 times with DMF (2.0 mL, vortex 30 sec) and then 3 times with DCM (2.0 mL, 
vortex 30 sec), dried under vacuum, and stored in the freezer at -20°C. The removal of 
the final Fmoc protecting group on the N-terminus was achieved using the previously 
described procedure.  
To determine if the correct peptide has been synthesized, a microcleave was 
performed before full cleavage from the resin. A small amount of resin (<5 mg) was 
added to a small peptide vessel and a solution of 95% trifluoroacetic acid/2.5% 
triisopropylsilane/2.5% water (500 μL) was added. The mixture was vortexed for 3-4 
hours, and the resulting liquid was precipitated with cold tert-butyl methyl ether (TBME) 
(2 mL). The precipitate was centrifuged (3000 xg for 10 min), the mother liquor was 
decanted. The pellet was dissolved in water (2 mL), frozen, and lyophilized. If the correct 
peptide was synthesized as determined by analytical HPLC/MS, then a full cleave was 
performed. The procedure for full cleaves identical to the microcleave procedure: a 
solution of 95% trifluoroacetic acid/2.5% triisopropylsilane/2.5% water (3 mL) was 
added to the resin and vortexed for 4-6 hours. The solution was drained, precipitated in 
TBMe (20 mL) and centrifuged (3000 xg for 10 min). The mother liquor was decanted, 
and the pellet was dissolved in water (20 mL) and lyophilized to obtain the crude fully 
deprotected peptide. 
5.4.3 Synthesis of ([Tyr4, Lys5(AMB19F3)] 
 AMBF3 was conjugated to the C-terminal lysine of the peptide by copper click 
chemistry as previously described32. 
5.4.4 General Radiochemistry Information 
All reagents and solvents used for radiosynthesis were purchased from Sigma-
Aldrich unless otherwise specified. 18F-fluoride was produced via the 18O(p,n) 18F 
reaction in a GE PETtrace 880 cyclotron (Lawson Health Research Institute, London, 
Ontario, Canada). A Biotage V-10 evaporator was used to remove solvent. A Waters 
 
 
220 
HPLC with a 1525 binary pump system (solvent A = MeCN + 0.1% TFA, solvent B = 
H2O + 0.1% TFA) and two detectors (Waters 2487 Dual λ absorbance detector set at 254 
nm and a radioactive flow count detector) were utilised for product analysis and 
purification. An analytical column (Agilent Eclipse XDB-C18, 4.6 × 150 mm, 5 μm) was 
used for determining radiochemical purity and molar activity of ([Tyr4, Lys5(AMB18F3)].  
5.4.5 Radiosynthesis of ([Tyr4, Lys5(AMB18F3)] 
 The micro QMA (a gift from Dr. Neil Vasdev) cartridge and reaction vessel setup 
was the same as previously described36. However, the cartridge was preconditioned with 
6 mL of 1 M HCl, 6 mL of brine, and finally 6 mL of milli-Q water. Once the fluoride-18 
was trapped on the micro QMA it was eluted into the plastic vessel (a 15 mL falcon tube 
cut at the 4 mL mark capped with a rubber septum) with 20 uL of pyridazine-HCl buffer 
(pH=2) and then azeotropically dried under nitrogen for 10 min at 110OC with an ascarite 
filled syringe as the vent needle. The peptide ([Tyr4, Lys5(AMB19F3)] was then added 
directly to the vessel at a 10 mM concentration in 10 uL of pyridazine-HCl buffer 
(pH=2). The vent ascarite filled syringe (a 5 mL syringe fitted with a 20-gauge needle 
with the plunger removed and packed with glass wool then filled to the 4 mL with 
ascarite) was removed and the reaction proceeded for 8 min at 110OC. After the reaction 
was complete it was quenched with 1 mL of 5% (v/v) NH4OH and directly loaded onto a 
C-18 light Sep-Pak cartridge precondition with 10 mL of EtOH and 10 mL of water. The 
cartridge was washed with 4 mL of water (2X), followed by elution of the final product 
with 1 mL of 1:1 ethanol: water solution. A 20:80 water:acetonitrile  HPLC gradient was 
used to determine radiochemical purity and molar activity. Over the course of four trials 
the decay corrected radiochemical yield was between 17 and 35%, a radiochemical purity 
>99% for each trial, and a radiochemical molar activity of 12 to 15 GBq/μmol. The 
retention times of the cold standard and “hot” peptide are almost identical ([Tyr4, 
Lys5(AMB19F3)], tR = 5.50 mins compared to tR = 5.48 mins for the “hot” peptide ([Tyr4, 
Lys5(AMB18F3)]), indicating that the precursor ([Tyr4, Lys5(AMB19F3)] has been 
selectively radiolabelled by IEX.  
5.4.6 Purification of RP-HPLC/ESI-MS 
([Tyr4, Lys5(AMB19F3)] and ([Tyr4, Lys5(N3)] was analyzed using a reverse-phase 
analytical HPLC column (Agilent Zorbax SB-C8 column 4.6 x 150 mm, 3.5 μm). This 
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system was equipped with a Waters 600 136 controller, Waters Prep degasser, and 
Waters Masslynx software (version 4.1). Employed mobile phases were 0.1% TFA in 
deionized water (eluent A) and 0.1% TFA in acetonitrile (eluent B). The flow rate was set 
at 1.5 mLmin-1 over 15 minutes. The column eluate was monitored using a Waters 2998 
Photodiode array detector set at 220 nm, 254 nm and 400 nm. Peptides were purified 
using a reverse-phase preparative HPLC column (Agilent Zorbax SB-C18 column 21.2 x 
150 mm, 5 μm) on the same system mentioned above. The detection method and eluents 
were the same as mentioned above for the analytical system and the flow rate was set at 
20 mLmin-1. The collected fractions were then lyophilized to a solid and analyzed by 
ESI-MS. Purity of final products was determined by analytical RP-HPLC (200-800 nm).  
5.4.7 Receptor Ligand Binding Assay 
Competitive ligand binding assays were performed in triplicate using 
HEK293/GHS-R1a cells and [125I]Ghrelin as the competitive ligand, as previously 
described29,30,35. Receptor binding affinities were calculated as IC50 values as previously 
described29,30,35. 
5.4.8 Molecular cloning and constructs  
YFP tagged human GHS-R1a from Addgene (hGHS-R1a) was made by replacing 
PAR4 in the previously published PAR4-YFP (Ramachandran et al., 2017) construct36 
with GHS-R1a using restriction enzymes digestion with EcoRI and Xhol and ligation. 
Constructs was verified by direct sequencing (University of Western Ontario, Robarts 
DNA sequencing facility). 
5.4.9 Stable Transfection of LNCaP with GHS-R1a 
 The LNCaP (metastatic prostate cancer derived from left supraclavicular lymph 
node) cell line (ATCC) was maintained in RPMI medium (Wisent) supplemented with 
10% fetal bovine serum (FBS; Wisent). Cells were plated at a density of 1 million cells in 
a 10 cm dish for 24 hrs. After 24 hrs 6 µg pcDNA-GHS-R1a-eYFP was added along with 
Fugene-6 (Promega) in a 1:3 ratio as per the protocol provided by Promega. After 48 
hours cells were rinsed with PBS (3x) and replaced with media containing 300 µg/mL of 
G418 (Wisent). Cells were then kept under selective pressure for 7 to 10 days. Cells were 
then sorted (by FLOW cytometry identify the YFP tagged GHS-R1a) for single cell 
populations at the London Regional Flow Cytometry Facility (LRFCF) by manager Dr. 
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Kristin Chadwick. A single cell population was collected and re-sorted by the same 
method mentioned above. This single cell clonal population was confirmed by confocal 
microscopy identifying the tagged GHS-R1a in yellow. Confocal microscopy confirmed 
90-95% of cells were expressing GHS-R1a with high cellular membrane expression 
(Figure 5.S1).   
5.4.10 Cellular Uptake  
 LNCaP cells stably transfected with GHS-R1a were plated at 150,000 cells per 
well in a 6 well plate for 48 hours. Post 48 hours the cells were first rinsed (3X) and then 
mechanically lifted in 1x HBSS and treated with 0.1 MBq of ([Tyr4, Lys5(AMB18F3)] per 
well for 20 min at 37OC and 5% CO2. After the incubation the cells were transferred to 
1.5 mL Eppendorf tubes and spun down at 13,000 G for 5 min. The supernatant was 
removed from cell pellet and collected in an additional 1.5 mL Eppendorf tubes. The cell 
pellet was washed with 1x HBSS and spun again at 13 000 Gs for 5 min. The 
supernatants were combined. The rinse fluid and cell pellet were counted on a gamma 
counter to measure a percent uptake value (counts in rinse versus counts in pellets). The 
same procedure was performed for blocking with 10 x concentration of ([Tyr4, 
Lys5(AMB19F3)]. This whole experiment was performed in triplicate.  
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Chapter 5 Supplementary Information 
HPLC-MS Traces 
[Tyr4, Lys5(N3)] (Found - [M+H]+ - 841.18, Calculated - [M+H]+ - 841.17) 
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[Tyr4, Lys5(AMB19F3)] (Found - [M+H]+ - 1006.30, Calculated - [M+H]+ - 1006.31) 
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Supplementary Figure 5.1 - Confocal microscopy images of stable transfect LNCaP 
with GHS-R1a-eYFP indicating the receptor is highly expressed and localized to the 
cell membrane 
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Chapter 6 
 
Targeting the GHS-R1a Homo-Oligomer: Bivalent Ligands with Exceptional 
Binding Affinity and Potency 
 
6.1 Introduction 
The growth hormone secretagogue receptor type 1a (GHS-R1a) is a G-protein 
coupled receptor (GPCR) that belongs to the rhodopsin-like family of GPCRs (Class A)1. 
It is primarily expressed in the pituitary gland and hypothalamus but has also shown 
expression in a wide range of other tissues such as the heart, lungs, and brain2. The 
natural ligand for this receptor, ghrelin, is a 28-amino acid peptide with an octanoylation 
on Ser-3, and this hydrocarbon tail is needed in order to bind the GHS-R1a causing an 
activation. Activation of this receptor has been identified in controlling a large number of 
human physiological functions including glucose metabolism, insulin release, gut 
motility, and many more2. However, its activation has been shown to be problematic in 
human disease such as causing an increase of cellular proliferation in prostate cancer 
through the p44/42 mitogen -activated protein kinase (MAPK) pathway3–6. The 
overexpression of GHS-R1a increases the motile phenotype in astrocytomas, in which 
increased GHS-R1a expression is correlated with a higher tumour grade7. Overexpression 
of GHS-R1a has more recently been demonstrated in some ovarian epithelial carcinomas, 
a disease with poor prognosis due to the late stages in which it is usually diagnosed8-12. 
Interestingly, activating this receptor with potent agonists (i.e. anamorelin) has also been 
identified to be beneficial in human disease, as is the case of cancer cachexia13. This 
makes GHS-R1a an attractive target in the development of ligands that can control its 
dysregulation within human diseases.  
GPCRs constitute the largest group of membrane receptors in eukaryotes and play 
a role in an incredible number of diversified functions in the human body. Significant 
progress has been made in understanding GPCR structures and modes of function. Recent 
years have seen an explosion in the number of studies showing that GPCRs not only exist 
as isolated entities but also may interact with themselves and/or other membrane protein 
to form homo-oligomers and hetero-oligomers respectively14-16. Most evidence indicates 
that oligomers may be a predominant species, with the potential for formation of higher-
order oligomers. GPCR oligomerization represents functional importance such as 
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enabling cross-talk, inducing activation of alternative signalling pathways, influencing 
pharmacology, influencing receptor internalization and is critical for receptor trafficking 
and function14,15,17,18. Therefore, GPCR oligomers offer attractive potential therapeutic 
targets for drug development.  
GHS-R exists in two distinct isoforms: GHS-R1a and GHS-R1b. GHS-R1a as 
mentioned previously is activated by ghrelin, to induce growth hormone release, 17 
however GHS-R1b is functionally inactive and does not bind ghrelin24-25. GHS-R1a has 
potential therapeutic application towards a range of diseases such as obesity, diabetes, 
and cancer19-23. Along with numerous other GPCRs, GHS-R1a has been proven to form a 
homo-oligomer. The first example of GHS-R1a homo-oligomerization was described in 
2005 by Holst et al. Holst and co-workers used transfected COS-7 cells with GHS-R1a 
and in the presence of the endogenous agonist ghrelin, along with the co-administration 
of other agonists (small molecules L 692,429 and MK-0677, as well as the peptide 
growth hormone releasing peptide-6 (GHRP-6)) there was a neutral, positive, or negative 
modulation in signalling26. Jiang and co-workers confirmed this oligomerization in a 
human embryonic kidney (HEK293) derived cell line co-transfected with GHS-R1a-
green fluorescent protein (GFP) and GHS-R1a-Renilla luciferase (rluc)26. Upon 
stimulation with human ghrelin a fluorescence resonance energy transfer (FRET) signal 
was observed. A time-resolved (Tr) FRET measurement was also observed by Kern et al. 
using a CLIP-GHS-R1a and SNAP-GHS-R1a HEK293 derived cell line28. The GHS-R1a 
homo-oligomerization was also observed by Leung et al. using bioluminescence 
resonance energy transfer (BRET) and co-immunoprecipitation28.  
GHS-R1a has the ability to not only oligomerize with itself but also with other 
GPCRs, including GHS-R1b receptor,27 prostaglandin E2 receptor (EP3-1),29 prostacyclin 
receptor (IP),29 thromboxane A2 receptor (TPα),29 Somatostatin receptor 5(SST5),30 
dopamine receptors (D1 and D2),27,31 melanocortin 3 receptor (MC3),32 and serotonin 2C 
receptor (5-HT2C)33. Kern et al. was one of the first to describe the oligomerization  
between the D1- and D2-like dopamine receptors and GHS-R1a. These receptors are 
coexpressed in a number of brain regions linked to food intake and reward behaviours. 
They demonstrated when there was a lack of ghrelin circulation in the brain the 
oligomerization between D1- and D2-like dopamine receptors and GHS-R1a leads to 
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anorexigenic effects. Rediger et al. demonstrated an additional example for the 
oligomerization between GHS-R1a and MC3R32. GHS-R1a and MC3R are coexpressed 
in the arcuate nuclease of neurons as observed by FRET. The stimulation of MC3R leads 
to the accumulation of cAMP by means of Gas33. cAMP increases by 2-fold when MC3R 
is stimulated and coupled with GHS-R1a, however GHS-R1a constitutive activity along 
with ghrelin induced activity decreases intracellular calcium by 40%. However, when the 
MC3R receptor is antagonized, there is an increase in GHS-R1a signalling underlying an 
increase in fat mass within a MC3R-/- knockout mouse model33. These are examples in 
which GHS-R1a hetero-oligomerization change the downstream signalling events leading 
to different physiological outcomes.  
The existence of multiple GHS-R1a oligomerization states significantly increases 
the pharmacological diversity of the GHS-R1a receptor, which is expected to result in 
enhanced specificity of GHS-R1a-targeted drugs34. On the other hand, GHS-R1a has a 
broad spectrum of functions and is associated with a wide range of diseases. Therefore, 
targeting the GHS-R1a monomer may suffer from low specificity as it will not only affect 
the biological function of interest, but will also affect the other systems where the 
receptor is involved. The ability to target the specific GHS-R1a homo- or hetero-oligomer 
is more desirable as it is likely to lead to a more selective pharmacotherapy35.  
Jiang et al. showed that the co-administration of human ghrelin and dopamine 
caused a 4-fold increase in cAMP signalling enhancing positive physiological outcomes 
associated with mood, learning and memory. This was only seen in the presence D1R and 
GHS-R1a oligomerization36. More recently Schellekens et al. demonstrated the positive 
effects of the oligomerization between the 5-hydroxytryptamine receptor 2C (5-HT2C – 
serotonin receptor). Oligomerization between GHS-R1a and 5-HT2C blocks ghrelin’s 
orexigenic effects as well as attenuation of ghrelin-induced food intake after the 
administration of human ghrelin and/or Lorcaserin (treatment for obesity)37. Both of these 
studies indicate how a combined treatment plan could be necessary to combat human 
diseases such as obesity, mood, memory, and learning.  
A powerful approach to pharmacologically targeting GPCR oligomers is the use 
of bivalent ligands consisting of two pharmacophores linked by a spacer with appropriate 
length38-40. Bivalent ligands are capable of binding to both receptors in the oligomer 
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simultaneously, resulting in dramatically enhanced binding affinity due to the total 
binding energy of two pharmacophores38-40. However negative cooperativity can lead to 
reduction in binding and efficacy when targeting GPCR oligomers. A number of bivalent 
ligands have been recently developed targeting other GPCR homo- and hetero-oligomers, 
but none has been developed for GHS-R1a38-40. In the present study, we reported the 
design, synthesis, binding affinity and signalling responses from bivalent ligands 
targeting GHS-R1a. Through a rational structure-based design approach, we discovered a 
bivalent ligand based on peptidomimetic G7039 that possesses exceptionally high 
binding affinity and is able to bind to oligomeric GHS-R1a in HEK293 cells. Compound 
6 not only displayed exceptional binding, but also caused an increase in b-arrestin 
recruitment thus changing the signalling of p44/42 MAPK pathway. However, signalling 
mechanism changes were evident when studies were conducted using G protein (Gq, 
Gq/11, Gi/o, and G12/13) signaling couple gene reporter assays. The molecular basis for 
cellular distribution of, and more importantly, the functional relevance in disease of the 
GHS-R1a homo-oligomer formation have been elusive. The bivalent ligand developed 
herein presents a powerful tool to enlighten how the homo-oligomer functions and has the 
potential to advance a promising novel therapeutic approach for homo-oligomer related 
pathological condition through fine-tuning GHS-R1a receptor-mediated activity. 
6.2 Results and Discussion 
6.2.1 Rationalizing the Design of our Bivalent Ligand 
Bivalent ligands intended to simultaneously bind to both receptors in the oligomer 
consist of two recognition elements linked by a spacer with optimal length. A number of 
studies have described that bivalent can be rationally designed if some important aspects 
such as suitable pharmacophore, spacer length, and attachment point are considered38-40. 
The peptidomimetic G7039, discovered by Genentech Inc from extensive medicinal 
chemistry studies on GHRP-6 and G-7502,41-42 was used as the pharmacophore due to it 
high binding affinity (IC50 = 5.2 nM as determined in our lab) and being readily 
synthesized via solid phase synthesis (Figure 6.1A).  
Theoretically, bivalent ligands successfully bridging two binding sites within the 
homo-oligomer should exhibit extremely high binding affinity as the result of the total 
binding free energy of two pharmacophores. Indeed, a number of bivalent ligands with 
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improved binding affinities as compared to their parent compounds have been reported43.  
Notably, the bivalent ligands mentioned in the literature are small molecule-based 
pharmacophores with spacer lengths ranging from about 6 to 20 atoms. It has been 
proposed that bivalent ligands with short spacer lengths are not able to extend sufficiently 
out of the transmembrane domain to enable the binding to its neighboring receptor44. It is 
more likely that these ligands bind to different sites (i.e., orthosteric site and allosteric 
site) on a single receptor as suggested by molecular modelling (therefore have been 
coined the name bitopic ligands)45. Moreover, Vagner et al. proposed that the enhanced 
binding affinities of bivalent ligands with short linkers (<20Å) relative to monomers was 
mainly due to the ‘statistical binding effect’, that is, the binding of one pharmacophore of 
a bivalent ligand to one receptor leads to an increased local concentration of the ligand, 
resulting in the increased statistical probability of binding the other receptor within the 
oligomer46-47. The ‘statistical binding effect’ suggests a ‘dual-acting phenotype’, rather 
than a true bivalent binding48. The crystal structure of GPCR oligomers as well as 
modeling studies estimated the distance between two adjacent binding sites to be in a 
drastically wide range ranging from 25 to 100Å, in the case of loosely packed receptors48.  
 
Figure 6.1 - Structure-based approach for the design of bivalent ligands. (A) 
Structure of G7039 and the (B) G7039-GHS-R1a complex model previously 
developed in our lab indicated that the (C) C-terminus is the suitable attachment 
point 
 
With the previous literature in mind, we set out to design a bivalent ligand with 
the appropriate linker length in order to target the GHS-R1a homo-oligomer. In order to 
better guide our attempt at the appropriate linker length we generated a homo-oligomer 
model based on the G7039-GHS-R1a complex model previously developed in our lab49 
and the crystal structure of the beta-1 adrenergic receptor oligomer (PDBID: 4GPO50). 
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Beta-1-adrenergic and GHS-R1a share a relatively high sequence similarity of about 
38%. Our homo-oligomer model of GHS-R1a in complex with G7039 showed a 
minimum distance of 50Å between the C-terminus attachment points of G7039 (Figure 
6.1C). However, the model indicated that a longer spacer length should be required to 
enable a bivalent ligand interaction with the oligomer for a number of reasons. First, the 
amides on the C-terminus are not facing straight towards each other due to the binding 
pattern of the ligand in the orthosteric site of the receptor. Second, the ligand is buried in 
the binding pocket to some extent and an additional spacer length will be needed to 
extend the ligand to the extracellular side. A third reason supporting the need for a longer 
linker is because the receptor binding pocket is partially blocked by the N-terminus of 
GHS-R1a. An estimation of the distance allowing the ligand to be accessible from 
extracellular side and at the same time get away with the N-terminus suggested a spacer 
length between 50-74Å is required to crosslink both receptors. We next considered the 
location to attach the linker between the two G7039 peptides. The G7039-GHS-R1a 
complex model shows that the positively charged N-terminus serves as an anchor point 
for binding via a charge-charge interaction with Glu124 on the GHS-R1a, while the C-
terminus is accessible from the extracellular side. Based on the model, the C-terminus is 
determined to be the suitable attachment points for linking two pharmacophores with a 
spacer (Figure 6.1B).  
 Furthermore, the composition of the spacer regarding hydrophilicity, flexibility, 
and the ease of synthesis was also considered. We decided to use PEG (polyethylene 
glycol) units as this would avoid cumulative increase in hydrophobicity51. The Fmoc-
AEEA (Fmoc-8-amino-3,6-dioxaoctanoic acid) was selected as it can be treated as an 
amino acid that is readily added on to the peptide via solid phase synthesis.  Each of the 
AEEA unit consists of 9 atoms and is about 10Å.  We concluded that 5-7 AEEA units 
will be necessary to enable a bivalent-binding mode, while a ligand containing a spacer 
shorter than that should not be able to bridge two binding sites. The ligands bearing 1-4 
AEEA units were synthesized as control agents to investigate more thoroughly how the 
spacer length affects the binding affinity. Additionally, the ligand with 8 AEEA units was 
also synthesized. 
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6.2.2 Synthesis 
The bivalent ligands based on G7039 were synthesized using standard Fmoc 
peptide chemistry on a solid support. They were synthesized with amino acids bearing 
standard protecting groups, with the exception of the C-teminus Lys, that contained the 
orthogonal protecting group allyloxycarbonyl (Alloc). The first G7039 unit with 
additional Alloc protected Lys at the C-terminus was synthesized on solid support using 
automated peptide synthesis. The selective deprotection of the lysine Alloc protecting 
group was carried out and the resulting free amine at the Lys side chain allows for the 
ligation of individual spacer (Fmoc-AEEA) with different lengths. 
The second G7039 pharmacophore was then coupled with the deprotected AEEA 
using automated peptide synthesis. After both G7039 pharmacophores were added to the 
solid support, all protecting groups were cleaved from resin (Scheme 6.1).  
 
Scheme 6.1 - Solid phase synthesis of peptidomimetics. a: Fmoc-Lys(Alloc)-OH; b: 
(1) piperidine/DMF, (2)Fmoc-amino acid; c: TPP palladium; d:Fmoc-AEEA; e: 
piperidine/DMF; f: Fmoc-amino acid; e: total deprotection from the resin using 
95% TFA, 2.5% TIPS, and 2.5% H2O 
6.2.3 Radioligand binding evaluation 
The bivalent ligands with a spacer length ranging from 13-76 atoms (17-92 Å) 
were synthesized. Their binding profiles (IC50) were determined by competitive 
radioligand ([125I]-ghrelin) binding assay using GHS-R1a transfected HEK293 cells as 
receptor source (Table 6.1, Figure 2). Compound 1 with the shortest spacer showed 
slightly increased binding affinity (1.6 nM) as compared to that of the parent ligand 
G7039 (5.2 nM). When the spacer length was increased to 22 atoms (28 Å), the binding 
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affinity increased to 0.55 nM (Compound 2). Further elongation of the spacer to 31atoms 
(38 Å) resulted in a slightly increased binding affinity for bivalent compound 3 (0.32 
nM). After this point, further extension of the spacer to 49 atoms (60 Å) resulted in 
comparable affinities for compounds 3, 4 and 5. All the binding displayed monophasic 
curves. However, the binding characteristics changed dramatically by the extension of the 
spacer to 58 atoms (70 Å) for compound 6, a biphasic competition curve with two 
individual values for IC50high and IC50low differing by about 2 orders of magnitude was 
observed indicating two binding states (Figure 6.2F). The high-affinity binding was 
determined to be 0.43 nM with a high-affinity population of 45%, while the affinity for 
the low-affinity binding was determined to be 0.00042 nM. The biphasic competition 
curve can be explained by the coexistence of different receptor subpopulations, which has 
been observed looking at other GPCRs52-54. Our data suggests that GHS-R1 also exists as 
two different receptor subpopulations, that is monomer and homo-oligomer. The low-
affinity binding corresponded to a monovalent-binding mode to the receptor, while the 
high-affinity binding represented to a bivalent receptor bridging mode of compound 6 to 
the GHS-R1 homo-oligomer. Interestingly, the ligands (compound 7, compound 8) with 
longer spacer length showed comparable binding affinities (0.31 nM and 0.22 nM, 
respectively) but displayed monophasic binding curves rather than biphasic ones, 
suggesting that ligands bearing a spacer that is too long (> 67atoms/82 Å) are not 
effective at bridging two receptors in the homo-oligomer. To factor out possible 
contributions of the spacer to binding affinity, monovalent ligand compound 10 
containing a spacer with 58 atoms (70 Å) was synthesized as control. The IC50 was 
determined to be 1.09 nM, suggesting that the spacer does not have appreciable 
contribution to the binding affinity (Table 6.2). This was also proven by a monophasic 
binding curve indicating that compound 10 does not target the homo-oligomer.   
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Table 6.1 - Binding affinities for bivalent ligands determined by [125I]-ghrelin 
displacement 
 
Bivalent ligands 
 
Compound 
Number 
n Spacer Length 
(atoms) 
Spacer Length 
(Å) 
IC50 (mean ± SE) Curve shapes 
1 1 13 17 1.60 ± 0.57 nM Monophasic 
2 2 22 28 0.55 ± 0.28 nM Monophasic 
3 3 31 38 0.32 ± 0.01 nM Monophasic 
4 4 40 49 0.30 ± 0.14 nM Monophasic 
5 5 49 60 0.23 ± 0.02 nM Monophasic 
6 6 58 70 IC50low =0.43 ± 0.30 
nM 
IC50high =0.42 ± 0.53 
pM 
Biphasic 
7 7 67 82 0.31 ± 0.04 nM Monophasic 
8 8 76 92 0.22 ± 0.13 nM Monophasic 
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Table 6.2 - Binding affinities for monovalent ligands determined by [125I]-ghrelin 
displacement 
 
Monovalent ligands 
 
Ligands 
(Compound 
Number) 
n Spacer Length 
(atoms) 
Spacer Length 
(Å) 
IC50 (mean ± SE) Curve shapes 
G7039 (9)    3.10 ± 2.97 nM Monophasic 
(10) 6 58 70 1.09 ± 0.04 nM Monophasic 
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Figure 6.2 - Radioligand binding curves for all bivalent ligands and monovalent 
ligand 
 
Vagner et al. noted that bivalent ligands with shorter spacer (<20Å) exhibited 
dual acting binding mode rather than bivalent binding mode due to the ‘statistical 
effect’47,51. We suggest that the bivalent ligands compound 1, compound 2, compound 3, 
compound 4, and compound 5 engage GHS-R1a receptor in a dual acting mode and the 
enhanced binding affinities of these bivalent ligands is due to the ‘statistical effect’. 
Among these ligands, the effect became more significant when the spacer is long enough 
to extend the second pharmacophore to the extracellular site and enable an increase in 
local concentration. With an optimal spacer length of 58 atoms/70 Å, the bivalent ligand 
compound 6 is capable of bridging two receptors in the oligomer, leading to a markedly 
boosted binding affinity (IC50high). However, due to the coexistence of monomer 
subpopulation in the cells, a monovalent binding mode is inevitable, leading to a higher 
binding affinity (IC50low). With an even longer spacer, the bivalent ligand is not able to 
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bridge both receptors in the oligomer due to the entropy cost, associated with restricting 
the second pharmacophore to the second binding site, being too great.  
 
Figure 6.3 - b-Arrestin 1 and 2 recruitment measuring the potency of the ligands 
(EC50) values. (A) b-Arrestin 1 recruitment indicating an entire log shift in potency 
increase for the bivalent ligand. (B) b-Arrestin 2 recruitment indicating an entire log 
shift in potency increase for the bivalent ligand. The bivalent ligand has an increase 
in net BRET ratio compared to the other ligands indicating that the bivalent ligand 
is more of a full agonist. (C) Measured EC50 values with the bivalent ligand being the 
most potent in the series (n=3 for both b-Arrestin 1 and 2 recruitment). *P<0.05 
compared to G7039 
From this point forward, four ligands were evaluated in terms of differences seen 
in downstream signalling with the GHS-R1a homo-oligomer versus the GHS-R1a 
monomeric receptor. The lead bivalent ligand (6) was compared to the controls consisting 
of human ghrelin, G7039 (9) and G7039-L (10). We used a bioluminescence resonance 
energy transfer (BRET) assay to monitor b-arrestin recruitment to GHS-R1a. This was 
accomplished by transiently transfecting HEK293 cells with an eYFP tagged GHS-R1a 
(GHSR-1a-eYFP) and a Renilla luciferase (rluc) tagged b-arrestin1 (b-Arrestin 1-rluc) or 
b-arrestin 2 (b-Arrestin 1-rluc) construct in a 10 to 1 ratio, respectively. Upon addition of 
the various ligands (Figure 6.3 panel C) at a concentration range from 1x10-5 M to 1x10-
13 M a net BRET ratio was measured to assess agonist stimulated arrestin recruitment to 
GHS-R1a. Previously it has been shown that when GHS-R1a is activated by an agonist 
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such as human ghrelin it causes the recruitment of both b-arrestin-1 and b-arrestin-255-57. 
It has been demonstrated that GHS-R1a forms a transient complex with b-arrestin-2 on 
the cell membrane provided by the stabilization of phosphate acceptor sites from the tail 
of the receptor. This was proven to be destabilized by mutagenesis experiments with the 
conserved residues (Pro 148, Ala 144 and Leu 149) seen within this region. This 
interaction with b-arrestin-2 is crucial in the induction of Ras Homolog Family Member 
A (RhoA) signalling and the remodelling of actin filaments58. We show that the bivalent 
ligand (6) has greater potency than ghrelin for activation of b-arrestin-1 and b-arrestin-2 
recruitment with EC50 values in the low nanomolar range (EC50 = 1.07 nM for β-Arr-1 
and EC50 = 3.09 nM for β-Arr-2). G7039-L (10), and the natural ligand for the receptor, 
ghrelin, have 2-80x fold reduction in the recruitment of b-arrestin-1 and b-arrestin-2 
(Figure 6.3). This increase in potency is possibly due to the activation of a homo-
oigomer receptor compared to a monomer. The homo-oligomeric complex is causing an 
increase in the localization of b-arrestin-1 and b-arrestin-2 to GHS-R1a at the membrane 
due GPCR oligomerization when targeting with bivalent based ligands47-48. It can also be 
noted that compound 9 has a significant increase in potency (pM) for b-arrestin-1 and b-
arrestin-2 recruitment compared to all other compounds. This is an interesting 
observation seen as this compound is only targeting the monomeric GHS-R1a.  
 To further assess whether or not this bivalent ligand (6) was targeting a homo-
oligomer, an assay was designed using transiently transfected cells with the BRET pair 
GHS-R1a-eYFP (2 μg) and GHS-R1a-rluc (2 μg). This particular assay has been used in 
the past to show GHS-R1a homo-oligomerization26-28. 48-hour post transfection cells 
were treated with the various ligands from a 1x10-5 M to 1x10-15 M concentration range 
and the net BRET signal monitored receptor oligomerization.  
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Figure 6.4 – Homo-oligomer assay indicating that the bivalent ligand is able to 
induce a homo-oligomer formation with GHS-R1a causing a net increase in BRET 
signal that is 3x greater compared to the control ligands. (A) Net BRET ratio 
measured over a concentration range. (B) Net BRET ratio a given high and low 
concentration. The control ligands have little to no increase in net BRET signal at 
both a high and low concentration (n=3) 
 
The data in Figure 6.4 panel A indicates that the bivalent ligand (6) targets the 
GHS-R1a homo-oligomr as there is an increasing net BRET signal, with a 4-log shift 
lower concentration (1x10-10M vs. 1x10-6M) compared to the control ligands. This 
bivalent ligang may also be involved in stabilizing the GHS-R1a oligomers. An increase 
in net BRET signal is only seen when higher concentrations (1x10-6M to 1x10-5M) of the 
control ligands are used and may be indicative of a signaling dependent clustering of the 
receptors in membrane microdomains or vesicles. Panel B in Figure 6.4 is an additional 
representation of a given high (1x10-6M) and low (1x10-11M) concentration again 
showing the bivalent ligand (6) is able to target the GHS-R1a oligomer. This assay 
indicated that 6 is able to target the receptor homo-oligomer, and possible stabilize its 
formation. The control ligands are only able to bind the monomer receptor as they do not 
show an increase in the net BRET signal at the wide range of concentrations assessed.  
Changes in intracellular calcium were then measured using LNCaP cells stably 
expressing GHS-R1a-eYFP. A leftward shift in the concentration effect curve was 
observed with compound 6 compared to ghrelin indicating that compound 6 is more 
potent then ghrelin (EC50 of 12 nM versus 121 nM). The Emax is comparable between both 
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ghrelin and compound 6, reaching 30% of the maximum calcium signal obtained with 
calcium ionophore (A23187) treatment (Figure 6.5).  
 
Figure 6.5 - Changes in intracellular calcium measured in LNCaP cells stably 
transfected with GHS-R1a. This is a percent calcium signal obtained with the 
treatment of calcium ionophore (n=3) 
 
A series of experiments were designed to investigate whether activation of GHS-
R1a homo-oligomer causes differential downstream signalling compared to when 
activating the GHS-R1a monomer. The downstream signals measured were the 
phosphorylation of extracellular signal–regulated kinases-1 and -2 (ERK-1/-2; a.k.a. 
p44/42), and gene reporters nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-kB), serum response element (SRE), serum response factor (SRF), nuclear factor of 
activated T-cells (NFAT), and cyclic AMP response element (CRE). GHS-R1a mediated 
phosphorylation of ERK-1/-2 (p-p44/42) involves both the interaction with b-arrestin and 
G protein components. GHS-R1a activation signalling occurs through a series of G-
protein components including Gq, Gq/11, Gi/o, and G12/1359-63. 
 
Figure 6.6 - (A) pERK/tERK ratio when treated with ghrelin and bivalent ligand 
from 0 to 30 min. (B) Representative blot from total data graphed in A. Ghrelin 
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induced a higher level of phosphorylation of ERK 1 and 2 compared to the bivalent 
at 10- and 20-min incubation. This was done in HEK293T cells that transiently 
expressed GHS-R1a-eYFP (eYFP used as loading control – data not shown) (n=3, 
p<0.05 for 10- and 20-min time points) 
 
 The bivalent ligand (6) caused less phosphorylation at 10- and 20-min. incubation 
periods compared to ghrelin. The signal intensity for the pERK/tERK ratio steadily 
increases to a maximum at 20 min followed by a steady decrease till 30 min (P<0.05). 
These results are the first indication that GHS-R1a homo-oligomer modulates 
downstream signalling differently compared to when it is activated as a monomer. Even 
though there was a greater increase in b-arrestin recruitment, it was believed that the 
activation of the oligomer would have caused an increase in ERK-1/-2 phosphorylation. 
However, since compound 6 is more involved in b-arrestin recruitment we expect a 
decrease in G-protein recruitment leading to a decrease in ERK phosphorylation (Figure 
6.6). Additional ERK phosphorylation was followed up by assessing the other ligands at 
various concentrations for a 20 min incubation period (Figure 6.7). 
 
Figure 6.7 - pERK/tERK ratio measured for all 4 ligands from a 1 to 100 nM 
concentration for a 20 min incubation period. Background (0 nM) was removed. (B) 
Representative western blot indicating there is an increase in pERK/tERK for 
ghrelin compared to compound 6. 0 nM concentration is vehicle control with HBSS 
and 0.1% DMSO. Only significance for the 100 nM concentration was seen 
(indicated by *) (n=3, P<0.05 for 100 nM concentration) 
 
At a concentration of 100 nM there was significantly less phosphorylation (2x to 
3x less) of ERK 1 and 2 with the bivalent ligand (6) compared to the other three 
monovalent ligands (P<0.05). No significance was seen with the lower concentrations. It 
must be noted that for all western blots eYFP was probed for, to ensure equivalent 
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receptor expression levels in cells from which lysates were obtained. Data does not 
change when the ratio of (pERK/tERK)/(eYFP) is assessed (data not shown). 
Next, we investigated the source of ERK activation downstream of GHS-R1a 
activation to further investigate our finding that the bivalent ligand (6) activated ERK to 
lesser magnitude than that found with ghrelin. ERK activation can occur downstream of 
both Gq/11 and b-arrestin signalling pathways64. Pre-incubation with with Gq/11 specific 
inhibitor, YM254890 (100 nM), was sufficiently able to inhibit ERK activation at 20 
minutes following ghrelin stimulation (100 nM; Figure 6.8). Thus, ERK activation 
occurs downstream of Gq/11 activation following GHS-R1a agonism with ghrelin. 
 
Figure 6.8 - (A) Stimulation of ERK (p-p44/42) phosphorylation with or without 
pre-incubation with Gq/11 inhibitor YM254890 (100 nM) and stimulation with 
ghrelin (100 nM). Data are shown as ratio of pERK/tERK. (B) Representative 
western blot indicating pERK is completely inhibited in the presence of YM254890. 
Significance was only observed between unstimulated and ghrelin treated vehicle 
control (indicated by *) (n=3, p<0.05) 
 
Finally, gene reporters were assessed to test the hypothesis that the GHS-R1a 
homo-oligomer leads to differential downstream signalling. The gene reporters that were 
studied have known upstream G-protein partners. SRE leads to mitogen activated protein 
kinase (MAPK) response and is downstream of Gq/11, Gs, and Gi. SRF is downstream of 
Gq/11, and G12/13. CRE is downstream of Gs. NFAT is downstream of Gq/11. Finally, NF-
kB is downstream of many pathways (Figure 6.9). The intention with using these gene 
reporters was to better understand how the GHS-R1a homo-oligomer modulates G-
protein partners when activated.  
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Figure 6.9 - Gene reporters assessed at a 100 nM concentration for ghrelin and the 
bivalent ligand. CRE and NFAT did not show any signal for all treatments. HBSS 
with 0.1% DMSO and Serum are control conditions. No significance was seen 
between Ghrelin vs. the Bivalent only trends were observed; (n=3) 
  
The bivalent ligand (6) showed differential signalling compared to the other three 
ligands, with 6 causing the greatest activation with SRF and SRE. Ghrelin was least 
potent in activating SRF and SRE. This was an expected result as the activation of GHS-
R1a is known to come from both Gq/11 and G12/13. However, receptor oligomerization led 
to an increase in the activation of these G-proteins when targeted with this highly potent 
homobivalent agonist. This was reversed for NF-kB, as the bivalent ligand (6) began to 
slow this signalling pathway, where ghrelin caused an activation of NF-kB. CRE and 
NFAT did not showing any activation with any of the four ligands. The lack of CRE 
activation is downstream of Gs and this data is not unexpected since GHS-R1a is not 
reported to couple to this G protein. The lack of NFAT activation was however somewhat 
unexpected since GHS-R1a coupling to Gaq/11 has been reported and NFAT gene 
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reported activity occurs downstream of Gaq/11. This discrepancy could stem from the 
time after agonist treatment at which these assays were done and represent a limitation of 
using gene reporters to probe signaling pathways. 1x HBSS was used as the negative 
control and showed no activation of any of the gene reporters. DMEM media containing 
10% FBS was used as a positive control causing an upregulation of SRF, SRE, and NF-
kB as these are serum response genes. The reduction in NF-kB is highly beneficial in 
terms of being able to agonize GHS-R1a in diseases such as cancer cachexia, without 
upregulating other pathways involved in inflammation13. This is the first known instant of 
targeting the GHS-R1a homo-oligomer with a homobivalent agonist resulting in changes 
in downstream signalling events.  
6.3 Conclusions 
 We report herein the development and characterization of a novel ligand targeting 
the GHS-R1a homo-oligomer. The ligand that was chosen was the established ghrelin 
peptidomimetic G7039, as the initial goal was to determine the spacer length between the 
two linked G7039 molecules in order to target the oligomerized GHS-R1a with high 
affinity and potency. An optimal spacer length of 58 atoms was determined in order for 
compound 6 to target the GHS-R1a homo-oligomer. The discovery of the spacer length 
sets the ground work to synthesize additional ghrelin ligands such as heterobivalent 
ligands (e.g. agonist linked to antagonist) and other homobivalent ligands (e.g. antagonist 
linked to antagonist). Also, based on the previous design of imaging agents derived from 
G7039, this high affinity probe can easily be converted into a PET imaging probe54. The 
linker region of compound 6 is also a potential sight to conjugate various fluorescent dyes 
and imaging moieties for various modalities such as PET, SPECT and confocal 
microscopy.  
 The second major outcome of this paper is when you target and activate the GHS-
R1a homo-oligomer using compound 6 there is the presence of differential downstream 
signalling. The bivalent ligand (6) caused 2 to 80-fold increase (versus human ghrelin and 
G7039-L) in b-arrestin-1 and b-arrestin-2 recruitment. This correlates to a large increase 
(versus human ghrelin and G7039) in binding (2000 to 11,000-fold increase) when 6 
targets the GHS-R1a homo-oligomer. Interestingly G7039 is 50-fold more potent in b-
arrestin-1 and b-arrestin-2 recruitment when targeting the GHS-R1a monomer. However, 
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even though compound 6 has the greatest affinity and potency, it caused a decrease in the 
phosphorylation of ERK-1/-2 compared to when ghrelin bound the monomeric GHS-R1a. 
GHS-R1a oligomerization is an explanation for this decrease in phosphorylation of ERK 
1 and 2 as well as the increase observed in b-arrestin recruitment when targeting the 
homo-oligomer with 6.  
b-arrestin commonly performs the role of desensitizing activated GPCRs leading 
to the cessation of G-protein signalling. This hypothesis is supported by the observation 
of inhibited ERK phosphorylation in the presence of Gq/11 inhibitor and stimulation with 
ghrelin. Thus, increasing b-arrestin recruitment may be contributing to increased 
desentization of Gq/11 signalling and the downstream ERK activation pathway. 
Compound 6 also caused an increase in SRF and SRE gene reporters compared to 
ghrelin. Interestingly this pattern was reversed for NF-kB as ghrelin caused a greater 
increase in NF-kB compared to compound 6. NF-kB is an inflammation biomarker, 
therefore 6 has the potential to treat diseases associated with lower levels of GHS-R1a 
activation (cancer cachexia) but not cause a drastic increase in inflammatory markers 
leading to further side effects13, 38-40.   
 This is the first ever demonstration of the development and assessment of a 
ghrelin homobivalent peptide ligand that targets the GHS-R1a homo-oligomer with the 
greatest known affinity for a peptide targeting this receptor. It was also discovered that 
the receptor homo-oligomer displays differential signalling mechanisms when looking at 
specific downstream genes and proteins.  
6.4 Materials and Methods  
6.4.1 General Information 
All reagents were obtained from Sigma-Aldrich, Fisher Scientific, Ark Pharm Inc 
or Oakwood Chemicals. The purity of the compounds was analyzed using analytical 
UHPLC. These results are summarized in Table S2 and Figure S4, with all compounds 
determined to have ≥95% purity. Acquity UHPLC H-Class system (Waters, Inc.) 
combined with a Xevo QTof mass spectrometer was used for analytical UHPLC-MS 
work. Waters Acquity UHPLC BEH C18 column (2.1 x 50 mm, 1.7 μm) was used. High 
resolution mass spectra were obtained on a Thermo Scientific DFS (Double Focusing 
 
 
249 
Sector) mass spectrometer. [125I]-Ghrelin for binding assay was purchased from Perkin 
Elmer 
6.4.2 General Fmoc Synthesis of bivalent ligands 
Automated peptide synthesis was carried out using Fmoc-based solid-phase 
peptide chemistry. Peptides were synthesized at a 0.1 mmol scale on Rink Amide MBHA 
resin (0.52 mmol/g) using a glass peptide reaction vessel. The resin was initially swelled 
with N,N-dimethylformamide (DMF), followed by Fmoc deprotection using 2 mL of 
20% piperidine in N,N-dimethylformamide (DMF) for two cycles (10 minutes, 5 
minutes). Amino acids were preactivated by combining 3 eq. of Fmoc-protected amino 
acid, 3 eq. of O-(6-chlorobenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate (HCTU) and 6 eq. of N,N-diisopropylethylamine (DIPEA) in 2 mL 
of DMF. The mixture was added to the resin and vortexed for 60 minutes. These cycles 
were repeated until all N-terminal amino acids were coupled to the resin. 
Allyloxycarbonyl deprotection of diaminopropionic acid was performed under inert 
atmospheric N2 conditions. DCM was dried over sieves for 24 hours before adding 1 mL 
to the resin. Two equivalents of phenylsilane in 1 mL dry DCM was then added to the 
peptide resin followed by 0.045 eq. of tetrakis(triphenylphosphine) palladium (0) in 1 mL 
dry DCM. The peptide vessel was removed from inert conditions and allowed to react for 
30 minutes. 4 eq. of HCTU and 6 eq. of DIPEA in DMF were used. The reaction mixture 
was left to couple overnight. Full deprotection of the synthesized peptide was performed 
by adding a 2 mL mixture of 95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane 
(TIS) and 2.5% water to the resin and allowed it to mix for 5 hours. The cleaved peptide 
was precipitated from solution using ice-cold tert-butyl methyl ether (TBME) and 
centrifuged (3000 rpm, 10 minutes) resulting in a crude peptide pellet. The supernatant 
was decanted and the resulting peptide pellet was dissolved in 20% acetonitrile in water, 
frozen at -78 °C and lyophilized to a white crude powder. Purification was performed 
using preparative HPLC-MS and purity of the resulting peptides were analyzed using 
analytical UHPLC. These results are summarized in Table 4, with all compounds 
determined to have ≥95% purity. 
Table 6.3 - Analytical data of bivalent and monovalent ligands 
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Compds. 
Calculated Mass Found Mass Purity 
(%) M+2 M+3 M+4 M+2 M+3 M+4 
1 927.0071 618.3407 464.0075 927.1216 618.0745 463.7966 98% 
2 999.5441 666.6987 500.2760 999.6514 666.4235 500.0591 98% 
3 1072.0810 715.0566 536.5444 1072.1301 715.0840 536.3059 97% 
4 1144.6180 763.4146 572.8129 1145.3213 763.1813 572.6222 96% 
5 1217.1549 811.7725 609.0814 1217.0791 811.7061 608.7670 99% 
6 1289.6919 860.1305 645.3499 1289.6057 860.0715 645.0356 98% 
7 1362.2288 908.4885 681.6183 1361.8447 908.2506 681.4270 99% 
8 1434.7658 956.8464 717.8868 1434.9236 956.6053 717.6960 99% 
10 898.9902 599.6628  899.2583 599.4990  99% 
 
6.4.3 Kaiser Test 
To qualitatively determine if there is free amine present (i.e. after a Fmoc-
deprotection, amino acid coupling, or alloc deprotection), a Kaiser test was performed. A 
small amount of resin (<5 mg) was placed in a small test tube. To the test tube, solutions 
of Phenol:EtOH (8:2 v/v), 0.001M KCN:pyridine (2:98 v/v) and ninhydrin in EtOH (5% 
w/v) were added. The test tube was heated to 70°C and the presence of a free amine was 
indicated by the resin beads turning blue. The lack of free amine was indicated by the 
presence of clear/yellow resin beads. 
6.4.4 Deprotection of Allyloxycarbonyl (Alloc) Proctecting Group 
Selective deprotection of the allyloxycarbonyl protecting group was accomplished 
by adding DCM (4.5 mL) to the resin-bound peptide and shaking gently for 10 minutes. 
After addition of phenylsilane (24 equiv.), the peptide vessel was flushed with nitrogen 
and allowed to react for 5 minutes. Then, tetrakis(triphenylphosphine) palladium (0) (0.1 
equiv.) was added to the mixture and the peptide vessel was again flushed with nitrogen, 
and the reaction was allowed to proceed for 10 minutes. Next, the peptide-resin was 
washed with DCM four times (1.5 mL), followed by a series of washings with 1.5 mL of 
DCM, DMF, MeOH, DMF, and DCM (30 sec each).  
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6.4.5 Purification of RP-HPLC/ESI-MS 
Peptides were analyzed using a reverse-phase analytical HPLC column (Agilent 
Zorbax SB-C8 column 4.6 x 150 mm, 3.5 μm). This system was equipped with a Waters 
600 136 controller, Waters Prep degasser, and Waters Masslynx software (version 4.1). 
Employed mobile phases were 0.1% TFA in deionized water (eluent A) and 0.1% TFA in 
acetonitrile (eluent B). The flow rate was set at 1.5mLmin-1 over 15 minutes. The column 
eluate was monitored using a Waters 2998 Photodiode array detector set at 220 nm, 254 
nm and 400 nm. Peptides were purified using a reverse-phase preparative HPLC column 
(Agilent Zorbax SB-C18 column 21.2 x 150 mm, 5 μm) on the same system mentioned 
above. The detection method and eluents were the same was mentioned above for the 
analytical system and the flow rate was set at 20 mLmin-1. The collected fractions were 
then lyophilized to a solid. For analytical UHPLC-MS, studies were performed on a 
Waters, Inc. Acquity UHPLC H-Class system, combined with a Xevo QTof mass 
spectrometer (ESI+, cone voltage = 30 V). A Waters Acquity UHPLC BEH C18 2.1 x 50 
mm, 1.7 μm column was used with a gradient solvent system consisting of 0.1% formic 
acid in acetonitrile and 0.1% formic acid in water. 
6.4.6 Coupling of Fmoc AEEA Linker 
After the Alloc protecting group has been removed, Fmoc-AEEA (1 to 8 linkers 
added) was coupled to additional C-terminal Lys residue of G7039. This was 
accomplished by adding Fmoc-AEEA (0.3 mmol) and the coupling reagent HATU (0.3 
mmol) dissolved in DMF (1.5 mL) to the resin. This mixture was vortexed for 2 hours, 
and the resin was then washed 3 times with DMF (2.0 mL, vortex 30 sec) and 3 times 
with DCM (2.0 mL, vortex 30 sec), then dried under vacuum. 
6.4.7 Competitive Binding Assay (IC50) 
The affinity for GHS-R1a was determined using a radioligand competitive 
binding assay. Assays were performed using GHS-R1a transfected HEK293 cells as 
receptor source and human [125I]-ghrelin(1-28) (Abcam) as the radioligand. Human 
ghrelin(1-28) was used as reference to ensure the validity of the results. A suspension of 
membrane from HEK293/GHS-R1a cells (50,000 cells per assay tube) were incubated 
with ghrelin(1-8) peptide analogues (at concentrations of 10-5 M, 10-6 M, 10-7 M, 10-8 M, 
10-9 M, 10-10 M and 10-11 M) and [125I]-ghrelin (15 pM per assay tube) in binding buffer 
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(25 mM HEPES, 5 mM magnesium chloride, 1 mM calcium chloride, 2.5 mM EDTA, 
and 0.4% BSA, pH 7.4). The resulting suspension was incubated for 20 minutes under 
shaking (550 rpm) at 37 °C. Unbound [125I]-ghrelin was removed and the amount of 
[125I]-ghrelin bound to the membranes was measured by gamma counter. IC50 values were 
determined by nonlinear regression analysis. All binding assays were performed in 
duplicate or triplicate. 
6.4.8 Molecular cloning and constructs  
YFP tagged human GHS-R1a from Addgene (hGHS-R1a) was made by replacing 
PAR4 in the previously published PAR4-YFP (Ramachandran et al., 2017) construct65 
with GHS-R1a using restriction enzymes digestion with EcoRI and Xhol and ligation. 
Constructs was verified by direct sequencing (University of Western Ontario, Robarts 
DNA sequencing facility). 
6.4.9 Bioluminescence Resonance Energy Transfer (BRET): β-Arrestin 1/2 
Recruitment Assay  
HEK293T cells were transfected with BRET pair GHS-R1a-eYFP (2 μg) and β-
arrestin-1-rluc or β-arrestin-2-rluc (0.2 μg) using calcium phosphate in tissue culture 
treated white 96-well plates. 48 hours after transfection, cells were treated with the 
agonists being tested, Renilla luciferase substrate (h-coelenterazine) was added to each 
well (5 μM final) and incubated (37 °C, 20 min), before measuring BRET ratios on a 
Berthold Mithras LB 940. Responses are expressed as net emission of eYFP/rluc 
(calculated by subtracting HBSS baseline eYFP/rluc ratio from agonist eYFP/rluc ratio) 
and normalized to a positive control. Experiments were performed in triplicate with 3 
separate cultures of cells and data was fitted with a non-linear regression analysis four-
parameter dose-response curve using GraphPad Prism 6 to determine EC50 values, as this 
fitting provided the greatest R squared value. 
6.4.10 Homodimer Assay  
HEK293T cells were transfected with BRET pair GHS-R1a-eYFP (2 μg) and 
GHS-R1a-rluc (2 μg) using calcium phosphate in tissue culture treated white 96-well 
plates. 48 hours after transfection, cells were treated with the agonists being tested, 
Renilla luciferase substrate (h-coelenterazine) was added to each well (5 μM final) and 
incubated (37 °C, 20 min), before measuring BRET ratios on a Berthold Mithras LB 940. 
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Increase in a net BRET signal indicated that each of the differentially tagged receptors 
were in close proximity.   
6.4.11 Gene Reporter Assay 
HEK293T cells are maintained in Dulbecco’s Modified Eagle’s medium (DMEM) 
from Sigma-Aldrich (D5796) with added 5% sodium pyruvate, 5% penicillin 
streptomycin, and 10% fetal bovine serum (FBS) at 37°C with 5% CO2. Cells were 
cultured in a T-75 flask to 95% confluency then lifted by trypsin-ETDA (0.25%). Once 
cells were counted and spun down at 1000 rpm they were resuspended and then re-plated 
in 10 cm culture dishes at 1 million cells per plate. Seeding was then accomplished for 24 
hrs at 37°C with 5% CO2. After 24 hrs cells were transiently transfected with 2 ug of 
GHS-R1a-eYFP and 2 ug of either NFAT/SRE/SRF/NF- kB/CRE-nluc by calcium 
phosphate transfection method for 24 hrs at 37°C with 5% CO2. Following the 24 hr 
transfection cells were rinsed 3x with PBS and then 11 mL of serum containing media 
was added. Plates were then allowed to sit at 37°C with 5% CO2 for 4 hrs before being 
lifted by pipette and re-plated in a 96-well white wall and white bottom plate. Cells then 
were maintained at 37°C with 5% CO2 for an additional 24 hrs before reporter assay was 
performed. All drugs being tested were dissolved in Hanks’ Balanced Salt Solution 
(HBSS) with 0.1% DMSO. The highest drug concentration of 10-5 M was first prepared, 
and each full log concertation was prepared by serial dilution thereafter. The control well 
contained just HBSS with 0.1% DMSO. The serum media was removed from the plate 
before then addition of the drug at varying concentrations (10-5 M to 10-17 M). The drugs 
were then incubated in the plate for 4 hrs at 37°C with 5% CO2. After 4 hours Nano-Glo 
luciferase (Promega) substrate is added to have a final concentration of 10-8 M and then 
placed at 37°C with 5% CO2 for 10 mins. The plate is then read by a Berthold Mithras 
LB 940 plater reader at a λ max of 460 nm. The HBSS control is then removed as the 
background to all other signals and a dose response plot is used to quantify the signal 
from the genes being up or down regulated. The entire experiment described above was 
completed in triplicates for each drug and gene being studied.  
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6.4.12 Western Blotting 
HEK293T cells are maintained in Dulbecco’s Modified Eagle’s medium (DMEM) 
from Sigma-Aldrich (D5796) with added 5% sodium pyruvate, 5% penicillin 
streptomycin, and 10% fetal bovine serum (FBS) at 37°C with 5% CO2. Cells were 
cultured in a T-75 flask to 95% confluency then lifted by trypsin-ETDA (0.25%). Once 
cells were counted and spun down at 1000 rpm they were resuspended and then re-plated 
in 6-well culture dishes at 500 000 cells per well. Seeding was then accomplished for 24 
hrs at 37°C with 5% CO2. After 24 hrs cells were transiently transfected with 0.33 ug of 
GHS-R1a-eYFP per well. Following 48 hours of transfection cells were rinsed 3x with 
PBS and 1 mL of serum free media was added to each well. The ligands were then added 
to have final concentrations of 1 nM, 10 nM, 100 nM, and no ligand as for the control. 
Plates were incubated at 37°C with 5% CO2 for 0 min, 5 min, 10 min, 20 min, and 30 
min. After the incubation period media was removed and cells were lysed and spun down 
at 17 G to collect total protein. SDS gel electrophoresis was ran in a 4 to 12% gradient gel 
for 1 hour, followed by transferring to the PVDF membrane for 90 min. pERK was 
measured with a specific primary antibody for 24 hours at 4°C, followed by stripping the 
blot and measuring tERK with an additional specific antibody for 24 hours at 4°C. Then 
the blot was stripped a third time and a specific primary antibody for eYFP was incubated 
for 24 hours at 4°C. The ratio of pERK to tERK was calculated and graphed to show 
difference in phosphorylation. All antibodies were purchased from Cell Signalling. GHS-
R1a stimulated ERK signalling in HEK-293 -/+ YM254890: Cells were cultured and 
prepared as described above. Either YM254890 (100 nM; FUJIFILM Wako Pure 
Chemical Corporation) or DMSO vehicle control (0.001%) were added to wells for 30 
minutes prior to agonist stimulation (ghrelin, 100 nM). Cells were incubated with ghrelin 
for 20 minutes. Lysates were prepared, processed and quantified as described above. 
6.4.13 Stable Transfection of LNCaP cells with GHS-R1a-eYFP. 
The LNCaP (metastatic prostate cancer derived from left supraclavicular lymph 
node) cell line (ATCC) was maintained in RPMI medium (Wisent) supplemented with 
10% fetal bovine serum (FBS; Wisent). Cells were plated at a density of 1 million cells in 
a 10 cm dish for 24 hrs. After 24 hrs 6 µg pcDNA-GHS-R1a-eYFP was added along with 
Fugene-6 (Promega) in a 1:3 ratio as per the protocol provided by Promega. After 48 
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hours cells were rinsed with PBS (3x) and replaced with serum media containing 300 
µg/mL of G418 (Wisent). Cells were then kept under selective pressure for 7 to 10 days. 
Cells were then sorted (by FLOW cytometry identify the YFP tagged GHS-R1a) for 
single cell populations at the London Regional Flow Cytometry Facility (LRFCF) by 
manager Dr. Kristin Chadwick. A single cell population was collected and re-sorted by 
the same method mentioned above. This single cell clonal population was confirmed by 
confocal microscopy identifying the tagged GHS-R1a in yellow. Confocal microscopy 
confirmed 90-95% of cells were expressing GHS-R1a with high cellular membrane 
expression 
6.4.14 Calcium Assay  
LNCaP cells stably transfected with GHS-R1a-eYFP (maintained in RPMI with 
10% FBS, 1% Pen-Strep, and 300 µg/mL G418 – Wisent) were grown to 75 to 85% 
confluency in a T-75 flask. Cells are lifted from the T-75 flask using 5ml of 1 mM EDTA 
in PBS (Wisent). Cell-PBS-EDTA suspension is spun at 1.0 x 103 rpm to pellet cells and 
PBS-EDTA is removed. Cells are then suspended in 500μl Fluo-4 NW (no wash, NW) 
dye solution and assay buffer (1x HBSS, 20mM HEPES) and incubated (r.t., 30 min.) on 
rocking platform. Fluo-4 NW cell suspension is then increased to volume required for 
assay with HBSS containing calcium chloride and magnesium chloride. Cells are aliquot 
into cuvettes (2ml/cuvette) containing a magnetic stir-bar to keep cells in suspension for 
assay. Individual cuvettes are loaded into a Photon Technologies Institute (PTI) 
spectrophotometer. Time-based assay parameters are assigned through PTI software as 
follows: excitation 480nm, emission 530nm with 8nm capture window, and 5000 secs 
duration. Individual cuvettes emission is collected for approximately 10 secs to obtain 
baseline emission. Agonist is pipette into cuvette and cellular response is measured. As a 
control 3-5 untreated cuvettes are treated with 3μM ionomycin calcium salt in DMSO to 
give the maximum response. Each agonist concentration is expressed as a percentage of 
average maximum response.  
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Chapter 6 Supplementary Information 
UPLC and ESI-MS tracers 
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Supplementary Figure 6.1 - pERK and tERK blots at 0, 5, 10, 20, and 30 min 
intervals with the treatment of Ghrelin versus Compound 6 (n=3) 
 
 
Supplementary Figure 6.2 - pERK and tERK blots for various concentrations of 
Compound 6, Compound 9, Compound 10, and Ghrelin for a 20 min incubation 
(n=3) 
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Supplementary Figure  6.3 - pERK and tERK blots with either DMSO vehicle 
control or YM254890 with/without ghrelin stimulation for 20 min incubation (n=3) 
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Supplementary Figure 6.4 - Confocal microscopy images of stable transfect LNCaP 
with GHS-R1a-eYFP indicating the receptor is highly expressed and localized to the 
cell membrane 
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Chapter 7 
 
7.1 Conclusion 
 The focus of this work was the development of chemical tools, both fluorescent 
and PET probes, that target the growth hormone secretagogue receptor-1a (GHS-
R1a). All of these chemical tools acted as agonists when targeting GHS-R1a leading 
to an activation in signalling. This receptor is an attractive GPCR target because of its 
wide range of physiological functions in the human body (e.g. metabolism, cardiac 
output, depression, neuroprotection)1-2. GHS-R1a is also highly dysregulated within 
certain disease states. It is over and differentially expressed in malignant prostate 
cancer versus benign, as well as upregulated in a variety of other cancers such as 
ovarian, lung, uterine3-4. GHS-R1a is also highly promiscuous, as it hetero-
oligomerizes with many other GPCRs such as the dopamine and melanocortin 
receptors. More recently, some have shown how GHS-R1a homo-oligomerizes with 
itself. However, within the scope of this work, the development of a ghrelin 
homobivalent ligand was used to target the GHS-R1a oligomer to elucidate the 
changes in the signaling cascade as a result of the oligomer. When GHS-R1a 
oligomerizes with itself or other GPCRs there are changes to the downstream 
signalling (e.g. changes in G-protein activation) leading to different physiological 
outcomes5-8.  
The natural ligand for the GHS-R1a is ghrelin, a 28-amino acid peptide that is 
derived from a 117- amino acid sequence (preproghrelin), through post-translational 
modifications, terminating with the octanoylation of Ser-3 by ghrelin O-acyl 
transferase (GOAT) producing the active form of the ligand3. This is the only known 
instance of a peptide being post-translationally modified with a fatty acid, and this 
modification is required for its binding to, and activation of GHS-R1a1-2. However, 
the natural ligand is highly susceptible to degradation by enzymes, due to its natural 
amide backbone and the 28 natural amino acids that make up the structure of the 
peptide. Also, the ester linkage for the attachment of the octanoyl chain to Ser in 
position three is susceptible to esterase hydrolysis. Therefore, this is changed to an 
amide linkage to improve stability but still maintain binding to GHS-R1a. There is a 
need to develop GHS-R1a targeting probes that have a structure with a greater level 
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of stability but still maintain binding towards the receptor. There is a greater interest 
in developing imaging-based probes to monitor the changes in GHS-Rla receptor 
expression in the presence or absence of diseases such as cancer, cardiovascular, and 
metabolic imbalance. The design of chemical probes driven towards therapy is also a 
consideration, as down regulation of this receptor is seen in diseases such as cancer 
cachexia (muscle wilting after chemotherapy)4.  
There are many styles of chemical probes that can be developed (e.g. small 
molecules, proteins, antibodies), however, peptides have several advantages. Peptides 
are easily synthesized by Fmoc solid phase peptide synthesis, and because of the ease 
of this synthesis technique they can be chemically changed without difficulty (e.g. D-
amino acids, amidated C-terminus, backbone stabilization). Peptides also have a 
greater affinity towards their target of interest, since most known targets only have 
one natural peptide ligand that binds to them and changes its state of activation. 
Peptides have a natural structure, their degradation by proteases can be readily 
determined, therefore this structure can be altered to improve their stability and 
efficacy as drug molecules.  
The first Chapter of this thesis focused on the development of a stabilized ghrelin 
fluorescent probe that was able to bind to the receptor with nanomolar affinity. With a 
lactam bridge stabilization in the backbone of a ghrelin 1 to 20 analogue (as 
determined by a staple scan), the peptide probe was fully stable over a 24-hour period 
when incubated with 25% human serum. This probe was demonstrated in an in vitro 
situation identifying receptor mediated binding in cells that artificially had over 
expression of the receptor, as well as in cells that had endogenous levels of GHS-R1a. 
This peptide probe was also able to detect changes in GHS-R1a expression in a 
mouse model of stroke by immunofluorescent imaging (ghrelin expression 
upregulated after stroke due to its neuroprotective effects). This work is not part of 
the immediate thesis but is an ongoing collaboration with Dr. Rithwik Ramachandran 
from the Department of Physiology and Pharmacology at Western University. By 
evaluating this probe in a mouse model of stroke, we can further validate the probe in 
a more realistic scenario of detecting the GHS-R1a dysregulated expression in an ex 
vivo situation. This chemical tool will be highly effective as an imaging probe in both 
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an in vitro and ex vivo situation as most known antibodies for this receptor have 
proven to have inadequate specificity.  
The second section of this thesis, encompassing Chapters 3-5, was a “roller 
coaster” in terms of probe synthesis and design (structure activity relationship studies 
– SAR studies) due to many challenges associated with receptor affinity, 
radiochemistry, and lipophilicity. This second section consists of three individual 
chapters and was driven towards applications in an in vivo imaging scenario. This 
research focussed on modifying a G7039 peptidomimetic first developed by 
Genentech. This peptide was originally developed to be used as a growth hormone 
drug, however due to its relatively small size (mimicking a small molecule class of 
drug) the conversion into an imaging agent was highly feasible. Prior work 
highlighted in Chapter 3 looked at the simple addition of 4-fluorobenzoic acid group 
onto the C-terminal portion and a fourth position changed from a Phe to a 1-
naphthylalanine (1-Nal). This proved to be ineffective when it came to imaging by 
PET (compound 17 in Chapter 3). It had a substantially lower affinity, a higher 
cLogP, and a lengthy radiosynthesis route. However, this project included an 
extensive SAR study that indicated which positions of this short 5-mer peptide could 
be altered without negatively affecting the binding towards GHS-R1a. This allowed 
for a follow up project that would focus on only altering the fourth position of the 5-
mer peptide, as well as changing the prosthetic group to improve lipophilicity, 
binding, and the radiosynthetic route.  
These findings led into the second part of the project (Chapter 4) that had the 
goals of reducing the cLogP of the compound, increasing the binding affinity to GHS-
R1a, and improving the radiosynthesis route. Converting the fluoride-19 (19F) group 
to a fluoride-18 (18F) group on the 4-fluorobenzoic acid prosthetic group in Chapter 3 
was too lengthy of a radiosynthetic route. In the end, two of these tasks were 
accomplished, and further opportunities for subsequent structural modifications 
(further changes to the radiosynthetic prosthetic group) were considered. The fourth 
position of G7039 was modified from a Phe to a Tyr, and the prosthetic group chosen 
was a 2-fluoropropanoic acid group on the C-terminal lysine. These changes resulted 
in a compound with an affinity that was sub-nanomolar and a reduced cLogP was 
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observed. This was thought to be the compound that would be labelled and provide 
decent PET images in an in vivo scenario. This was not the case as the 2-
fluoropropioic acid labelling with 18F proved to be low yielding and thus had a similar 
issue to that found when using the 4-fluorobenzoic acid prosthetic group. However, 
this new peptidomimetic proved to have low nanomolar affinity and picomolar 
activity as measured by b-arrestin recruitment. This is believed to be due to the Tyr in 
the fourth position forming a new H-bond interaction with Arg 283 in the binding 
pocket of the receptor (determined by molecular docking). When Ser was placed in 
the fourth position binding and activity decreased. A lowered Emax was identified for 
compounds 3 and 6, indicating that they act as a partial agonists when targeting GHS-
R1a. Compound 5 in Chapter 4 still has the potential to be labelled with 18F, however 
it has a greater potential as a drug therapeutic for diseases where GHS-R1a activation 
is lowered. 
The final stage of this peptidomimetic work was to see if it was possible to change 
the prosthetic group of the C-terminal Lys a third time while leaving the Tyr in the 
fourth position (Chapter 5). An alkyne containing ammonium methyltrifluoroborate 
(AMBF3) was chosen as the new prosthetic group for its ease in conjugation to a 
peptide as well as an efficient radiosynthetic route. This particular prosthetic group is 
easily installed onto the previous peptide (compound 5 in Chapter 4) by copper click 
chemistry using a Lys azide on the C-terminus instead of the previous standard Lys 
group in the fifth position. Once installed the binding affinity was found to still be 
sub-nanomolar, however the cLogP was three-fold less than the original G7039 
peptidomimetic. This drastic decrease in cLogP will help with the past issues of the 
tracer being retained in lipophilic organs such as the liver. This tracer can now be 
directly labelled in one step with no HPLC purification and great radiochemical data. 
The “hot” 18F compound displayed a 10 to 12% uptake in cells expressing GHS-R1a. 
This chemical tool can now be used as a PET tracer to identify the over expression of 
GHS-R1a in an in vivo cancer mouse model.  
Despite the challenges (affinity, lipophilicity, and radiosynthetic route), the three 
iterations of peptidomimetics each had a positive outcome for its intended purpose. 
The Chapter 3 outcome helped guide further SAR studies. Chapter 4 confirmed that 
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only select positions of this class of ghrelin peptidomimetic can be altered in order to 
maintain affinity and potency when targeting GHS-R1a (confirmed by molecular 
docking). Chapter 5 finally was the improved avenue towards a simplistic and 
efficient radiosynthetic route for a novel and improved PET tracer. Each of these 
unique peptidomimetic ghrelin derivates all have applications towards imaging the 
dysregulated GHS-R1a by PET. The three generations of peptidomimetics are 
depicted in Figure 7.1.  
 
Figure 7.1 - Three generations of ghrelin peptidomimetics with changes to the 
fourth position (highlighted in green from structures A to C) from a naphthyl-
alanine group (structures A) to a tyrosine (structure A and C), and the use of 3    
different prosthetic groups (highlighted in red from structures A through C) 
from generation 1 through 3 conjugated on to the C-terminal lysine 
 
The final project was the study of GHS-R1a homo-oligomerization, but more so 
the design of chemical tools to target this homo-oligomer. This project was the most 
challenging due to the complexity of the assays involved in studying this 
oligomerization. GHS-R1a has a wide functioning role in human diseases such as 
obesity, diabetes, stress, anxiety, and depression. Because of its broad range of 
function in the human body it has been shown that GHS-R1a preferentially 
oligomerizes with other GPCRs that have similar physiological effects. This makes it 
very difficult to target GHS-R1a with potent agonists and antagonists with high 
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efficacy. However, by having a greater understanding of receptor oligomerization one 
could anticipate designing specific drugs in terms of pharmacological treatment while 
minimizing side effects. Jiang et al. in 2006 was able to first observe a GHS-R1a 
homo-oligomer in HEK293 cells that were over expressing GHS-R1a-Rluc and GHS-
R1a-GFP by a BRET signal that gave a hyperbolic shape. GHS-R1a has been shown 
to oligomerize with other GPCRs such as the dopamine receptors (D1R and D2R), the 
serotonin receptor (5-HT2C), the melanocortin receptor (MC3R), and the cannabinoid 
receptors (CB1 and CB2)7. GHS-R1a cross talk has widely had a focus driven 
towards the neuroendocrine system in human physiology, however little work has 
focussed on the implications of self-oligomerization. The dimerization with other 
receptors has been shown to either attenuate or cause an augmentation of the 
downstream cascade of signalling events associated with GPCR activation. Examples 
of such oligomerization is between GHS-R1a and melanocortin-3 receptor 
(homeostatic control of food intake) and this oligomerization causes an attenuation of 
signalling when GHS-R1a is activated by ghrelin and simultaneously associated with 
melanocortin-3 receptor9. This leads to a reduction in signalling events such as the 
slowing down of appetite response, whereas when ghrelin acts alone on its receptor it 
causes an increase in appetite. 
Many in the field have targeted GPCR hetero-oligomers with two separate 
ligands. This approach has a major limitation when it comes to designing a novel drug 
for a receptor oligomer in terms of drug dosing and formulation. Knowing that this is 
a possible mechanism in which a ligand can bind and change the active state of a 
GPCR oligomer, one can develop novel heterobivalent and homobivalent ligands that 
would modulate the signalling in a differential fashion when compared to the 
monomer. There is still limited knowledge about the GHS-R1a homo-oligomer and 
until our work, there are no known homobivalent ligands that can target this homo-
oligomer simultaneously and stabilize its formation. Our studies showed that the 
homobivalent ligand (compound 6 in Chapter 6) possesses exceptionally high binding 
affinity and can bind to both receptors within the GHS-R1a homo-oligomer in 
HEK293 cells. This is indicated by a bivalent binding curve. In addition, we 
demonstrated that this chemical probe is a strong agonist by its activation of b-
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arrestin-1 and b-arrestin-2 recruitment in the low nanomolar range. The monomeric 
version of the heterobivalent ligand; G7039-L (10), the unmodified G7039 
peptidomimetic (9), and the natural ligand for the receptor; ghrelin, are 2-15x less 
potent then homobivalent ligand based on EC50 values for b-arrestin-1 and b-arrestin-
2 recruitment. We determined that there was 3-fold increase in homo-oligomerization 
BRET response with the homobivalent ligand (6 ) compared to ghrelin, G7039 (9), 
and G7039-L (10). GHS-R1a activation triggers several signaling pathways that can 
be harnessed for therapeutic response in disease states (e.g. inflammation, diabetes, 
and hypotensive effects), leading to the potential for the homobivalent ligand (6) to be 
used as a therapeutic agent. Targeting the homo-oligomer system with a novel ghrelin 
homobivalent ligand (6) has caused a 12,000-fold increase in binding compared to 
ghrelin targeting the monomer receptor, however there is a reduction in the MAPK 
and NF-kB signalling that is partially due to this receptor oligomerization. Being that 
NF-kB is a typical protein involved in the inflammation signalling cascade, this is a 
promising agonist that could be used in the treatment of diseases lacking GHS-R1a 
signalling (i.e. cancer cachexia) but being able to slow down inflammatory signalling 
responses. Ligands that are capable of targeting these receptor oligomers holds great 
promise as a new class of therapeutics, but equally important, are a powerful chemical 
biology tool for understanding the function, mechanism, and disease significance of 
GPCR oligomers, for which there is limited knowledge to date. 
Overall in my PhD I was able to develop several different styles of chemical 
probes targeting GHS-R1a with different degrees of affinity and potency. Each of 
these probes was modified in such away to have applications in the direction of either 
imaging or therapy and opens the door to further probe development to study this 
receptor in human physiology and disease.  
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